Any feedback?
No. of entries
Information on EC 1.1.1.62 - 17beta-estradiol 17-dehydrogenase
for references in articles please use BRENDA:EC1.1.1.62
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
EC Tree 1 Oxidoreductases
1.1 Acting on the CH-OH group of donors
1.1.1 With NAD+ or NADP+ as acceptor
1.1.1.62 17beta-estradiol 17-dehydrogenase
IUBMB Comments
The enzyme oxidizes or reduces the hydroxy/keto group on C17 of estrogens and androgens in mammals and regulates the biological potency of these steroids. The mammalian enzyme is bifunctional and also catalyses EC 1.1.1.270, 3β-hydroxysteroid 3-dehydrogenase . The enzyme also acts on (S)-20-hydroxypregn-4-en-3-one and related compounds, oxidizing the (S)-20-group, but unlike EC 1.1.1.149, 20α-hydroxysteroid dehydrogenase, it is Si-specific with respect to NAD(P)+.
The expected taxonomic range for this enzyme is: Eukaryota, Bacteria
- 1.1.1.62
- progesterone
- estrone
- androgen
- testosterone
- 17beta-hsds
- ovarian
- aromatase
-
steroidogenic
- endometrium
- androstenedione
-
aldo-keto
-
steroidogenesis
- progestin
-
granulosa
- luteal
- akr1c2
-
alpha-hsd
-
sulfatase
- medicine
-
alpha-dihydroprogesterone
-
corpora
- pregnenolone
-
d-bifunctional
-
endometriotic
- hsd17b3
-
3beta-hydroxysteroid
-
luteolysis
- cyp19a1
-
alpha-hydroxyprogesterone
-
vlcfas
- cochliobolus
-
17-ketosteroids
- hsd3b2
-
3alpha-hydroxysteroid
- sult1e1
-
5alpha-reductase
- srd5a1
- 5alpha-dihydrotestosterone
- lunatus
- 3betahsd
- p450arom
-
alpha-diol
-
17-keto
-
c19-steroids
- diagnostics
- drug development
showSynonyms
hsd17b4, hsd17b2, 20 alpha-hydroxysteroid dehydrogenase, 17betahsd, 17-hsd, akr1c4, hsd17b12, 17hsd1, 17beta-hsd type 1, 17betahsd1, more
topPlease wait a moment until the data is sorted. This message will disappear when the data is sorted.
SYNONYM 
ORGANISM
UNIPROT
COMMENTARY 
LITERATURE
17-HOR
-
-
-
-
17-HSD
-
-
-
-
17beta,20alpha-hydroxysteroid dehydrogenase
-
-
-
-
17beta-estradiol dehydrogenase
-
-
-
-
17beta-HSD
17beta-HSD1
17beta-HSD10
17beta-HSD12
17beta-HSD2
17beta-HSDcl
17beta-hydroxysteroid dehydrogenase
17beta-hydroxysteroid dehydrogenase type 1
17beta-hydroxysteroid dehydrogenase type 10
17beta-hydroxysteroid dehydrogenase type 14
17beta-hydroxysteroid dehydrogenase type 2
17beta-hydroxysteroid dehydrogenase type 7
17beta-hydroxysteroid dehydrogenase type I
17betaHSD1
20 alpha-hydroxysteroid dehydrogenase
-
-
-
-
20-alpha-HSD
-
-
-
-
20alpha-hydroxysteroid dehydrogenase
AKR1C3
C6Y55_RS00895
C6Y55_RS01070
C6Y55_RS01190
C6Y55_RS15130
dehydrogenase, estradiol 17beta-
-
-
-
-
E2DH
-
-
-
-
EDH
-
-
-
-
estradiol 17beta-dehydrogenase
-
-
-
-
estradiol dehydrogenase
-
-
-
-
estrogen 17-oxidoreductase
-
-
-
-
HSD17B1
HSD17B4
Ke6 protein
-
-
-
-
microsomal 17-beta-hydroxysteroid dehydrogenase
-
-
-
-
oestradiol-17beta hydroxysteroid dehydrogenase
-
-
-
-
placental 17-beta-hydroxysteroid dehydrogenase
-
-
-
-
PRAP
-
-
-
-
PRL receptor associated protein
-
-
-
-
testicular 17-beta-hydroxysteroid dehydrogenase
-
-
-
-
type 1 17beta-hydroxysteroid dehydrogenase
type 2 3alpha-hydroxysteroid dehydrogenase/type 5 17beta-hydroxysteroid dehydrogenase
-
additional information
17beta-HSD
-
-
-
-
17beta-HSD1
-
-
17beta-HSD1
-
17beta-hydroxysteroid dehydrogenase
-
-
-
-
17beta-hydroxysteroid dehydrogenase type 1
-
-
17beta-hydroxysteroid dehydrogenase type 1
-
20alpha-hydroxysteroid dehydrogenase
-
-
-
-
additional information
-
the enzyme belongs to the cP1 subfamily of the short-chain dehydrogenase/reductase superfamily
additional information
-
the enzyme belongs to the short-chain dehydrogenase/reductase superfamily
additional information
-
17beta-HSDs belong to the aldo-keto reductase family or the short-chain dehydrogenase family, overview
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
REACTION
REACTION DIAGRAM
COMMENTARY
ORGANISM
UNIPROT
LITERATURE
17beta-estradiol + NAD(P)+ = estrone + NAD(P)H + H+
5 isoforms with different substrate specificities and tissue distribution, 17beta-HSD1 predominantly catalyzes the reaction of estrone to estradiol-17beta, 17beta-HSD2 catalyzes the reaction of estradiol-17beta to estrone and testosterone to androstenedione, 17beta-HSD3 and 5 catalyzes the reaction of androstenedione to testosterone, 17beta-HSD4 catalyzes the reaction of estradiol-17beta to estrone with low substrate affinty
-
17beta-estradiol + NAD(P)+ = estrone + NAD(P)H + H+
17beta-HSD2 and 5 catalyzes the reaction of estradiol-17beta to estrone and testosterone to androstenedione, 17beta-HSD2 also has 20alpha-HSD activity
-
17beta-estradiol + NAD(P)+ = estrone + NAD(P)H + H+
isoforms differs in substrate specificity and tissue distribution, some enzyme forms displays also other activities such as type 4 that acts also as a short chain alcohol dehydrogenase and hydratase and type 10, that is identical to endoplasmic amyloid-beta-binding protein and mitochondrial short chain L-3-hydroxyacyl-CoA dehydrogenase
-
17beta-estradiol + NAD(P)+ = estrone + NAD(P)H + H+
active site structure of isozymes 17beta-HSD1 and 17beta-HSD14
-
17beta-estradiol + NAD(P)+ = estrone + NAD(P)H + H+
structure-function analysis, dimerization is crucial for catalytic activity
-
17beta-estradiol + NAD(P)+ = estrone + NAD(P)H + H+
cofactor binding residues are Tyr49, Thr202, Ala50, and Asn51, Theorell-Chance reaction mechanism
-
17beta-estradiol + NAD(P)+ = estrone + NAD(P)H + H+
a structural analysis of available crystal structures is performed and representative conformations are assigned to each step of the putative kinetic mechanism. An essential role played by the backbone and side chain motions, especially of the betaFalphaG-loop, in cofactor and substrate binding is disclosed. A selected-fit mechanism is suggested for 17beta-HSD1, where ligand-binding induces concerted motions of the FG-segment and the C-terminal part guide the enzyme along its preferred catalytic pathway
17beta-estradiol + NAD(P)+ = estrone + NAD(P)H + H+
-
-
-
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
REACTION TYPE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
oxidation
-
-
-
-
redox reaction
-
-
-
-
reduction
-
-
-
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
PATHWAY SOURCE
PATHWAYS
MetaCyc
estradiol biosynthesis I (via estrone)
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
SYSTEMATIC NAME
IUBMB Comments
17beta-estradiol:NAD(P)+ 17-oxidoreductase
The enzyme oxidizes or reduces the hydroxy/keto group on C17 of estrogens and androgens in mammals and regulates the biological potency of these steroids. The mammalian enzyme is bifunctional and also catalyses EC 1.1.1.270, 3beta-hydroxysteroid 3-dehydrogenase [3]. The enzyme also acts on (S)-20-hydroxypregn-4-en-3-one and related compounds, oxidizing the (S)-20-group, but unlike EC 1.1.1.149, 20alpha-hydroxysteroid dehydrogenase, it is Si-specific with respect to NAD(P)+.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
CAS REGISTRY NUMBER
COMMENTARY
9028-61-9
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
SUBSTRATE
PRODUCT
REACTION DIAGRAM
ORGANISM
UNIPROT
LITERATURE
COMMENTARY
Reversibility
r=reversible
ir=irreversible
?=not specified
r=reversible
ir=irreversible
?=not specified
1,2-dimethyl-6-dehydroestrone + NADH
1,2-dimethyl-6-dehydroestradiol + NAD+
-
Substrates: -
Products: -
Products: -
?
1,2-dimethylestradiol + NAD+
1,2-dimethylestrone + NADH
-
Substrates: -
Products: -
Products: -
r
1,2-dimethylestrone + NADH
1,2-dimethylestradiol + NAD+
-
Substrates: -
Products: -
Products: -
r
1,4-diacetoxy-1,3,5(10)-estratrien-17-one + NADH
17beta-hydroxy-1,4-diacetoxy-1,3,5(10)-estratriene + NAD+
-
Substrates: -
Products: -
Products: -
?
1,4-dihydroxy-1,3,5(10)-estratrien-17-one + NADH
1,4,17-trihydroxy-1,3,5(10)-estratrien + NAD+
-
Substrates: -
Products: -
Products: -
?
1-methyl-6-dehydroestradiol + NAD+
1-methyl-6-dehydroestrone + NADH
-
Substrates: -
Products: -
Products: -
r
1-methyl-6-dehydroestrone + NADH
1-methyl-6-dehydroestradiol + NAD+
-
Substrates: -
Products: -
Products: -
r
11-ketoequilenin acetate + NADH
17beta-hydroxy-11-ketoequilenin acetate + NAD+
-
Substrates: -
Products: -
Products: -
?
11alpha-hydroxyestradiol + NAD+
11alpha-hydroxyestrone + NADH
-
Substrates: -
Products: -
Products: -
?
11beta-hydroxyestradiol + NAD+
11beta-hydroxyestrone + NADH
-
Substrates: -
Products: -
Products: -
?
17beta-hydroxyestra-4-en-3-one + NADP+
estra-4-en-3,17-dione + NADPH + H+
-
Substrates: -
Products: -
Products: -
r
18-nor-D-homoestrone 3-methyl ether + NADH
18-nor-D-homoestradiol 3-methyl ether + NAD+
-
Substrates: -
Products: -
Products: -
?
19-nortestosterone + NAD+
4-estren-3,17-dione + NADH
-
Substrates: 2% of the activity with estradiol-17beta
Products: -
Products: -
?
2,4-dinitroestradiol + NAD+
2,4-dinitroestrone + NADH
-
Substrates: -
Products: -
Products: -
r
2,4-dinitroestrone + NADH
2,4-dinitroestradiol + NAD+
-
Substrates: -
Products: -
Products: -
r
2,4-dinitroestrone 3-oxyacetic acid ether + NADH
2,4-dinitroestradiol 3-oxyacetic acid ether + NAD+
-
Substrates: -
Products: -
Products: -
?
2,5(10)-estradiene-1,4,17-trione + NADH
17beta-hydroxy-2,5(10)-estradiene-1,4-dione + NAD+
-
Substrates: -
Products: -
Products: -
?
2-nitroestrone 3-oxyacetic acid ester + NADH + H+
2-nitroestradiol-17beta-3-oxyacetic acid ester + NAD+
-
Substrates: -
Products: -
Products: -
?
3-hydroxy-2,5(10)-estradiene-1,4,17-trione + NADH
3,17beta-dihydroxy-2,5(10)-estradiene-1,4-dione + NAD+
-
Substrates: -
Products: -
Products: -
?
3-methyl-O-estradiol + NAD(P)+
3-methyl-O-estrone + NAD(P)H
-
Substrates: -
Products: -
Products: -
?
3beta-hydroxyandrost-5-en-17-one + NADPH
3beta,17beta-dihydroxyandrost-5-ene + NADP+
-
Substrates: i.e. dehydroepiandrosterone
Products: -
Products: -
?
4-aminoestrone 3,4-diacetate + NADH
4-aminoestradiol 3,4-diacetate + NAD+
-
Substrates: -
Products: -
Products: -
?
4-androstenedione + NAD(P)H + H+
testosterone + NAD(P)+
Substrates: -
Products: -
Products: -
?
4-estrene-3,17-dione + NADH + H+
4-estrene-17beta-ol-3-one + NAD+
Substrates: -
Products: -
Products: -
r
4-estrene-3,17-dione + NADPH
4-estrene-17beta-ol-3-one + NADP+
-
Substrates: -
Products: -
Products: -
r
4-estrene-3,17-dione + NADPH + H+
4-estrene-17beta-ol-3-one + NADP+
Substrates: -
Products: -
Products: -
r
4-methyl-1,3,5(10)-estratriene-1,17beta-diol + NAD+
1-hydroxy-4-methyl-1,3,5(10)-estratriene-17-one + NADH
-
Substrates: -
Products: -
Products: -
?
4-oestrene-17beta-ol-3-one + NADP+
4-oestrene-3,17-dione + NADPH + H+
Substrates: -
Products: -
Products: -
?
5,7,9-estratrien-3beta-ol-17-one + NADH
5,7,9-estratriene-3beta,17beta-diol + NAD+
-
Substrates: -
Products: -
Products: -
?
5,7,9-estratriene-3beta,17beta-diol + NAD+
5,7,9-estratriene-3beta-ol-17-one + NADH
-
Substrates: -
Products: -
Products: -
?
5-androstene-3beta,17beta-diol + NAD+
5-androstene-3-beta-ol-17-one + NADH
-
Substrates: 5.9% of the activity with estradiol
Products: -
Products: -
?
5-androstene-3beta,17beta-diol + NAD+
? + NADH + H+
Substrates: -
Products: -
Products: -
?
5-androstene-3beta-ol-17-one + NADPH
5-androstene-3beta,17beta-diol + NADP+
Substrates: -
Products: -
Products: -
?
5alpha-androstane-3,17-dione + NADH + H+
5alpha-androstane-17beta-ol-3-one + NAD+
Substrates: -
Products: -
Products: -
r
5alpha-dihydrotestosterone + NAD+
5alpha-androstan-3,17-dione + NADH + H+
-
Substrates: 3.2% of the activity with estradiol
Products: -
Products: -
?
5alpha-dihydrotestosterone + NADH
5alpha-androstanedione + NAD+
-
Substrates: -
Products: -
Products: -
?
5alpha-dihydrotestosterone + NADPH
5alpha-androstane-3,17-dione + NADP+
-
Substrates: -
Products: -
Products: -
?
5alpha-dihydrotestosterone + NADPH + H+
5alpha-androstane-3beta,17beta-diol + 5alpha-androstane-3,17-dione + NADP+
Substrates: -
Products: -
Products: -
?
5alpha-dihydrotestosterone + NADPH + H+
? + NADP+
Substrates: kinetics demonstrates positive cooperativity
Products: -
Products: -
?
5beta-pregnan-20alpha-ol-3-one + NADPH
5beta-pregnane-3,20-dione + NADP+
-
Substrates: -
Products: -
Products: -
?
6-dehydroestrone 3-benzoate + NADH
6-dehydro-17beta-estradiol 3-benzoate + NAD+
-
Substrates: -
Products: -
Products: -
?
6-ketoestrone + NADH
6-ketoestradiol-17beta + NAD+
-
Substrates: -
Products: -
Products: -
?
6alpha,7alpha-dihydroxyestrone + NADH
6alpha,7alpha-dihydroxyestradiol + NAD+
-
Substrates: -
Products: -
Products: -
?
6alpha-hydroxyestradiol + NAD+
6alpha-hydroxyestrone + NADH
-
Substrates: -
Products: -
Products: -
?
7-ketoestrone + NADH
7-ketoestradiol-17beta + NAD+
-
Substrates: -
Products: -
Products: -
?
7alpha-hydroxyestradiol + NAD+
7alpha-hydroxyestrone + NADH
-
Substrates: -
Products: -
Products: -
?
7alpha-hydroxyestrone + NADH
7alpha-hydroxyestradiol + NAD+
-
Substrates: -
Products: -
Products: -
r
7beta-hydroxyestrone + NADH
7beta-hydroxyestradiol + NAD+
-
Substrates: -
Products: -
Products: -
?
allopregnanolone + NAD+
5alpha-dihydroprogesterone + NADH + H+
Substrates: -
Products: -
Products: -
?
androst-4-ene-3,17-dione + NADPH
androst-4-ene-17beta-ol-3-one + NADP+
-
Substrates: -
Products: -
Products: -
?
androstendiol + NAD(P)+
dehydroepiandrosterone + NAD(P)H + H+
Substrates: -
Products: -
Products: -
?
androstenedione + NAD(P)H + H+
testosterone + NADP+
Substrates: -
Products: -
Products: -
?
androsterone + NAD(P)H
5alpha-androstane-3alpha,17beta-diol + NAD(P)+ + H+
Substrates: -
Products: -
Products: -
?
androsterone + NADH + H+
5alpha-androstane-3alpha,17beta-diol + NAD+
Substrates: -
Products: -
Products: -
?
dehydroepiandrosterone + NAD(P)H
5-androstene-3beta,17beta-diol + NAD(P)+
Substrates: -
Products: -
Products: -
?
dehydroepiandrosterone + NAD(P)H
androst-5-ene-3beta,17beta-diol + NAD(P)+
Substrates: -
Products: -
Products: -
?
dehydroepiandrosterone + NAD(P)H + H+
androstendiol + NAD(P)+
Substrates: -
Products: -
Products: -
?
dehydroepiandrosterone + NADPH + H+
5-androstene-3beta,17beta-diol + NADP+
Substrates: -
Products: -
Products: -
?
dehydroepiandrosterone + NADPH + H+
androstenediol + NADP+
Substrates: -
Products: -
Products: -
?
dihydrotestosterone + NAD(P)H + H+
androstane-3beta,17beta-diol + NAD(P)+
-
Substrates: -
Products: -
Products: -
?
DL-3-deoxyequilenin + NADH
17beta-hydroxy-DL-3-deoxyequilin + NAD+
-
Substrates: -
Products: -
Products: -
?
DL-6-methoxy-3-deoxy-equilenin + NADH + H+
17beta-hydroxy-DL-6-methoxy-3-deoxyequilenin + NAD+
-
Substrates: -
Products: -
Products: -
?
epitestosterone + NADP+
4-androsten-3,17-dione + NADPH + H+
-
Substrates: poor substrate
Products: -
Products: -
?
estradiol + NADP+
estrone + NADPH
-
Substrates: the equilibrium state is 92% estradiol to 8% estrone
Products: -
Products: -
?
estradiol-17alpha + NADP+
estrone + NADPH
-
Substrates: at about 3% of the activity with estradiol-17beta
Products: -
Products: -
?
estrone + NADH + H+
17beta-estradiol + NAD+
Substrates: -
Products: -
Products: -
?
estrone 3-methyl ether + NADH
3-O-methyl-17beta-estradiol + NAD+
-
Substrates: -
Products: -
Products: -
?
estrone 3-oxyacetic acid ether + NADH
17beta-estradiol 3-O-oxyacetic acid ether + NAD+
-
Substrates: -
Products: -
Products: -
?
estrone 3-sulfate + NADPH
17beta-estradiol 3-sulfate + NADP+
-
Substrates: -
Products: -
Products: -
r
pregn-4-en-20alpha-ol-3-one + NADP+
progesterone + NADPH
-
Substrates: -
Products: -
Products: -
?
progesterone + NADPH + H+
4-pregnen-3beta-ol-20-one + NADP+
Substrates: -
Products: -
Products: -
?
testosterone + NAD(P)+
4-androstene-3,17-dione + NAD(P)H
-
Substrates: 17beta-HSD2 and 5, key role in regulating steroid receptor occupancy in normal and tumor tissues
Products: -
Products: -
?
testosterone + NAD(P)+
androstenedione + NAD(P)H + H+
Substrates: -
Products: -
Products: -
?
testosterone + NAD+
DELTA4-3,17-androstendione + NADH + H+
Substrates: -
Products: -
Products: -
?
17beta-estradiol + NAD(P)+
estrone + NAD(P)H + H+
Substrates: -
Products: -
Products: -
r
17beta-estradiol + NAD(P)+
estrone + NAD(P)H + H+
Substrates: -
Products: -
Products: -
?
17beta-estradiol + NAD(P)+
estrone + NAD(P)H + H+
Substrates: -
Products: -
Products: -
?
17beta-estradiol + NAD(P)+
estrone + NAD(P)H + H+
Substrates: -
Products: -
Products: -
?
17beta-estradiol + NAD(P)+
estrone + NAD(P)H + H+
Substrates: -
Products: -
Products: -
r
17beta-estradiol + NAD+
estrone + NADH + H+
Substrates: -
Products: -
Products: -
r
17beta-estradiol + NAD+
estrone + NADH + H+
Substrates: -
Products: -
Products: -
?
17beta-estradiol + NAD+
estrone + NADH + H+
Substrates: -
Products: -
Products: -
?
17beta-estradiol + NAD+
estrone + NADH + H+
-
Substrates: high efficiency, over 98% of 17beta-estradiol was oxidized into estrone in 5 min
Products: -
Products: -
?
17beta-estradiol + NAD+
estrone + NADH + H+
ANI02794.1
Substrates: -
Products: -
Products: -
?
17beta-estradiol + NAD+
estrone + NADH + H+
ANI02794.1
Substrates: transformation efficiency of 17beta-estradiol into estrone is over 96.6% in five minutes
Products: -
Products: -
?
17beta-estradiol + NAD+
estrone + NADH + H+
-
Substrates: -
Products: -
Products: -
?
17beta-estradiol + NAD+
estrone + NADH + H+
-
Substrates: high efficiency, over 98% of 17beta-estradiol was oxidized into estrone in 5 min
Products: -
Products: -
?
17beta-estradiol + NAD+
estrone + NADH + H+
ANI02794.1
Substrates: -
Products: -
Products: -
?
17beta-estradiol + NAD+
estrone + NADH + H+
ANI02794.1
Substrates: transformation efficiency of 17beta-estradiol into estrone is over 96.6% in five minutes
Products: -
Products: -
?
17beta-estradiol + NAD+
estrone + NADH + H+
A0A1Z3FWF0
Substrates: -
Products: -
Products: -
?
17beta-estradiol + NAD+
estrone + NADH + H+
-
Substrates: -
Products: -
Products: -
?
17beta-estradiol + NAD+
estrone + NADH + H+
-
Substrates: -
Products: -
Products: -
?
17beta-estradiol + NADP+
estrone + NADPH
-
Substrates: isozyme 17beta-HSD4
Products: -
Products: -
?
17beta-estradiol + NADP+
estrone + NADPH + H+
Substrates: -
Products: -
Products: -
?
17beta-estradiol + NADP+
estrone + NADPH + H+
Substrates: -
Products: -
Products: -
?
20alpha-hydroxy-4-pregnen-3-one + NADP+
4-pregnen-3,20-dione + NADPH
-
Substrates: low activity
Products: -
Products: -
?
20alpha-hydroxy-4-pregnen-3-one + NADP+
4-pregnen-3,20-dione + NADPH
-
Substrates: -
Products: -
Products: -
?
3-O-methyl-17beta-estradiol + NAD+
3-O-methylestrone + NADH
-
Substrates: -
Products: -
Products: -
?
3-O-methyl-17beta-estradiol + NAD+
3-O-methylestrone + NADH
-
Substrates: 85% of the activity with estradiol-17beta
Products: -
Products: -
?
4-androstene-3,17-dione + NADPH + H+
testosterone + NADP+
-
Substrates: -
Products: -
Products: -
r
4-androstene-3,17-dione + NADPH + H+
testosterone + NADP+
-
Substrates: 17beta-HSD3 and 5, formation of active androgens in testis and prostate
Products: -
Products: -
?
4-androstene-3,17-dione + NADPH + H+
testosterone + NADP+
-
Substrates: -
Products: -
Products: -
?
4-androstene-3,17-dione + NADPH + H+
testosterone + NADP+
-
Substrates: -
Products: -
Products: -
r
5alpha-androstane-3alpha,17beta-diol + NAD+
androsterone + NADH + H+
Substrates: -
Products: -
Products: -
?
5alpha-androstane-3alpha,17beta-diol + NAD+
androsterone + NADH + H+
-
Substrates: -
Products: -
Products: -
?
5alpha-dihydrotestosterone + NADP+
5alpha-androstan-3,17-dione + NADPH
-
Substrates: -
Products: -
Products: -
?
5alpha-dihydrotestosterone + NADP+
5alpha-androstan-3,17-dione + NADPH
Substrates: the enzyme could play a critical role in estrogen-sensitive cells, since it inactivates 5alpha-dihydrotestosterone that generally shows antagonistic effect in the cells
Products: -
Products: -
?
5alpha-dihydrotestosterone + NADP+
5alpha-androstan-3,17-dione + NADPH
Substrates: -
Products: -
Products: -
?
androst-4-ene-3,17-dione + NADH + H+
testosterone + NAD+
Substrates: -
Products: -
Products: -
r
androst-4-ene-3,17-dione + NADH + H+
testosterone + NAD+
Substrates: -
Products: -
Products: -
?
androstenedione + NADPH + H+
testosterone + NADP+
-
Substrates: 50% of the activity with estradiol-17beta
Products: -
Products: -
?
dihydrotestosterone + NADPH + H+
5alpha-androstane-3beta,17beta-diol + NADP+
Substrates: -
Products: -
Products: -
?
dihydrotestosterone + NADPH + H+
5alpha-androstane-3beta,17beta-diol + NADP+
Substrates: -
Products: -
Products: -
?
dihydrotestosterone + NADPH + H+
5alpha-androstane-3beta,17beta-diol + NADP+
Substrates: the enzyme show positive cooperativity
Products: -
Products: -
?
estradiol-17beta + NAD(P)+
estrone + NAD(P)H
-
Substrates: 17beta-HSD2 and 5, key role in regulating steroid receptor occupancy in normal and tumor tissues
Products: -
Products: -
?
estradiol-17beta + NAD(P)+
estrone + NAD(P)H + H+
-
Substrates: 17beta-HSD4 is involved in etsrogen inactivation and may protect against an excessive accumulation of E2 in human ovarian epithelial cells
Products: -
Products: -
?
estradiol-17beta + NAD(P)+
estrone + NAD(P)H + H+
Substrates: 7beta-HSD type 2
Products: -
Products: -
?
estradiol-17beta + NAD(P)+
estrone + NAD(P)H + H+
Substrates: -
Products: -
Products: -
?
estradiol-17beta + NAD(P)+
estrone + NAD(P)H + H+
-
Substrates: -
Products: -
Products: -
ir
estradiol-17beta + NAD+
estrone + NADH
-
Substrates: enzyme prefers NAD+ over NADP+
Products: -
Products: -
?
estradiol-17beta + NAD+
estrone + NADH
-
Substrates: -
Products: -
Products: -
?
estradiol-17beta + NAD+
estrone + NADH
-
Substrates: -
Products: -
Products: -
r
estradiol-17beta + NAD+
estrone + NADH
-
Substrates: -
Products: -
Products: -
?
estradiol-17beta + NAD+
estrone + NADH
-
Substrates: type 1 enzyme is a cytosolic isoform highly specific for estradiol. Type 2 is a membrane bound isoform reactive with both estradiol and testosterone
Products: -
Products: -
?
estradiol-17beta + NAD+
estrone + NADH
-
Substrates: reversible at neutral pH, reduction of estrone at 5% of the activity of reduction of estradiol-17beta
Products: -
Products: -
r
estradiol-17beta + NAD+
estrone + NADH
-
Substrates: reduction of estrone is 400fold slower than oxidation of 17beta-estradiol
Products: -
Products: -
r
estradiol-17beta + NAD+
estrone + NADH + H+
-
Substrates: vitamin K2 binds 17beta-hydroxysteroid dehydrogenase 4 and modulates estrogen metabolism. Vitamin K2 decreases the estradiol-17beta/estrone ratio in cells by 25%
Products: -
Products: -
?
estradiol-17beta + NAD+
estrone + NADH + H+
-
Substrates: enzyme catalyzes the reduction of estrone to estradiol, the rate is 2.3% of the activity with estradiol
Products: -
Products: -
?
estradiol-17beta + NAD+
estrone + NADH + H+
Substrates: 17beta-HSD2
Products: -
Products: -
?
estradiol-17beta + NAD+
estrone + NADH + H+
-
Substrates: activity with NAD+ is barely detectable
Products: -
Products: -
?
estradiol-17beta + NAD+
estrone + NADH + H+
-
Substrates: activity with NAD+ is 2.2-3.8fold lower than with NADP+, depending on sample
Products: -
Products: -
?
estradiol-17beta + NADP+
estrone + NADPH
-
Substrates: rate of oxidation of estradiol-17beta at the optimum, pH 9.9, is three to four times faster than that of the reverse reaction at pH 7.4
Products: -
Products: -
r
estradiol-17beta + NADP+
estrone + NADPH
-
Substrates: -
Products: -
Products: -
r
estradiol-17beta + NADP+
estrone + NADPH
-
Substrates: maximal activity with NADP+ is approximately 1/3 of that with NAD+
Products: -
Products: -
r
estradiol-17beta + NADP+
estrone + NADPH
-
Substrates: 17beta-HSD2, important role in peripheral inactivation of androgens and estrogens, 17beta-HSD4, low substrate affinity
Products: -
Products: -
?
estradiol-17beta + NADP+
estrone + NADPH
-
Substrates: reverse reaction catalyzed by different isoforms of the enzyme
Products: -
Products: -
?
estradiol-17beta + NADP+
estrone + NADPH
-
Substrates: reversible at neutral pH, reduction of estrone at 5% of the activity of reduction of estradiol-17beta
Products: -
Products: -
r
estradiol-17beta + NADP+
estrone + NADPH
-
Substrates: 17% of the activity with NAD+
Products: -
Products: -
r
estradiol-17beta + NADP+
estrone + NADPH
-
Substrates: activity with NADP+ is only 30% of the activity with NAD+
Products: -
Products: -
r
estradiol-17beta + NADP+
estrone + NADPH + H+
-
Substrates: -
Products: -
Products: -
?
estradiol-17beta + NADP+
estrone + NADPH + H+
Substrates: -
Products: -
Products: -
?
estradiol-17beta + NADP+
estrone + NADPH + H+
Substrates: -
Products: -
Products: -
r
estradiol-17beta + NADP+
estrone + NADPH + H+
Substrates: -
Products: -
Products: -
?
estradiol-17beta + NADP+
estrone + NADPH + H+
-
Substrates: -
Products: -
Products: -
?
estradiol-17beta + NADP+
estrone + NADPH + H+
-
Substrates: -
Products: -
Products: -
?
estradiol-17beta + NADP+
estrone + NADPH + H+
-
Substrates: -
Products: -
Products: -
?
estrone + NAD(P)H
estradiol + NAD(P)+
-
Substrates: normal and tubal pregancies possess identical expression of 17HSD1 in syncytiotrophoblast cells and therefore, similar estradiol production in the placenta. Association of 17HSD1 with extravillous cells indicates that the enzyme perhaps plays a role in trophoblast invasion.Increased expression of 17HSD1 in epithelial cells of fallopian tube may lead to a local estradiol supply sufficient for maintenance of tubal pregnancy
Products: -
Products: -
?
estrone + NAD(P)H
estradiol-17beta + NAD(P)+
-
Substrates: final step in the synthesis of active estrogens
Products: -
Products: -
r
estrone + NAD(P)H
estradiol-17beta + NAD(P)+
Substrates: the enzyme produces active estradiol for cell proliferation
Products: -
Products: -
?
estrone + NAD(P)H + H+
17beta-estradiol + NAD(P)+
Substrates: the product 17beta-estradiol plays a central role in the etiology of estrogen dependent diseases
Products: -
Products: -
?
estrone + NAD(P)H + H+
17beta-estradiol + NAD(P)+
Substrates: -
Products: -
Products: -
?
estrone + NAD(P)H + H+
17beta-estradiol + NAD(P)+
Substrates: -
Products: -
Products: -
?
estrone + NAD(P)H + H+
estradiol + NAD(P)+
-
Substrates: the enzyme efficiently converts estrone to estradiol and enhances the estrogen-dependent growth of cultured MCF-7 cells in the presence of hormonally less active estrone. The reaction is reversible in vitro, but in cultured cells the production of estradiol is the predominant rection in physiological conditions
Products: -
Products: -
r
estrone + NAD(P)H + H+
estradiol + NAD(P)+
Substrates: type 12 17beta-hydroxysteroid dehydrogenase plays a role in estrogen formation. Type 12 17beta-hydroxysteroid dehydrogenase is the major estrogenic 17beta-HSD responsible for the conversion of estrone to estradiol in women, especially in the ovary, the predominant source of estrogens before menopause
Products: -
Products: -
?
estrone + NAD(P)H + H+
estradiol + NAD(P)+
-
Substrates: 17beta-hydroxysteroid dehydrogenase has a pivotal role in regulating the synthesis of estradiol within breast tumours. 17beta-hydroxysteroid dehydrogenase activity contributes to the high estradiol concentrations found in most breast tumours
Products: -
Products: -
?
estrone + NAD(P)H + H+
estradiol-17beta + NAD(P)+
-
Substrates: type 1 17beta-hydroxysteroid dehydrogenase plays a critical role in the biosynthesis of estradiol
Products: -
Products: -
?
estrone + NAD(P)H + H+
estradiol-17beta + NAD(P)+
Substrates: -
Products: -
Products: -
?
estrone + NAD(P)H + H+
estradiol-17beta + NAD(P)+
Substrates: -
Products: -
Products: -
?
estrone + NAD(P)H + H+
estradiol-17beta + NAD(P)+
Substrates: -
Products: -
Products: -
?
estrone + NAD(P)H + H+
estradiol-17beta + NAD(P)+
Substrates: 7beta-HSD type 1
Products: -
Products: -
?
estrone + NAD(P)H + H+
estradiol-17beta + NAD(P)+
Substrates: -
Products: -
Products: -
?
estrone + NAD(P)H + H+
estradiol-17beta + NAD(P)+
Substrates: -
Products: -
Products: -
?
estrone + NAD(P)H + H+
estradiol-17beta + NAD(P)+
Substrates: -
Products: -
Products: -
?
estrone + NADH
estradiol-17beta + NAD+
-
Substrates: enzyme prefers NAD+ over NADP+
Products: -
Products: -
?
estrone + NADH
estradiol-17beta + NAD+
-
Substrates: -
Products: -
Products: -
r
estrone + NADH
estradiol-17beta + NAD+
-
Substrates: type 1 enzyme, catalyzes the conversion of the low activity estrogen, estrone, into highly active estradiol, both in the gonads and in target tissues
Products: -
Products: -
?
estrone + NADH
estradiol-17beta + NAD+
Substrates: key enzyme responsible for elevated levels of 17beta-estradiol in breast tumor tissues
Products: -
Products: -
?
estrone + NADH
estradiol-17beta + NAD+
-
Substrates: exposure to epidermal growth factor slowly induces a cellular state in which enzyme activity is subject to modulation by both progesterone and estradiol
Products: -
Products: -
?
estrone + NADH
estradiol-17beta + NAD+
-
Substrates: 17beta-estradiol is a potent stimulator of certain endocrine-dependent forms of breast cancer. The enzyme catalyzes the last step in the biosynthesis of 17beta-estradiol from the less potent estrogen, estrone
Products: -
Products: -
?
estrone + NADH
estradiol-17beta + NAD+
-
Substrates: the reductive activity predominates in hormone dependent breast tumors. This gives rise to high concentrations of estradiol in breast cancer
Products: -
Products: -
?
estrone + NADH
estradiol-17beta + NAD+
-
Substrates: trans-retinoic acid increases expression of the enzyme in a dose-dependent and time-dependent manner in T47D breast cancer cells, the increased expression is associated with an increase in reductive activity of the enzyme
Products: -
Products: -
?
estrone + NADH
estradiol-17beta + NAD+
-
Substrates: reversible at neutral pH, reduction of estrone at 5% of the activity of reduction of estradiol-17beta
Products: -
Products: -
r
estrone + NADH
estradiol-17beta + NAD+
-
Substrates: reduction of estrone is 400fold slower than oxidation of 17beta-estradiol
Products: -
Products: -
r
estrone + NADH
estradiol-17beta + NAD+
-
Substrates: progesterone treatment of ovariectomized gilts stimulates oxidative activity in uterus, anterior pituitary, skeletal muscle and kidney, constitutive levels of activity in adrenals, lung and liver
Products: -
Products: -
?
estrone + NADH + H+
estradiol-17beta + NAD+
-
Substrates: -
Products: -
Products: -
?
estrone + NADH + H+
estradiol-17beta + NAD+
Substrates: 17beta-HSD1
Products: -
Products: -
?
estrone + NADPH
17beta-estradiol + NADP+
-
Substrates: -
Products: -
Products: -
r
estrone + NADPH
17beta-estradiol + NADP+
-
Substrates: convertion of the weak androgen estrone into the potent estrogen 17beta-estradiol
Products: -
Products: -
?
estrone + NADPH
17beta-estradiol + NADP+
-
Substrates: the reversible reaction constitutes an important pre-receptor control mechanism for nuclear receptor ligands, since the conversion switches between the 17beta-hydroxy receptor ligands and their inactive 17-oxo metabolites
Products: -
Products: -
r
estrone + NADPH
17beta-estradiol + NADP+
-
Substrates: isozyme 17beta-HSD1
Products: -
Products: -
?
estrone + NADPH
17beta-estradiol + NADP+
-
Substrates: substrate of e.g. isozyme 17beta-HSD3, 17beta-HSD8, and 17beta-HSD14
Products: -
Products: -
r
estrone + NADPH
17beta-estradiol + NADP+
-
Substrates: type 8 17beta-HSD can downregulate 17beta-estradiol levels in a large variety of tissues
Products: -
Products: -
?
estrone + NADPH
17beta-estradiol + NADP+
-
Substrates: type 8 17beta-HSD is substrate-specific
Products: -
Products: -
?
estrone + NADPH + H+
17beta-estradiol + NAD(P)+
Substrates: steroid hormone pathway
Products: -
Products: -
?
estrone + NADPH + H+
17beta-estradiol + NAD(P)+
Substrates: -
Products: -
Products: -
?
estrone + NADPH + H+
17beta-estradiol + NADP+
Substrates: -
Products: -
Products: -
?
estrone + NADPH + H+
17beta-estradiol + NADP+
Substrates: -
Products: -
Products: -
?
estrone + NADPH + H+
17beta-estradiol + NADP+
Substrates: most active enzyme in regards to 17beta-estradiol production
Products: -
Products: -
?
estrone + NADPH + H+
17beta-estradiol + NADP+
Substrates: -
Products: -
Products: -
?
estrone + NADPH + H+
17beta-estradiol + NADP+
Substrates: -
Products: -
Products: -
?
estrone + NADPH + H+
17beta-estradiol + NADP+
Substrates: the enzyme show positive cooperativity
Products: -
Products: -
?
estrone + NADPH + H+
estradiol + NADP+
Substrates: -
Products: -
Products: -
?
estrone + NADPH + H+
estradiol + NADP+
Substrates: kinetics demonstrates positive cooperativity
Products: -
Products: -
?
estrone + NADPH + H+
estradiol-17beta + NADP+
-
Substrates: final step in the synthesis of active estrogens
Products: -
Products: -
?
estrone + NADPH + H+
estradiol-17beta + NADP+
Substrates: final step in the synthesis of active estrogens, important in the maintenance of pregnancy
Products: -
Products: -
?
estrone + NADPH + H+
estradiol-17beta + NADP+
Substrates: final step in the synthesis of active estrogens, important in the maintenance of pregnancy
Products: -
Products: -
r
estrone + NADPH + H+
estradiol-17beta + NADP+
Substrates: -
Products: -
Products: -
?
estrone + NADPH + H+
estradiol-17beta + NADP+
Substrates: reductive activity is 1.5-3fold higher than oxidative activity
Products: -
Products: -
r
estrone + NADPH + H+
estradiol-17beta + NADP+
-
Substrates: rate of oxidation of estradiol-17beta at the optimum, pH 9.9, is three to four times faster than that of the reverse reaction at pH 7.4
Products: -
Products: -
r
estrone + NADPH + H+
estradiol-17beta + NADP+
-
Substrates: -
Products: -
Products: -
r
estrone + NADPH + H+
estradiol-17beta + NADP+
-
Substrates: type 1 enzyme is a cytosolic isoform highly specific for estradiol. Type 2 is a membrane bound isoform reactive with both estradiol and testosterone
Products: -
Products: -
?
estrone + NADPH + H+
estradiol-17beta + NADP+
-
Substrates: final step in the synthesis of active estrogens
Products: -
Products: -
?
estrone + NADPH + H+
estradiol-17beta + NADP+
Substrates: final step in the synthesis of active estrogens
Products: -
Products: -
?
estrone + NADPH + H+
estradiol-17beta + NADP+
-
Substrates: 17beta-HSD1, final step in the synthesis of active estrogens
Products: -
Products: -
?
estrone + NADPH + H+
estradiol-17beta + NADP+
-
Substrates: final step in the synthesis of active estrogens, maintenance of a proper balance of inactive estrone and active estradiol-17beta in brain
Products: -
Products: -
?
estrone + NADPH + H+
estradiol-17beta + NADP+
Substrates: -
Products: -
Products: -
?
estrone + NADPH + H+
estradiol-17beta + NADP+
-
Substrates: reverse reaction catalyzed by different isoforms of the enzyme
Products: -
Products: -
?
estrone + NADPH + H+
estradiol-17beta + NADP+
-
Substrates: final step in synthesis of estradiol
Products: -
Products: -
?
estrone + NADPH + H+
estradiol-17beta + NADP+
-
Substrates: -
Products: -
Products: -
?
estrone + NADPH + H+
estradiol-17beta + NADP+
Substrates: -
Products: -
Products: -
?
estrone + NADPH + H+
estradiol-17beta + NADP+
-
Substrates: final step in the synthesis of active estrogens
Products: -
Products: -
?
estrone + NADPH + H+
estradiol-17beta + NADP+
-
Substrates: -
Products: -
Products: -
r
estrone + NADPH + H+
estradiol-17beta + NADP+
-
Substrates: reversible at neutral pH, reduction of estrone at 5% of the activity of oxidation of estradiol-17beta
Products: -
Products: -
r
estrone + NADPH + H+
estradiol-17beta + NADP+
-
Substrates: related to nuclear maturation in oocytes
Products: -
Products: -
?
testosterone + NAD+
4-androstene-3,17-dione + NADH + H+
-
Substrates: 2.4% of the activity with estradiol
Products: -
Products: -
?
testosterone + NAD+
4-androstene-3,17-dione + NADH + H+
-
Substrates: -
Products: -
Products: -
?
testosterone + NAD+
androst-4-ene-3,17-dione + NADH + H+
Substrates: -
Products: -
Products: -
?
testosterone + NAD+
androst-4-ene-3,17-dione + NADH + H+
Substrates: -
Products: -
Products: -
?
testosterone + NAD+
androst-4-ene-3,17-dione + NADH + H+
Substrates: -
Products: -
Products: -
?
testosterone + NAD+
androstenedione + NADH + H+
Substrates: -
Products: -
Products: -
?
testosterone + NAD+
androstenedione + NADH + H+
Substrates: -
Products: -
Products: -
?
testosterone + NADP+
4-androstene-3,17-dione + NADPH + H+
-
Substrates: poor substrate
Products: -
Products: -
?
testosterone + NADP+
4-androstene-3,17-dione + NADPH + H+
-
Substrates: -
Products: androstenedione
Products: androstenedione
r
testosterone + NADP+
4-androstene-3,17-dione + NADPH + H+
-
Substrates: 75% of the activity with estradiol-17beta
Products: -
Products: -
r
testosterone + NADP+
4-androstene-3,17-dione + NADPH + H+
-
Substrates: -
Products: -
Products: -
?
testosterone + NADP+
4-androstene-3,17-dione + NADPH + H+
-
Substrates: 17beta-HSD2, important role in peripheral inactivation of androgens and estrogens
Products: -
Products: -
?
testosterone + NADP+
4-androstene-3,17-dione + NADPH + H+
-
Substrates: -
Products: -
Products: -
?
testosterone + NADP+
4-androstene-3,17-dione + NADPH + H+
-
Substrates: activity is 22fold lower than with estradiol-17beta
Products: -
Products: -
?
testosterone + NADP+
4-androstene-3,17-dione + NADPH + H+
-
Substrates: -
Products: -
Products: -
?
testosterone + NADP+
4-androstene-3,17-dione + NADPH + H+
-
Substrates: lower activity than with estradiol 17beta
Products: -
Products: -
?
testosterone + NADP+
4-androstene-3,17-dione + NADPH + H+
-
Substrates: -
Products: -
Products: -
?
testosterone + NADP+
4-androstene-3,17-dione + NADPH + H+
-
Substrates: activity is 2.3-2.8fold lower than with estradiol-17beta, depending on sample
Products: -
Products: -
?
additional information
?
-
-
Substrates: type 1 enzyme is a cytosolic isoform highly specific for estradiol. Type 2 enzyme is a membrane bound isoform reactive with both estradiol and testosterone
Products: -
Products: -
?
additional information
?
-
-
Substrates: the isozymes constitute by showing different properties a complex system ensuring cell-specific adaptation and regulation of sex steroid hormone levels, isozyme 17beta-HSD1 is the major determinant of peripheral and gonadal estradiol synthesis
Products: -
Products: -
?
additional information
?
-
-
Substrates: 17beta-HSD isozymes differ in their expression pattern, nucleotide cofactor preferences, steroid substrate specificity, and subcellular localization, detailed overview, substrate are androgens, estrogens, cholesterol, progestins, and eicosanoids, isozyme 17beta-HSD3 also shows 3beta-hydroxysteroid dehydrogenase, EC 1.1.1.51, isozyme 17beta-HSD8 also shows, to a lessser extent, NAD+-dependent testosterone oxidation to androstenedione, EC 1.1.1.63
Products: -
Products: -
?
additional information
?
-
-
Substrates: human 17beta-hydroxysteroid dehydrogenases are multifunctional enzymes, isozyme 17beta-HSD4 also performs beta-oxidation of branched fatty acids, like pristanic acid, and in bile acid synthesis, e.g. of di- and trihydroxycholestanoic acids, overview
Products: -
Products: -
?
additional information
?
-
-
Substrates: A-stereospecificity in hydrogen transfer
Products: -
Products: -
?
additional information
?
-
-
Substrates: expression is stimulated 2fold by dexamethasone but is completly downregulated by phorbol ester
Products: -
Products: -
?
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
NATURAL SUBSTRATE
NATURAL PRODUCT
REACTION DIAGRAM
ORGANISM
UNIPROT
LITERATURE
COMMENTARY
REVERSIBILITY
r=reversible
ir=irreversible
?=not specified
r=reversible
ir=irreversible
?=not specified
4-androstene-3,17-dione + NADPH + H+
testosterone + NADP+
-
Substrates: 17beta-HSD3 and 5, formation of active androgens in testis and prostate
Products: -
Products: -
?
4-estrene-3,17-dione + NADPH
4-estrene-17beta-ol-3-one + NADP+
-
Substrates: -
Products: -
Products: -
r
5alpha-androstane-3alpha,17beta-diol + NAD+
androsterone + NADH + H+
Substrates: -
Products: -
Products: -
?
5alpha-dihydrotestosterone + NADP+
5alpha-androstan-3,17-dione + NADPH
Substrates: the enzyme could play a critical role in estrogen-sensitive cells, since it inactivates 5alpha-dihydrotestosterone that generally shows antagonistic effect in the cells
Products: -
Products: -
?
androstenedione + NAD(P)H + H+
testosterone + NADP+
Substrates: -
Products: -
Products: -
?
estradiol-17beta + NAD(P)+
estrone + NAD(P)H
-
Substrates: 17beta-HSD2 and 5, key role in regulating steroid receptor occupancy in normal and tumor tissues
Products: -
Products: -
?
estradiol-17beta + NAD(P)+
estrone + NAD(P)H + H+
-
Substrates: 17beta-HSD4 is involved in etsrogen inactivation and may protect against an excessive accumulation of E2 in human ovarian epithelial cells
Products: -
Products: -
?
estradiol-17beta + NAD+
estrone + NADH + H+
-
Substrates: vitamin K2 binds 17beta-hydroxysteroid dehydrogenase 4 and modulates estrogen metabolism. Vitamin K2 decreases the estradiol-17beta/estrone ratio in cells by 25%
Products: -
Products: -
?
estradiol-17beta + NADP+
estrone + NADPH
-
Substrates: 17beta-HSD2, important role in peripheral inactivation of androgens and estrogens, 17beta-HSD4, low substrate affinity
Products: -
Products: -
?
estrone + NAD(P)H
estradiol + NAD(P)+
-
Substrates: normal and tubal pregancies possess identical expression of 17HSD1 in syncytiotrophoblast cells and therefore, similar estradiol production in the placenta. Association of 17HSD1 with extravillous cells indicates that the enzyme perhaps plays a role in trophoblast invasion.Increased expression of 17HSD1 in epithelial cells of fallopian tube may lead to a local estradiol supply sufficient for maintenance of tubal pregnancy
Products: -
Products: -
?
estrone + NAD(P)H + H+
17beta-estradiol + NAD(P)+
Substrates: the product 17beta-estradiol plays a central role in the etiology of estrogen dependent diseases
Products: -
Products: -
?
estrone + NAD(P)H + H+
estradiol-17beta + NAD(P)+
-
Substrates: type 1 17beta-hydroxysteroid dehydrogenase plays a critical role in the biosynthesis of estradiol
Products: -
Products: -
?
estrone + NADH + H+
17beta-estradiol + NAD+
Substrates: -
Products: -
Products: -
?
estrone + NADPH + H+
17beta-estradiol + NAD(P)+
Substrates: steroid hormone pathway
Products: -
Products: -
?
estrone 3-sulfate + NADPH
17beta-estradiol 3-sulfate + NADP+
-
Substrates: -
Products: -
Products: -
r
testosterone + NAD(P)+
4-androstene-3,17-dione + NAD(P)H
-
Substrates: 17beta-HSD2 and 5, key role in regulating steroid receptor occupancy in normal and tumor tissues
Products: -
Products: -
?
testosterone + NAD+
androst-4-ene-3,17-dione + NADH + H+
Substrates: -
Products: -
Products: -
?
testosterone + NAD+
DELTA4-3,17-androstendione + NADH + H+
Substrates: -
Products: -
Products: -
?
testosterone + NADP+
4-androstene-3,17-dione + NADPH + H+
-
Substrates: 17beta-HSD2, important role in peripheral inactivation of androgens and estrogens
Products: -
Products: -
?
17beta-estradiol + NAD(P)+
estrone + NAD(P)H + H+
Substrates: -
Products: -
Products: -
r
17beta-estradiol + NAD(P)+
estrone + NAD(P)H + H+
Substrates: -
Products: -
Products: -
r
17beta-estradiol + NAD+
estrone + NADH + H+
Substrates: -
Products: -
Products: -
r
17beta-estradiol + NAD+
estrone + NADH + H+
Substrates: -
Products: -
Products: -
?
17beta-estradiol + NAD+
estrone + NADH + H+
Substrates: -
Products: -
Products: -
?
17beta-estradiol + NAD+
estrone + NADH + H+
ANI02794.1
Substrates: -
Products: -
Products: -
?
17beta-estradiol + NAD+
estrone + NADH + H+
-
Substrates: -
Products: -
Products: -
?
17beta-estradiol + NAD+
estrone + NADH + H+
ANI02794.1
Substrates: -
Products: -
Products: -
?
17beta-estradiol + NADP+
estrone + NADPH + H+
Substrates: -
Products: -
Products: -
?
17beta-estradiol + NADP+
estrone + NADPH + H+
Substrates: -
Products: -
Products: -
?
estrone + NAD(P)H
estradiol-17beta + NAD(P)+
-
Substrates: final step in the synthesis of active estrogens
Products: -
Products: -
r
estrone + NAD(P)H
estradiol-17beta + NAD(P)+
Substrates: the enzyme produces active estradiol for cell proliferation
Products: -
Products: -
?
estrone + NAD(P)H + H+
estradiol + NAD(P)+
-
Substrates: the enzyme efficiently converts estrone to estradiol and enhances the estrogen-dependent growth of cultured MCF-7 cells in the presence of hormonally less active estrone. The reaction is reversible in vitro, but in cultured cells the production of estradiol is the predominant rection in physiological conditions
Products: -
Products: -
r
estrone + NAD(P)H + H+
estradiol + NAD(P)+
Substrates: type 12 17beta-hydroxysteroid dehydrogenase plays a role in estrogen formation. Type 12 17beta-hydroxysteroid dehydrogenase is the major estrogenic 17beta-HSD responsible for the conversion of estrone to estradiol in women, especially in the ovary, the predominant source of estrogens before menopause
Products: -
Products: -
?
estrone + NAD(P)H + H+
estradiol + NAD(P)+
-
Substrates: 17beta-hydroxysteroid dehydrogenase has a pivotal role in regulating the synthesis of estradiol within breast tumours. 17beta-hydroxysteroid dehydrogenase activity contributes to the high estradiol concentrations found in most breast tumours
Products: -
Products: -
?
estrone + NADH
estradiol-17beta + NAD+
-
Substrates: type 1 enzyme, catalyzes the conversion of the low activity estrogen, estrone, into highly active estradiol, both in the gonads and in target tissues
Products: -
Products: -
?
estrone + NADH
estradiol-17beta + NAD+
Substrates: key enzyme responsible for elevated levels of 17beta-estradiol in breast tumor tissues
Products: -
Products: -
?
estrone + NADH
estradiol-17beta + NAD+
-
Substrates: exposure to epidermal growth factor slowly induces a cellular state in which enzyme activity is subject to modulation by both progesterone and estradiol
Products: -
Products: -
?
estrone + NADH
estradiol-17beta + NAD+
-
Substrates: 17beta-estradiol is a potent stimulator of certain endocrine-dependent forms of breast cancer. The enzyme catalyzes the last step in the biosynthesis of 17beta-estradiol from the less potent estrogen, estrone
Products: -
Products: -
?
estrone + NADH
estradiol-17beta + NAD+
-
Substrates: the reductive activity predominates in hormone dependent breast tumors. This gives rise to high concentrations of estradiol in breast cancer
Products: -
Products: -
?
estrone + NADH
estradiol-17beta + NAD+
-
Substrates: trans-retinoic acid increases expression of the enzyme in a dose-dependent and time-dependent manner in T47D breast cancer cells, the increased expression is associated with an increase in reductive activity of the enzyme
Products: -
Products: -
?
estrone + NADH
estradiol-17beta + NAD+
-
Substrates: progesterone treatment of ovariectomized gilts stimulates oxidative activity in uterus, anterior pituitary, skeletal muscle and kidney, constitutive levels of activity in adrenals, lung and liver
Products: -
Products: -
?
estrone + NADPH
17beta-estradiol + NADP+
-
Substrates: -
Products: -
Products: -
r
estrone + NADPH
17beta-estradiol + NADP+
-
Substrates: convertion of the weak androgen estrone into the potent estrogen 17beta-estradiol
Products: -
Products: -
?
estrone + NADPH
17beta-estradiol + NADP+
-
Substrates: the reversible reaction constitutes an important pre-receptor control mechanism for nuclear receptor ligands, since the conversion switches between the 17beta-hydroxy receptor ligands and their inactive 17-oxo metabolites
Products: -
Products: -
r
estrone + NADPH
17beta-estradiol + NADP+
-
Substrates: isozyme 17beta-HSD1
Products: -
Products: -
?
estrone + NADPH
17beta-estradiol + NADP+
-
Substrates: type 8 17beta-HSD can downregulate 17beta-estradiol levels in a large variety of tissues
Products: -
Products: -
?
estrone + NADPH + H+
17beta-estradiol + NADP+
Substrates: -
Products: -
Products: -
?
estrone + NADPH + H+
17beta-estradiol + NADP+
Substrates: most active enzyme in regards to 17beta-estradiol production
Products: -
Products: -
?
estrone + NADPH + H+
17beta-estradiol + NADP+
Substrates: -
Products: -
Products: -
?
estrone + NADPH + H+
estradiol-17beta + NADP+
-
Substrates: final step in the synthesis of active estrogens
Products: -
Products: -
?
estrone + NADPH + H+
estradiol-17beta + NADP+
Substrates: final step in the synthesis of active estrogens, important in the maintenance of pregnancy
Products: -
Products: -
?
estrone + NADPH + H+
estradiol-17beta + NADP+
Substrates: final step in the synthesis of active estrogens, important in the maintenance of pregnancy
Products: -
Products: -
r
estrone + NADPH + H+
estradiol-17beta + NADP+
-
Substrates: final step in the synthesis of active estrogens
Products: -
Products: -
?
estrone + NADPH + H+
estradiol-17beta + NADP+
Substrates: final step in the synthesis of active estrogens
Products: -
Products: -
?
estrone + NADPH + H+
estradiol-17beta + NADP+
-
Substrates: 17beta-HSD1, final step in the synthesis of active estrogens
Products: -
Products: -
?
estrone + NADPH + H+
estradiol-17beta + NADP+
-
Substrates: final step in the synthesis of active estrogens, maintenance of a proper balance of inactive estrone and active estradiol-17beta in brain
Products: -
Products: -
?
estrone + NADPH + H+
estradiol-17beta + NADP+
-
Substrates: final step in synthesis of estradiol
Products: -
Products: -
?
estrone + NADPH + H+
estradiol-17beta + NADP+
-
Substrates: final step in the synthesis of active estrogens
Products: -
Products: -
?
estrone + NADPH + H+
estradiol-17beta + NADP+
-
Substrates: related to nuclear maturation in oocytes
Products: -
Products: -
?
testosterone + NAD+
androstenedione + NADH + H+
Substrates: -
Products: -
Products: -
?
testosterone + NAD+
androstenedione + NADH + H+
Substrates: -
Products: -
Products: -
?
additional information
?
-
-
Substrates: the isozymes constitute by showing different properties a complex system ensuring cell-specific adaptation and regulation of sex steroid hormone levels, isozyme 17beta-HSD1 is the major determinant of peripheral and gonadal estradiol synthesis
Products: -
Products: -
?
additional information
?
-
-
Substrates: expression is stimulated 2fold by dexamethasone but is completly downregulated by phorbol ester
Products: -
Products: -
?
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
COFACTOR
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
additional information
-
cofactor binding mechanism and specificity involving residues Tyr49, Thr202, Ala50, and Asn51, overview
-
NAD+
-
cofactor
NAD+
-
activity with NAD+ is 2.2-3.8fold lower than with NADP+, depending on sample
NADP+
mutant enzyme Y49D show activity with NADP+, wild-type enzyme shows no activity
NADPH
mutant enzyme Y49D show activity with NADPH, wild-type enzyme shows no activity
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
METALS and IONS
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
(10R,13S,17R)-10,13-dimethyl-1,2,7,8,9,10,11,12,13,14,15,16-dodecahydro-3'H-spiro[cyclopenta[a]phenanthrene-17,2'-furan]-3,5',6(4'H)-trione
-
0.003 mM, 45% inhibition, substrate: 4-androstene-3,17-dione
(10R,13S,17R)-10,13-dimethyl-1,6,7,8,9,10,11,12,13,14,15,16-dodecahydro-3'H-spiro[cyclopenta[a]phenanthrene-17,2'-furan]-3,5'(2H,4'H)-dione
-
0.003 mM, 61% inhibition, substrate: 4-androstene-3,17-dione; 0.003 mM, 63% inhibition, substrate: 4-androstene-3,17-dione
(13alpha)-3-hydroxyestra-1(10),2,4-trien-17-one
inhibits the enzyme activity effectively, enzyme affinity is similar to that of the natural estrone substrate
(13S,17R)-13-methyl-4',5',6,7,8,9,11,12,13,14,15,16-dodecahydro-3'H-spiro[cyclopenta[a]phenanthrene-17,2'-furan]-3,5'-diol
-
0.003 mM, 61% inhibition, substrate: 4-androstene-3,17-dione
(13S,17R)-3-hydroxy-13-methyl-3',4',6,7,8,9,11,12,13,14,15,16-dodecahydro-5'H-spiro[cyclopenta[a]phenanthrene-17,2'-furan]-5'-one
-
0.003 mM, 79% inhibition, substrate: 4-androstene-3,17-dione
(13S,17R)-3-hydroxy-13-methyl-5'-propyl-4',5',6,7,8,9,11,12,13,14,15,16-dodecahydrospiro[cyclopenta[a]phenanthrene-17,2'-pyran]-6'(3'H)-one
-
0.003 mM, 83% inhibition, substrate: 4-androstene-3,17-dione
(13S,17R)-3-hydroxy-5',13-dimethyl-4',5',6,7,8,9,11,12,13,14,15,16-dodecahydrospiro[cyclopenta[a]phenanthrene-17,2'-pyran]-6'(3'H)-one
-
0.003 mM, 94% inhibition, substrate: 4-androstene-3,17-dione
(13S,17R)-5',13-dimethyl-4',5',6,7,8,9,11,12,13,14,15,16-dodecahydrospiro[cyclopenta[a]phenanthrene-17,2'-pyran]-6'(3'H)-one
-
0.003 mM, 94% inhibition, substrate: 4-androstene-3,17-dione
(13S,17R)-5',5',13-trimethyl-4',5',6,7,8,9,11,12,13,14,15,16-dodecahydrospiro[cyclopenta[a]phenanthrene-17,2'-pyran]-6'(3'H)-one
-
0.003 mM, 95% inhibition, substrate: 4-androstene-3,17-dione
(13S,17S)-13-methyl-4',5',6,7,8,9,11,12,13,14,15,16-dodecahydrospiro[cyclopenta[a]phenanthrene-17,2'-pyran]-6'(3'H)-one
-
0.003 mM, 95% inhibition, substrate: 4-androstene-3,17-dione
(13S,17S)-3-hydroxy-13-methyl-3',4',6,7,8,9,11,12,13,14,15,16-dodecahydro-5'H-spiro[cyclopenta[a]phenanthrene-17,2'-furan]-5'-one
-
0.003 mM, 45% inhibition, substrate: 4-androstene-3,17-dione
(13S,17S)-3-hydroxy-13-methyl-4',5',6,7,8,9,11,12,13,14,15,16-dodecahydrospiro[cyclopenta[a]phenanthrene-17,2'-pyran]-6'(3'H)-one
-
0.003 mM, 95% inhibition, substrate: 4-androstene-3,17-dione
(13S,17S)-3-hydroxy-13-methyl-6,7,8,9,11,12,13,14,15,16-decahydro-7'H-spiro[cyclopenta[a]phenanthrene-17,2'-oxepan]-7'-one
-
0.003 mM, 93% inhibition, substrate: 4-androstene-3,17-dione
(15alpha)-3-hydroxy-N-(5-methyl-1,3-thiazol-2-yl)-17-oxoestra-1(10),2,4-triene-15-carboxamide
-
(15beta)-15-(4-morpholin-4-yl-4-oxobutyl)-17-oxoestra-1(10),2,4-trien-3-yl sulfamate
0.0001 mM, 10% inhibition
(16alpa,17beta)-16-(3-bromopropyl)estra-1(10),2,4-triene-3,17-diol
EM-251
(16beta)-3-hydroxy-16-methyl-17-oxoestra-1(10),2,4-triene-16-carbonitrile
-
(16Z)-3-hydroxy-16-(2,2,2-trifluoro-1-hydroxyethylidene)estra-1(10),2,4-trien-17-one
-
(17beta)-3,17-dihydroxy-N-(pyridin-3-ylmethyl)estra-1(10),2,4-triene-16-carboxamide
-
(1Z)-N'-[[(3,5-dimethylisoxazol-4-yl)carbonyl]oxy]-2-[4-(1,2,3-thiadiazol-4-yl)phenyl]ethanimidamide
-
(2'R,13S)-3-hydroxy-13-methyl-6,7,8,9,11,12,13,14,15,16-decahydrospiro[cyclopenta[a]phenanthrene-17,2'-pyran]-6'(3'H)-one
-
0.003 mM, 92% inhibition, substrate: 4-androstene-3,17-dione
(2'R,13S)-3-hydroxy-4',13-dimethyl-4',5',6,7,8,9,11,12,13,14,15,16-dodecahydrospiro[cyclopenta[a]phenanthrene-17,2'-pyran]-6'(3'H)-one
-
0.003 mM, 94% inhibition, substrate: 4-androstene-3,17-dione
(2'R,13S)-3-hydroxy-5',5',13-trimethyl-4',5',6,7,8,9,11,12,13,14,15,16-dodecahydrospiro[cyclopenta[a]phenanthrene-17,2'-pyran]-6'(3'H)-one
-
0.003 mM, 94% inhibition, substrate: 4-androstene-3,17-dione
(2'R,13S)-5'-cyclopropyl-3-hydroxy-13-methyl-4',5',6,7,8,9,11,12,13,14,15,16-dodecahydrospiro[cyclopenta[a]phenanthrene-17,2'-pyran]-6'(3'H)-one
-
0.003 mM, 91% inhibition, substrate: 4-androstene-3,17-dione
(2'R,13S)-methyl 3-hydroxy-13-methyl-6'-oxo-3',4',5',6,6',7,8,9,11,12,13,14,15,16-tetradecahydrospiro[cyclopenta[a]phenanthrene-17,2'-pyran]-5'-carboxylate
-
0.003 mM, 92% inhibition, substrate: 4-androstene-3,17-dione
(2E)-3-[2-hydroxy-6-(3-hydroxyphenyl)-1-naphthyl]-N-methylacrylamide
58% inhibition at 0.001 mM
(2E)-3-[2-hydroxy-6-(3-hydroxyphenyl)-1-naphthyl]-N-phenylacrylamide
60% inhibition at 0.001 mM
(2R,4aS,4bR,10bS,12aS)-9-chloro-2-fluoro-8-hydroxy-12a-methyl-3,4,4a,4b,5,6,10b,11,12,12a-decahydrochrysen-1(2H)-one
-
(2S,4aS,4bR,10bS,12aS)-9-chloro-2-fluoro-8-hydroxy-12a-methyl-3,4,4a,4b,5,6,10b,11,12,12a-decahydrochrysen-1(2H)-one
-
(2Z,2'E)-N,N'-1H-1,5-benzodiazepine-2,4-diylbis(3-phenylprop-2-enamide)
30% inhibition at 0.006 mM
(3-amino-5-[13-[(16beta,17beta)-3,17-dihydroxyestra-1(10),2,4-trien-16-yl]tridecyl]phenyl)acetic acid
-
(3-[(4-aminophenyl)carbonyl]-5-[13-[(16beta,17beta)-3,17-dihydroxyestra-1(10),2,4-trien-16-yl]tridecyl]phenyl)acetic acid
-
(3-[13-[(16beta,17beta)-3,17-dihydroxyestra-1(10),2,4-trien-16-yl]tridecyl]phenyl)acetic acid
-
(4aR,6aS,7S)-7-[heptyl(methyl)amino]-1,4a,6a-trimethylhexadecahydro-2H-indeno[5,4-f]quinolin-2-one
-
(4aR,6aS,7S)-7-[heptyl(methyl)amino]-4a,6a-dimethylhexadecahydro-2H-indeno[5,4-f]quinolin-2-one
-
(4aS,4bR,10bS,12aS)-8-hydroxy-12a-methyl-9-(2-phenylethyl)-3,4,4a,4b,5,6,10b,11,12,12a-decahydrochrysen-1(2H)-one
-
(4aS,4bR,10bS,12aS)-8-hydroxy-12a-methyl-9-prop-2-en-1-yl-3,4,4a,4b,5,6,10b,11,12,12a-decahydrochrysen-1(2H)-one
-
(4aS,4bR,10bS,12aS)-8-hydroxy-9-iodo-12a-methyl-3,4,4a,4b,5,6,10b,11,12,12a-decahydrochrysen-1(2H)-one
-
(4aS,4bR,10bS,12aS)-8-hydroxy-9-methoxy-12a-methyl-3,4,4a,4b,5,6,10b,11,12,12a-decahydrochrysen-1(2H)-one
-
(4aS,4bR,10bS,12aS)-9-bromo-8-hydroxy-12a-methyl-3,4,4a,4b,5,6,10b,11,12,12a-decahydrochrysen-1(2H)-one
-
(4aS,4bR,10bS,12aS)-9-chloro-8-hydroxy-12a-methyl-3,4,4a,4b,5,6,10b,11,12,12a-decahydrochrysen-1(2H)-one
-
(4R,5R)-4-(2-fluorophenyl)-5-[hydroxy(5-phenylthiophen-2-yl)methyl]-1-methylpyrrolidin-2-one
-
(4R,5R)-5-[hydroxy[5-(pyridin-3-yl)thiophen-2-yl]methyl]-1-methyl-4-phenylpyrrolidin-2-one
-
(4S,5S)-5-[biphenyl-3-yl(hydroxy)methyl]-4-(2-fluorophenyl)-1-methylpyrrolidin-2-one
-
(4S,5S)-5-[biphenyl-4-yl(hydroxy)methyl]-4-(2-fluorophenyl)-1-methylpyrrolidin-2-one
-
(4S,5S)-5-[hydroxy[5-(pyridin-3-yl)thiophen-2-yl]methyl]-1-methyl-4-phenylpyrrolidin-2-one
-
(6-hydroxy-1,3-benzothiazol-2-yl)(3-hydroxyphenyl)methanone
modeling of binding to crystal structure shows five hydrogen bond interactions and a cation-pi-interaction
(6aS)-2-(benzyloxy)-6a-methyl-9-[(2E)-4-morpholin-4-yl-4-oxobut-2-en-1-yl]-5,6,6a,10,10a,10b,11,12-octahydro-4bH-naphtho[2',1':4,5]indeno[2,1-d]isoxazole
0.0001 mM, 21% inhibition
(6aS)-2-hydroxy-6a,8-dimethyl-5,6,6a,7,8,10,10a,10b,11,12-decahydronaphtho[2',1':4,5]indeno[1,2-c]pyrazol-9(4bH)-one
0.01 mM, 32% inhibition
(6aS)-2-hydroxy-6a-methyl-5,6,6a,7,8,10,10a,10b,11,12-decahydronaphtho[2',1':4,5]indeno[1,2-c]pyrazol-9(4bH)-one
0.01 mM, 86% inhibition
(6aS)-2-hydroxy-6a-methyl-N-(2-pyridin-3-ylethyl)-4b,5,6,6a,8,10,10a,10b,11,12-decahydronaphtho[2',1':4,5]indeno[1,2-c]pyrazole-9-carboxamide
(6aS)-2-hydroxy-6a-methyl-N-(pyridin-2-ylmethyl)-4b,5,6,6a,8,10,10a,10b,11,12-decahydronaphtho[2',1':4,5]indeno[1,2-c]pyrazole-9-carboxamide
(6aS)-2-hydroxy-6a-methyl-N-(pyridin-3-ylmethyl)-4b,5,6,6a,8,10,10a,10b,11,12-decahydronaphtho[2',1':4,5]indeno[1,2-c]pyrazole-9-carboxamide
(6aS)-2-hydroxy-6a-methyl-N-[(1-methyl-1H-pyrrol-2-yl)methyl]-4b,5,6,6a,8,10,10a,10b,11,12-decahydronaphtho[2',1':4,5]indeno[1,2-c]pyrazole-9-carboxamide
0.01 mM, 90% inhibition, IC50: 0.0023 mM
(6aS)-2-hydroxy-6a-methyl-N-[(5-methylpyrazin-2-yl)methyl]-4b,5,6,6a,8,10,10a,10b,11,12-decahydronaphtho[2',1':4,5]indeno[1,2-c]pyrazole-9-carboxamide
0.01 mM, 80% inhibition
(6aS)-3-ethyl-2-hydroxy-6a-methyl-N-(2-pyridin-3-ylethyl)-4b,5,6,6a,8,10,10a,10b,11,12-decahydronaphtho[2',1':4,5]indeno[1,2-c]pyrazole-9-carboxamide
-
(6aS)-6a-methyl-4b,5,6,6a,8,10,10a,10b,11,12-decahydronaphtho[2',1':4,5]indeno[1,2-c]pyrazol-2-ol
-
(6aS)-6a-methyl-9-(4-morpholin-4-yl-4-oxobutyl)-4b,5,6,6a,7,10,10a,10b,11,12-decahydronaphtho[2',1':4,5]indeno[1,2-c]pyrazol-2-ol
0.0001 mM, 53% inhibition
(6aS)-6a-methyl-9-(trifluoromethyl)-4b,6,6a,7,9a,10,10a,10b,11,12-decahydronaphtho[2',1':4,5]indeno[1,2-c]pyrazole-2,6b(5H)-diol
-
(6aS)-8-(2-methoxyethyl)-6a-methyl-4b,5,6,6a,8,10,10a,10b,11,12-decahydronaphtho[2',1':4,5]indeno[1,2-c]pyrazol-2-ol
-
(6aS)-9-(hydroxymethyl)-6a-methyl-4b,5,6,6a,8,10,10a,10b,11,12-decahydronaphtho[2',1':4,5]indeno[1,2-c]pyrazol-2-ol
-
(6aS,6bR,10aR)-2-hydroxy-6a-methyl-5,6,6a,6b,9,10,10a,11,11a,11b,12,13-dodecahydronaphtho[2',1':4,5]indeno[1,2-b]pyran-8(4bH)-one
-
0.003 mM, 52% inhibition, substrate: 4-androstene-3,17-dione
(6aS,6bS,10aS)-2-hydroxy-6a-methyl-5,6,6a,6b,9,10,10a,11,11a,11b,12,13-dodecahydronaphtho[2',1':4,5]indeno[1,2-b]pyran-8(4bH)-one
-
0.003 mM, 85% inhibition, substrate: 4-androstene-3,17-dione
(6aS,6bS,11aS)-2-hydroxy-6a-methyl-4b,5,6,6a,6b,9,10,11,11a,12,12a,12b,13,14-tetradecahydro-8H-naphtho[2',1':4,5]indeno[1,2-b]oxepin-8-one
-
0.003 mM, 91% inhibition, substrate: 4-androstene-3,17-dione
(6aS,6bS,9aR)-2-hydroxy-6a-methyl-4b,5,6,6a,6b,9,9a,10,10a,10b,11,12-dodecahydro-8H-naphtho[2',1':4,5]indeno[1,2-b]furan-8-one
-
0.003 mM, 62% inhibition, substrate: 4-androstene-3,17-dione
(8R,9S,13S,14S,17S)-3-hydroxy-13-methyl-4',5',6,7,8,9,11,12,13,14,15,16-dodecahydrospiro[cyclopenta[a]phenanthrene-17,2'-pyran]-6'(3'H)-one
85% inhibition at 0.001 mM
(S)-2-Methoxy-6a-methyl-5,6,6a,10,10a,10b,11,12-octahydro-4bH-7-oxa-8-aza-pentaleno[2,1-a]phenanthrene
-
-
(S)-6a-Methyl-5,6,6a,10,10a,10b,11,12-octahydro-4bH-7-oxa-8-aza-pentaleno[2,1-a]phenanthren-2-ol
-
-
([4-[(3-methoxyphenyl)methyl]piperazin-1-yl]methyl)-17alpha-methylandrostane-3alpha,17beta-diol
0.1 mM, 21.9% inhibition in the reaction with allopregnanolone. 0.3 mM, 22.6% inhibition in the reaction with 17beta-estradiol
([4-[(3-methoxyphenyl)methyl]piperazin-1-yl]methyl)-17alpha-pregn-20-yne-3alpha,17-diol
0.1 mM, 20.0% inhibition in the reaction with allopregnanolone. 0.3 mM, 44.5% inhibition in the reaction with 17beta-estradiol
1-(3'-ethyl-4'-hydroxy-biphenyl-4-yl)-ethanone
37°C, 0.01 mM, 51% inhibition, substrate: estradiol-17beta, 7beta-HSD type 2; 37°C, 0.01 mM, 73% inhibition, substrate: estrone, 7beta-HSD type 1; 73% inhibition at 0.001 mM
1-(3-ethyl-4'-hydroxy-biphenyl-4-yl)-ethanone
37°C, 0.01 mM, 71% inhibition, substrate: estrone, 7beta-HSD type 1; 71% inhibition at 0.001 mM
1-(4'-hydroxy-2'-methyl-biphenyl-4-yl)-ethanone
89% inhibition at 0.001 mM
1-(4'-hydroxy-2'_methyl-biphenyl-4-yl)-ethanone
37°C, 0.01 mM, 89% inhibition, substrate: estrone, 7beta-HSD type 1
1-(4'-hydroxy-biphenyl-4-yl)-ethanone
37°C, 01 mM, 97% inhibition, substrate: estrone, 7beta-HSD type 1; 97% inhibition at 0.001 mM
1-(4-hydroxy-phenyl)-butan-1-one
-
weak inhibitor with 35.1% inhibition at 0.1 mM
1-(4-hydroxy-phenyl)-decan-1-one
-
weak inhibitor with 28.2% inhibition at 0.1 mM
1-(4-hydroxy-phenyl)-dodecan-1-one
-
weak inhibitor with 42.5% inhibition at 0.1 mM
1-(4-hydroxy-phenyl)-ethanone
-
weak inhibitor with 20.8% inhibition at 0.1 mM
1-(4-hydroxy-phenyl)-heptan-1-one
-
weak inhibitor with 47.6% inhibition at 0.1 mM
1-(4-hydroxy-phenyl)-hexan-1-one
-
weak inhibitor with 45.7% inhibition at 0.1 mM
1-(4-hydroxy-phenyl)-octan-1-one
-
weak inhibitor with 36.9% inhibition at 0.1 mM
1-(4-hydroxy-phenyl)-pentan-1-one
-
weak inhibitor with 39.8% inhibition at 0.1 mM
1-(4-hydroxy-phenyl)-propan-1-one
-
weak inhibitor with 17.5% inhibition at 0.1 mM
1-(4-hydroxy-phenyl)-undecan-1-one
-
weak inhibitor with 30.6% inhibition at 0.1 mM
1-(4-hydroxyphenyl)-nonan-1-one
-
weak inhibitor with 36.3% inhibition at 0.1 mM
1-(6-hydroxy-9H-fluoren-2-yl)-ethanone
37°C, 0.01 mM, 86% inhibition, substrate: estrone, 7beta-HSD type 1; 86% inhibition at 0.001 mM
1-Chloro-4-(2,2-dichloro-1-(5-Chloro-phenyl)-ethyl)-benzene
-
oxidation of estradiol
1-Chloro-4-(2,2-dichloro-1-(6-Chloro-phenyl)-ethyl)-benzene
-
oxidation of estradiol
1-[(3-hydroxyphenyl)sulfanyl]-5-oxo-4,5,7,8,9,10,11,13-octahydro-3H-indeno[2',1':4,5]pyrimido[1,2-a]azepine-2-carbaldehyde
-
1-[2-[4-(6-Methoxy-2-phenyl-3,4-dihydro-naphthalen-1-yl)-phenoxy]-ethyl]-pyrrolidine
-
oxidation of estradiol
1-[5-(3'-hydroxybiphenyl-3-yl)-2-thienyl]ethanone
0.001 mM, 10 min, 22% inhibition; 0.001 mM, 10 min, 23% inhibition
1-[5-(3'-Hydroxybiphenyl-4-yl)-2-thienyl]ethanone
0.001 mM, 10 min, 10% inhibition; 0.001 mM, 10 min, 38% inhibition
10-((13S,16S,17S)-3,17-Dihydroxy-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-16-yl)-decanoic acid 5-(6-amino-purin-9-yl)-3,4-dihydroxy-tetrahydro-furan-2-ylmethyl ester
-
IC50: 140 nM
11-((13S,17R)-17-Ethynyl-3,17-dihydroxy-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-7-yl)-undecanoic acid butyl-methyl-amide
-
-
13-oxo-4-(phenylsulfanyl)-1,2,7,8,9,10,11,13-octahydro[1]benzothieno[2',3':4,5]pyrimido[1,2-a]azepine-3-carbaldehyde
0.001 mM, 80% inhibition
13-oxo-4-(propylsulfanyl)-1,2,7,8,9,10,11,13-octahydro[1]benzothieno[2',3':4,5]pyrimido[1,2-a]azepine-3-carbaldehyde
0.001 mM, 74% inhibition
16-oxo-estrone
-
40 mM, pH 8.5, t1/2: 0.8-1 h, at pH 7.2 inhibition is competitive against estradiol and non-competitive against NAD+
16alpha-bromopropyl-estradiol
-
IC50: 0.00046 mM, reduction of estrone, the inhibitor is totally inactive against type 2 17beta-HSD and type type 1 17beta-HSD
17,17-difluoro-3beta-([4-[(3-methoxyphenyl)methyl]piperazin-1-yl]methyl)androstan-3alpha-ol
0.1 mM, 38.6% inhibition in the reaction with allopregnanolone. 0.3 mM, 13.3% inhibition in the reaction with 17beta-estradiol
17-(1-hydroxy-prop-2-ynyl)-10,13-dimethyl-1,2,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-cyclopenta[a]phenanthren-3-one
-
suicide inhibitor
2'-AMP
-
competitive with respect to NAD(H) or NADP(H) and noncompetitive with respect to the steroid
2'-methoxy-N-(3-methoxyphenyl)-N-methyl-[1,1'-biphenyl]-4-sulfonamide
23% inhibition at 0.001 mM
2'-methoxy-N-methyl-N-phenyl-[1,1'-biphenyl]-4-sulfonamide
10% inhibition at 0.001 mM
2,2'-diimino-7,7'-dimethyl-5,5'-bis(1-methylethyl)-2H,2'H-8,8'-binaphtho[1,8-bc]furan-3,3',4,4'-tetrol
-
2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)ethyl (2E)-3-(3,4,5-trimethoxyphenyl)prop-2-enoate
44% inhibition at 0.006 mM
2-(2,6-dibromo-4-methylphenoxy)-N'-[(E)-(2,4-dihydroxy-6-methylphenyl)methylidene]acetohydrazide
64% inhibition at 0.02 mM
2-(2,6-dibromo-4-methylphenoxy)-N'-[(E)-(2,4-dimethoxyphenyl)methylidene]acetohydrazide
38% inhibition at 0.02 mM
2-(2-bromo-4,6-dimethylphenoxy)-N'-[(E)-(2,4-dihydroxyphenyl)methylidene]acetohydrazide
91% inhibition at 0.02 mM
2-(2-bromo-4-methylphenoxy)-N'-[(1E)-1-(2,4-dihydroxyphenyl)ethylidene]acetohydrazide
-
2-(3-hydroxyphenyl)quinolin-6-ol
0.001 mM, 63% inhibition, substrate: estrone
2-chloro-4-[5-(2,6-difluoro-3-hydroxybenzoyl)thiophen-2-yl]phenyl sulfamate
dual inhibitor, acts both on steroid sulfatase and hydroxy steroid dehydrogenase 17beta-HSD1, reverses estrogen-induced T-47D cell proliferation
2-ethyl-17-oxo-16-[2-oxo-2-[(pyridin-3-ylmethyl)amino]ethyl]estra-1(10),2,4-trien-3-yl sulfamate
-
2-ethyl-3-sulfamoyloxy-17-oxo-estra-1,3,5(10)-trien-16-methylcarboxylic acid-S-alpha-methylbenzyl amide
-
50% inhibition at 0.001 mM
2-ethyl-3-sulfamoyloxy-17-oxo-estra-1,3,5(10)-trien-16alpha/beta-methylcarboxylic acid-(5-methylpyrimidinyl-2-ylmethyl)amide
-
37% inhibition at 0.001 mM
2-ethyl-3-sulfamoyloxy-17-oxo-estra-1,3,5(10)-trien-16alpha/beta-methylcarboxylic acid-(pyridine-3-ylmethyl)amide
-
64% inhibition at 0.01 mM
2-hydroxy-6-(3-hydroxyphenyl)-N-(5-methyl-1,3,4-thiadiazol-2-yl)-1-naphthamide
73% inhibition at 0.001 mM
2-hydroxy-6-(3-hydroxyphenyl)-N-methyl-1-naphthamide
76% inhibition at 0.001 mM
2-hydroxy-6-(3-hydroxyphenyl)-N-phenyl-1-naphthamide
80% inhibition at 0.001 mM
2-hydroxy-N,6-bis(3-hydroxyphenyl)-1-naphthamide
70% inhibition at 0.001 mM
2-[(16beta)-2-ethyl-3-hydroxy-17-oxoestra-1(10),2,4-trien-16-yl]-N-(pyridin-3-ylmethyl)acetamide
-
2-[2-ethyl-3-hydroxy-17-oxoestra-1(10),2,4-trien-16-yl]-N-(pyridin-2-ylmethyl)acetamide
-
2-[2-ethyl-3-hydroxy-17-oxoestra-1(10),2,4-trien-16-yl]-N-(pyridin-3-ylmethyl)acetamide
-
2-[3-hydroxy-17-oxoestra-1(10),2,4-trien-16-yl]-N-(2-pyridin-2-ylethyl)acetamide
0.01 mM, 58% inhibition
2-[3-hydroxy-17-oxoestra-1(10),2,4-trien-16-yl]-N-(pyridin-2-ylmethyl)acetamide
0.01 mM, 82% inhibition
2-[3-hydroxy-17-oxoestra-1(10),2,4-trien-16-yl]-N-(pyridin-3-ylmethyl)acetamide
-
2-[5-(3-ethyl-4-hydroxyphenyl)-1-oxo-indan-2-yl]-N-pyridin-3-ylmethyl-acetamide
37°C, 0.001 mM, 39% inhibition, substrate: estrone, 7beta-HSD type 1; 39% inhibition at 0.001 mM
3'-(1-benzothien-2-yl)biphenyl-3-ol
0.001 mM, 10 min, 39% inhibition; 0.001 mM, 10 min, 49% inhibition
3'-(2-thienyl)biphenyl-3-ol
0.001 mM, 10 min, 40% inhibition; 0.001 mM, 10 min, 48% inhibition
3'-(5-chloro-2-thienyl)biphenyl-3-ol
0.001 mM, 10 min, 31% inhibition; 0.001 mM, 10 min, 71% inhibition
3'-(5-methyl-2-thienyl)biphenyl-3-ol
0.001 mM, 10 min, 32% inhibition; 0.001 mM, 10 min, 36% inhibition
3'-hydroxy-N-(3-hydroxybenzyl)-N-methyl-[1,10-biphenyl]-4-sulfonamide
57% inhibition at 0.001 mM
3'-hydroxy-N-(3-hydroxyphenyl)-N-methyl-[1,10-biphenyl]-3-sulfonamide
42% inhibition at 0.001 mM; 68% inhibition at 0.001 mM
3'-hydroxy-N-(3-hydroxyphenyl)-N-methyl-[1,10-biphenyl]-4-sulfonamide
14% inhibition at 0.001 mM; 50% inhibition at 0.001 mM
3'-hydroxy-N-(3-hydroxyphenyl)-N-methylbiphenyl-3-carboxamide
35% inhibition
3'-hydroxy-N-(3-methoxyphenyl)-N-methyl-[1,10-biphenyl]-4-sulfonamide
15% inhibition at 0.001 mM; 38% inhibition at 0.001 mM
3'-methoxy-N-(2-methoxyphenyl)-N-methyl-[1,1'-biphenyl]-4-sulfonamide
10% inhibition at 0.001 mM; 17% inhibition at 0.001 mM
3'-methoxy-N-(3-methoxybenzyl)-N-methyl-[1,10-biphenyl]-4-sulfonamide
45% inhibition at 0.001 mM
3'-methoxy-N-(3-methoxybenzyl)-N-methylbiphenyl-3-carboxamide
11% inhibition
3'-methoxy-N-(3-methoxyphenyl)-N-methyl-[1,1'-biphenyl]-4-sulfonamide
10% inhibition at 0.001 mM; 27% inhibition at 0.001 mM
3'-methoxy-N-(3-methoxyphenyl)-N-methyl-[1,10-biphenyl]-3-sulfonamide
26% inhibition at 0.001 mM
3'-methoxy-N-(3-methoxyphenyl)-N-methylbiphenyl-4-carboxamide
35% inhibition at 0.001 mM
3'-methoxy-N-(4-methoxyphenyl)-N-methyl-[1,1'-biphenyl]-4-sulfonamide
22% inhibition at 0.001 mM
3,3',4,4'-tetrahydroxy-7,7'-dimethyl-5,5'-bis(1-methylethyl)-2H,2'H-8,8'-binaphtho[1,8-bc]furan-2,2'-dione
-
3,5,7,4'-tetrahydroxyflavone
-
IC50 between 0.001 and 0.005 mM, reduction of estra-4-en-3,17-dione
3-(17beta-hydroxy-3-methoxy-estra-1,3,5(10)-trien-16beta-ylmethyl)-benzamide
0.01 mM, 90% inhibition, substrate: estrone
3-(17beta-hydroxy-estra-1,3,5(10)-trien-16beta-ylmethyl)-benzamide
0.01 mM, 79% inhibition, substrate: estrone
3-(2-furylmethyl)-8-hydroxy-2-(2-phenylethyl)[1]benzothieno[2,3-d]pyrimidin-4(3H)-one
33% inhibition at 100 nM, 78% inhibition at 0.001 mM
3-(3,17beta-dihydroxy-2-methoxy-estra-1,3,5(10)-trien-16beta-ylmethyl)-benzamide
0.01 mM, 81% inhibition, substrate: estrone
3-(3,17beta-dihydroxy-estra-1,3,5(10)-trien-16beta-ylmethyl)-benzamide
0.001 mM, 94% inhibition, substrate: estrone
3-(3-hydroxy-17-oxo-estra-1,3,5(10)-trien-16beta-ylmethyl)-benzamide
0.001 mM, 88% inhibition, substrate: estrone
3-(3-hydroxyphenyl)quinolin-7-ol
0.001 mM, 57% inhibition, substrate: estrone
3-(3-methoxy-17-oxo-estra-1,3,5(10)-trien-16beta-ylmethyl)-benzamide
0.01 mM, 76% inhibition, substrate: estrone
3-(6-hydroxy-2-naphthyl)benzoic acid
0.001 mM, 76% inhibition, substrate: estrone
3-(hydroxymethyl)-4-(phenylsulfanyl)-2,7,8,9,10,11-hexahydro[1]benzothieno[2',3':4,5]pyrimido[1,2-a]azepin-13(1H)-one
0.001 mM, 52% inhibition
3-([(16beta,17beta)-3,17-dihydroxyestra-1(10),2,4-trien-16-yl]methyl)benzamide
-
-
3-([(16beta,17beta)-3-(2-bromoethyl)-17-hydroxyestra-1(10),2,4-trien-16-yl]methyl)benzamide
-
a potent and steroidal nonestrogenic inhibitor of 17beta-HSD1, inhibits the transformation of estrone into estradiol by 17beta-HSD1 in T-47D cells. The comppound does not inhibit enzymes 17beta-HSD2, 17beta-HSD7, 17beta-HSD12, and CYP3A4, and does not stimulate the proliferation of estrogen-sensitive MCF-7 cells. Kinetic and molecular modeling (docking) experiments show that compound is a competitive and irreversible inhibitor of 17beta-HSD1
3-acetyl-2-oxo-2H-chromen-7-yl trifluoromethanesulfonate
IC50 value of 360 nM against recombinant enzyme in bacterial homogenate
3-acetyl-7-(4-hydroxyphenyl)-2H-chromen-2-one
IC50 value of 270 nM against recombinant enzyme in bacterial homogenate, and high selectivity for isoform 17beta-HSD1 over 17beta-HSD2 and against the alpha and beta estrogen receptors
3-benzyl-2-(2-bromo-3,4,5-trimethoxyphenyl)-8-hydroxy[1]benzothieno[2,3-d]pyrimidin-4(3H)-one
3-benzyl-8-hydroxy-2-(2-methylprop-1-en-1-yl)[1]benzothieno[2,3-d]pyrimidin-4(3H)-one
82% inhibition at 100 nM, 97% inhibition at 0.001 mM
3-benzyl-8-hydroxy-2-(2-thienyl)[1]benzothieno[2,3-d]pyrimidin-4(3H)-one
83% inhibition at 100 nM, 89% inhibition at 0.001 mM
3-benzyl-8-hydroxy-2-(3-methoxyphenyl)[1]benzothieno[2,3-d]pyrimidin-4(3H)-one
89% inhibition at 100 nM, 95% inhibition at 0.001 mM
3-butyl-8-hydroxy-2-(3,4,5-trimethoxybenzyl)[1]benzothieno[2,3-d]pyrimidin-4(3H)-one
0.001 mM,k 95% inhibition
3-butyl-8-hydroxy-2-(3,4,5-trimethoxyphenyl)[1]benzothieno[2,3-d]pyrimidin-4(3H)-one
86% inhibition at 100 nM, 95% inhibition at 0.001 mM
3-hydroxy-1,3,5(10)-triene-[17,16-c]-(5'-carboxylic acid)-pyrazole
-
0.01 mM: 32% inhibition
3-hydroxy-1,3,5(10)-triene-[17,16-c]-(5'-hydroxymethyl)-pyrazole
-
0.01 mM: 94% inhibition, IC50: 0.00095 mM
3-hydroxy-1,3,5(10)-triene-[17,16-c]-[5'-(carboxylic acid ethyl ester)]-pyrazole
-
0.01 mM: 94% inhibition, IC50: 0.00185 mM
3-hydroxy-13alpha-D-secooxime
displays an outstanding cofactor dependence, i.e. more efficient inhibition in the presence of NADH than NADPH
3-hydroxy-13beta-D-secoalcohol
displays an outstanding cofactor dependence, i.e. more efficient inhibition in the presence of NADH than NADPH
3-hydroxy-2-methoxy-17-oxoestra-1(10),2,4-triene-16-carbonitrile
0.01 mM, 35% inhibition
3-hydroxy-7-(3-hydroxyphenyl)-1-naphthonitrile
99% inhibition at 0.001 mM
3-hydroxy-7-(3-hydroxyphenyl)-N-methyl-2-naphthamide
18% inhibition at 0.001 mM
3-hydroxy-7-(3-hydroxyphenyl)-N-phenyl-2-naphthamide
62% inhibition at 0.001 mM
3-hydroxy-estra-1,3,5(10)-triene-[17,16-c]-(1'-isobutyl)-pyrazole
-
0.01 mM: 77% inhibition
3-hydroxy-estra-1,3,5(10)-triene-[17,16-c]-(1'-methoxyethyl)-pyrazole
-
0.01 mM: 95% inhibition, IC50: 0.00053 mM
3-hydroxy-estra-1,3,5(10)-triene-[17,16-c]-(1'-methyl acetate)-pyrazole
-
0.01 mM: 95% inhibition, IC50: 0.00092 mM
3-hydroxy-estra-1,3,5(10)-triene-[17,16-c]-(1'-methyl)-pyrazole
-
0.01 mM: 94% inhibition, IC50: 0.00275 mM
3-hydroxy-estra-1,3,5(10)-triene-[17,16-c]-(1'-propionitrile)-pyrazole
-
0.01 mM: 95% inhibition, IC50: 0.00073 mM
3-hydroxy-estra-1,3,5(10)-triene-[17,16-c]-(2'-isobutyl)-pyrazole
-
0.01 mM: 70% inhibition
3-hydroxy-estra-1,3,5(10)-triene-[17,16-c]-(2'-methoxy-ethyl)-pyrazole
-
0.01 mM: 83% inhibition
3-hydroxy-estra-1,3,5(10)-triene-[17,16-c]-(2'-methyl acetate)-pyrazole
-
0.01 mM: 79% inhibition
3-hydroxy-estra-1,3,5(10)-triene-[17,16-c]-(2'-methyl)-pyrazole
-
0.01 mM: 43% inhibition
3-hydroxy-estra-1,3,5(10)-triene-[17,16-c]-(5'-ethylme-thylcarbamoyl)-pyrazole
-
0.01 mM: 88% inhibition
3-hydroxy-estra-1,3,5(10)-triene-[17,16-c]-(5'-isopropylcarbamoyl)-pyrazole
-
0.01 mM: 57% inhibition
3-hydroxy-estra-1,3,5(10)-triene-[17,16-c]-(5'-methyl)-pyrazole
-
0.01 mM: 75% inhibition
3-hydroxy-estra-1,3,5(10)-triene-[17,16-c]-(5'-methyl-carbamoyl)-pyrazole
-
0.01 mM: 62% inhibition
3-hydroxy-estra-1,3,5(10)-triene-[17,16-c]-[5'-(1''-methylpiperazin-4''-ylmethyl)carbamoyl]-pyrazole
-
0.01 mM: 50% inhibition
3-hydroxy-estra-1,3,5(10)-triene-[17,16-c]-[5'-(1'-methylpyrrol-2''-ylmethyl)carbamoyl]-pyrazole
-
0.01 mM: 89% inhibition, IC50: 0.0023 mM
3-hydroxy-estra-1,3,5(10)-triene-[17,16-c]-[5'-(5''-methylpyrazin-2''-ylmethyl)carbamoyl]-pyrazole
-
0.01 mM: 80% inhibition
3-hydroxy-estra-1,3,5(10)-triene-[17,16-c]-[5'-(pyridin-2''-ylmethyl)carbamoyl]-pyrazole
-
0.01 mM: 93% inhibition, IC50: 0.00088 mM
3-hydroxy-estra-1,3,5(10)-triene-[17,16-c]-[5'-(pyridin-3''-ylethyl)carbamoyl]-pyrazole
-
0.01 mM: 99% inhibition, IC50: 0.0003 mM
3-hydroxy-estra-1,3,5(10)-triene-[17,16-c]-[5'-(pyridin-3''-ylmethyl)carbamoyl]-pyrazole
-
0.01 mM: 92% inhibition, IC50: 0.00078 mM
3-hydroxy-estra-1,3,5(10)-triene-[17,16-c]-[5'-(tetrahydrofuran-2''-ylmethyl)carbamoyl]-pyrazole
-
0.01 mM: 87% inhibition
3-hydroxy-N-(3'-hydroxy-[1,1'-biphenyl]-3-yl)-N-methylbenzenesulfonamide
17% inhibition at 0.001 mM; 88% inhibition at 0.001 mM
3-hydroxy-N-(3'-hydroxy-[1,1'-biphenyl]-4-yl)-N-methylbenzenesulfonamide
22% inhibition at 0.001 mM; 66% inhibition at 0.001 mM
3-hydroxy-N-(6-hydroxy-1,3-benzothiazol-2-yl)benzamide
modeling of binding to crystal structure shows five hydrogen bond interactions and a cation-pi-interaction
3-hydroxyestra-1,3,5(10),7-tetraen-17-one
-
IC50: 0.0019 mM, oxidation of estradiol
3-methoxy-N-(3'-methoxy-[1,1'-biphenyl]-3-yl)-N-methylbenzenesulfonamide
14% inhibition at 0.001 mM; 68% inhibition at 0.001 mM
3-methoxy-N-(3'-methoxy-[1,10-biphenyl]-4-yl)-Nmethylbenzenesulfonamide
18% inhibition at 0.001 mM; 25% inhibition at 0.001 mM
3-phenoxybenzyl (2E)-3-(1,3-benzodioxol-5-yl)prop-2-enoate
14% inhibition at 0.006 mM
3-[(15beta)-3-hydroxy-17-oxoestra-1(10),2,4-trien-15-yl]-N-(4-methyl-1,3-thiazol-2-yl)propanamide
-
3-[(15beta)-3-methoxy-17-oxoestra-1(10),2,4-trien-15-yl]-N-(5-methyl-1,3-thiazol-2-yl)propanamide
-
3-[(4bS,6aS,6bR,10S,10aS,11aS,11bR)-9-hexyl-2,10a-dihydroxy-6a-methyl-8-oxo-4b,5,6,6a,6b,8,9,10,10a,11,11a,11b,12,13-tetradecahydronaphtho[20,10:4,5]indeno[2,1-][1,3]oxazin-10-yl]benzamide
-
3-[(4bS,6aS,6bR,10S,10aS,11aS,11bR)-9-octyl-2,10a-dihydroxy-6a-methyl-8-oxo-4b,5,6,6a,6b,8,9,10,10a,11,11a,11b,12,13-tetradecahydronaphtho[20,10:4,5]indeno[2,1-][1,3]oxazin-10-yl]benzamide
-
3-[(4bS,6aS,6bR,10S,11aR,11bR)-9-butyl-2-hydroxy-6a-methyl-8-oxo-4b,5,6,6a,6b,8,9,10,11a,11b,12,13-dodecahydronaphtho[20,10:4,5]indeno[2,1-e][1,3]oxazin-10-l]benzamide
-
3-[(4bS,6aS,6bR,10S,11aR,11bR)-9-ethyl-2-hydroxy-6a-methyl-8-oxo-4b,5,6,6a,6b,8,9,10,11a,11b,12,13-dodecahydronaphtho[20,10:4,5]indeno[2,1-e][1,3]oxazin-10-l]benzamide
-
3-[(4bS,6aS,6bR,10S,11aR,11bR)-9-hexyl-2-hydroxy-6a-methyl-8-oxo-4b,5,6,6a,6b,8,9,10,11a,11b,12,13-dodecahydronaphtho[20,10:4,5]indeno[2,1-e][1,3]oxazin-10-l]benzamide
-
3-[(4bS,6aS,6bR,10S,11aR,11bR)-9-octyl-2-hydroxy-6a-methyl-8-oxo-4b,5,6,6a,6b,8,9,10,11a,11b,12,13-dodecahydronaphtho[20,10:4,5]indeno[2,1-e][1,3]oxazin-10-l]benzamide
-
3-[(5-bromofuran-2-yl)methyl]-8-hydroxy-2-(3,4,5-trimethoxybenzyl)[1]benzothieno[2,3-d]pyrimidin-4(3H)-one
0.001 mM, 95% inhibition
3-[(5-bromofuran-2-yl)methyl]-8-hydroxy-2-(3,4,5-trimethoxyphenyl)[1]benzothieno[2,3-d]pyrimidin-4(3H)-one
94% inhibition at 100 nM, 99% inhibition at 0.001 mM
3-[(6aS)-2-hydroxy-6a-methyl-4b,6,6a,10,10a,10b,11,12-octahydronaphtho[2',1':4,5]indeno[1,2-c]pyrazol-8(5H)-yl]propanenitrile
-
3-[(6aS,6bR,10S,10aS)-9-butyl-2,10a-dihydroxy-6a-methyl-8-oxo-4b,5,6,6a,6b,8,9,10,10a,11,11a,11b,12,13-tetradecahydronaphtho[2',1':4,5]indeno[2,1-e][1,3]oxazin-10-yl]benzamide
-
3-[(6aS,6bR,10S,10aS)-9-ethyl-2,10a-dihydroxy-6a-methyl-8-oxo-4b,5,6,6a,6b,8,9,10,10a,11,11a,11b,12,13-tetradecahydronaphtho[2',1':4,5]indeno[2,1-e][1,3]oxazin-10-yl]benzamide
-
3-[1-(4-hydroxyphenyl)-1H-1,2,3-triazol-4-yl]-phenol
17beta-HSD1; substrate: estradiol-17beta, 17beta-HSD2
3-[2-(2-thienyl)pyridin-4-yl]phenol
0.001 mM, 10 min, 33% inhibition; 0.001 mM, 10 min, 62% inhibition
3-[2-(5-chloro-2-thienyl)pyridin-4-yl]phenol
0.001 mM, 10 min, 39% inhibition; 0.001 mM, 10 min, 63% inhibition
3-[2-hydroxy-6-(3-hydroxyphenyl)-1-naphthyl]-N-methylpropanamide
80% inhibition at 0.001 mM
3-[3-(4-hydroxyphenyl)isoxazol-5-yl]-phenol
17beta-HSD1; substrate: estradiol-17beta, 17beta-HSD2
3-[4-(4-hydroxyphenyl)-1,3-oxazol-2-yl]phenol
substrate: estradiol-17beta, 17beta-HSD2
3-[4-(4-hydroxyphenyl)-1H-1,2,3-triazol-1-yl]-phenol
17beta-HSD1; substrate: estradiol-17beta, 17beta-HSD2
3-[4-(5-chloro-2-thienyl)pyridin-2-yl]phenol
0.001 mM, 10 min, 25% inhibition; 0.001 mM, 10 min, 61% inhibition
3-[5-(4-hydroxyphenyl)-1,3-oxazol-2-yl]-phenol
substrate: estradiol-17beta, 17beta-HSD2, very good selectivity, high cell permeability and medium CaCo-2 permeability; very good selectivity, high cell permeability and medium CaCo-2 permeability, 17beta-HSD1
3-[5-(5-chloro-2-thienyl)pyridin-3-yl]phenol
0.001 mM, 10 min, 40% inhibition; 0.001 mM, 10 min, 46% inhibition
3-[6-(5-chloro-2-thienyl)pyridin-2-yl]phenol
0.001 mM, 10 min, 21% inhibition; 0.001 mM, 10 min, 40% inhibition
3-[[(16beta,17beta)-3-(2-bromoethyl)-17-hydroxyestra-1,3,5(10)-trien-16-yl]methyl] benzamide
irreversible inhibitor
3alpha-hydroxy-3beta-([4-[(2-methoxy-4-methylphenyl)methyl]piperazin-1-yl]methyl)-androstan-17-one
-
-
3alpha-hydroxy-3beta-([4-[(3-methoxy-4-methylphenyl)methyl]piperazin-1-yl]methyl)-androstan-17-one
-
-
3alpha-hydroxy-3beta-([4-[(3-methoxy-4-methylphenyl)methyl]piperazin-1-yl]methyl)androstan-17-one
0.1 mM, 12.5% inhibition in the reaction with allopregnanolone. 0.3 mM, 31.0% inhibition in the reaction with 17beta-estradiol
3alpha-hydroxy-3beta-([4-[(3-methoxyphenyl)methyl]piperazin-1-yl]methyl)-16,16-dimethylandrostan-17-one
0.1 mM, 11.1% inhibition in the reaction with allopregnanolone. 0.3 mM, 24.6% inhibition in the reaction with 17beta-estradiol
3alpha-hydroxy-3beta-([4-[(3-methoxyphenyl)methyl]piperazin-1-yl]methyl)-androstan-17-one
-
-
3alpha-hydroxy-3beta-([4-[(3-methoxyphenyl)methyl]piperazin-1-yl]methyl)androstan-17-one
0.1 mM, 14.7% inhibition in the reaction with allopregnanolone. 0.3 mM, 30.0% inhibition in the reaction with 17beta-estradiol
3alpha-hydroxy-3beta-([4-[(quinolin-3-yl)methyl]piperazin-1-yl]methyl)-androstan-17-one
-
-
3alpha-hydroxy-3beta-([4-[(quinolin-3-yl)methyl]piperazin-1-yl]methyl)androstan-17-one
0.1 mM, 15.2% inhibition in the reaction with allopregnanolone. 0.3 mM, 36.1% inhibition in the reaction with 17beta-estradiol
3alpha-hydroxy-3beta-[(4-[[3-methoxy-4-(trifluoromethyl)phenyl]methyl]piperazin-1-yl)methyl]-androstan-17-one
-
-
3beta-([4-[(3-methoxyphenyl)methyl]piperazin-1-yl]methyl)androstane-3alpha,17alpha-diol
0.1 mM, 41.7% inhibition in the reaction with allopregnanolone. 0.3 mM, 31.7% inhibition in the reaction with 17beta-estradiol
3beta-([4-[(3-methoxyphenyl)methyl]piperazin-1-yl]methyl)androstane-3alpha,17beta-diol
0.1 mM, no inhibition in the reaction with allopregnanolone. 0.3 mM, 13.7% inhibition in the reaction with 17beta-estradiol
3beta-[(4-[[3-methoxy-4-(trifluoromethyl)phenyl]methyl]piperazin-1-yl)methyl]-17alpha-pregn-20-yne-3alpha,17-diol
-
metabolic stability and selectivity of inhibition for 17beta-HSD10 over 17beta-HSD3
-
3beta-[(4-[[3-methoxy-4-(trifluoromethyl)phenyl]methyl]piperazin-1-yl)methyl]-androstane-3alpha,17alpha-diol
-
metabolic stability and selectivity of inhibition for 17beta-HSD10 over 17beta-HSD3
3beta-[[4-(4-benzoylbenzoyl)piperazin-1-yl]methyl]-3alpha-hydroxyandrostan-17-one
0.1 mM, 8.0% inhibition in the reaction with allopregnanolone. 0.3 mM, 58.8% inhibition in the reaction with 17beta-estradiol
3beta-[[4-([1,1'-biphenyl]-4-carbonyl)piperazin-1-yl]methyl]-3?-hydroxyandrostan-17-one
0.1 mM, 19.3% inhibition in the reaction with allopregnanolone. 0.3 mM, 29.4% inhibition in the reaction with 17beta-estradiol
3beta-[[4-([1,1'-biphenyl]-4-carbonyl)piperazin-1-yl]methyl]-3alpha-hydroxyandrostan-17-one
-
-
4'-(2-thienyl)biphenyl-3-ol
0.001 mM, 10 min, 22% inhibition; 0.001 mM, 10 min, 36% inhibition
4'-(3-thienyl)biphenyl-3-ol
0.001 mM, 10 min, 36% inhibition; 0.001 mM, 10 min, 41% inhibition
4'-(6-methoxypyridin-3-yl)biphenyl-3-ol
0.001 mM, 10 min, 35% inhibition; 0.001 mM, 10 min, 58% inhibition
4'-methoxy-N-(3-methoxyphenyl)-N-methyl-[1,1'-biphenyl]-4-sulfonamide
13% inhibition at 0.001 mM
4-(17beta-hydroxy-3-methoxy-estra-1,3,5(10)-trien-16beta-ylmethyl)-benzamide
0.01 mM, 38% inhibition, substrate: estrone
4-(3'-ethyl-4'-hydroxy-3-methyl-biphenyl)-4-oxo-N-pyridin-3-ylethyl-butyramide
15% inhibition at 0.001 mM
4-(3'-ethyl-4'-hydroxy-3-methyl-biphenyl)-4-oxo-N-pyridin-3-ylmethyl-butyramide
21% inhibition at 0.001 mM; 37°C, 0.001 mM, 21% inhibition, substrate: estrone,7beta-HSD type 1
4-(3'-ethyl-4'-hydroxy-biphenyl)-2,2-dimethyl-4-oxo-N-pyridin-3-ylethyl-butyramide
15% inhibition at 0.001 mM; 37°C, 0.001 mM, 15% inhibition, substrate: estrone, 7beta-HSD type 1
4-(3'-ethyl-4'-hydroxy-biphenyl)-2,2-dimethyl-4-oxo-N-pyridin-3-ylmethyl-butyramide
38% inhibition at 0.001 mM
4-(3'-ethyl-4'-hydroxy-biphenyl)-4-oxo-N-(2-hydroxyethyl)-butyramide
23% inhibition at 0.001 mM; 37°C, 0.001 mM, 23% inhibition, substrate: estrone, 7beta-HSD type 1
4-(3'-ethyl-4'-hydroxy-biphenyl)-4-oxo-N-pyridin-3-ylethyl-butyramide
17% inhibition at 0.001 mM; 37°C, 0.001 mM, 17% inhibition, substrate: estrone, 7beta-HSD type 1
4-(3'-ethyl-4'-hydroxy-biphenyl)-4-oxo-N-pyridin-3-ylmethyl-butyramide
24% inhibition at 0.001 mM; 37°C, 0.001 mM, 24% inhibition, substrate: estrone, 7beta-HSD type 1; 37°C, 0.01 mM, 12% inhibition, substrate: estradiol-17beta, 7beta-HSD type 2
4-(3'-ethyl-4'-methoxy-biphenyl)-2,2-dimethyl-4-oxo-N-pyridin-3-ylmethyl-butyramide
17% inhibition at 0.001 mM; 37°C, 0.001 mM, 17% inhibition, substrate: estrone, 7beta-HSD type 1
4-(3,17beta-dihydroxy-estra-1,3,5(10)-trien-16beta-ylmethyl)-benzamide
0.01 mM, 74% inhibition, substrate: estrone
4-(3-ethyl-4-hydroxy-3-methyl-biphenyl)-4-oxo-N-pyridin-3-ylethyl-butyramide
37°C, 0.001 mM, 15% inhibition, substrate: estrone, 7beta-HSD type 1
4-(3-ethyl-4-hydroxy-biphenyl)-2,2-dimethyl-4-oxo-N-pyridin-3-ylmethyl-butyramide
37°C, 0.001 mM, 38% inhibition, substrate: estrone, 7beta-HSD type 1
4-(3-Hydroxy-17-oxo-estra-1,3,5(10)-trien-16beta-ylmethyl)-benzamide
0.01 mM, 76% inhibition, substrate: estrone
4-(3-methoxy-17-oxo-estra-1,3,5(10)-trien-16beta-ylmethyl)-benzamide
0.01 mM, 56% inhibition, substrate: estrone
4-(4-[[3alpha-hydroxy-17-oxoandrostan-3beta-yl]methyl]piperazine-1-carbonyl)benzonitrile
-
-
4-(dimethylsulfamoyl)-N-(4-[[3alpha-hydroxy-17-oxoandrostan-beta?-yl]methyl]piperazin-1-yl)benzene-1-carbothioamide
0.1 mM, 13.3% inhibition in the reaction with allopregnanolone. 0.3 mM, 0.3% inhibition in the reaction with 17beta-estradiol
4-(octanoylamino)phenyl (2E)-3-phenylprop-2-enoate
15% inhibition at 0.006 mM
4-chloro-N-(3-hydroxy-4-methylphenyl)benzenesulfonamide
45% inhibition at 0.02 mM
4-cyanophenyl (2E)-3-(1,3-benzodioxol-5-yl)prop-2-enoate
76% inhibition at 0.006 mM
4-fluoro-3-hydroxy-N-(3'-hydroxybiphenyl-3-yl)-N-methylbenzenesulfonamide
80% inhibition at 0.001 mM; 96% inhibition at 0.001 mM
4-fluoro-3-methoxy-N-(3'-methoxybiphenyl-3-yl)-N-methylbenzenesulfonamide
17% inhibition at 0.001 mM
4-methyl-3-(trifluoromethyl)-5-[[4-(trifluoromethyl)benzyl]sulfanyl]-4H-1,2,4-triazole
-
4-methyl-5-[6-(2,2,2-trifluoroethoxy)pyridin-3-yl]-4H-1,2,4-triazole-3-thiol
-
4-methyl-N-[4-[4-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]benzenesulfonamide
-
4-propanoylphenyl 3-(acetylamino)benzenesulfonate
67% inhibition at 0.02 mM
4-[(15beta)-3-hydroxy-17-oxo-2-propylestra-1(10),2,4-trien-15-yl]-N-[2-(7-methyl-1H-indol-2-yl)ethyl]butanamide
0.0001 mM, 69% inhibition
4-[(15beta)-3-hydroxy-17-oxoestra-1(10),2,4-trien-15-yl]-N-[2-(7-methyl-1H-indol-3-yl)ethyl]butanamide
-
4-[[3alpha-hydroxy-17-oxoandrostan-3beta-yl]methyl]-N-[[3-(trifluoromethyl)phenyl]methyl]piperazine-1-carbothioamide
-
-
5'-O-(10-[3',17'beta-dihydroxy-1',3',5'(10')-estratrien-16'alpha-yl]-decanoyl)adenosine
-
IC50: 140 nM
5'-O-(11-[3',17'beta-dihydroxy-1',3',5'(10')-estratrien-16'alpha-yl]-undecanoyl) adenosine
-
IC50: 310 nM
5'-O-(11-[3',17'beta-dihydroxy-1',3',5'(10')-estratrien-16'alpha/beta-yl]-undecanoyl)adenosine
-
IC50: 90 nM
5'-O-(11-[3',17'beta-dihydroxy-1',3',5'(10')-estratrien-16'beta-yl]-undecanoyl)adenosine
-
IC50: 120 nM
5'-O-(12-[3',17'beta-(dihydroxy)-1',3',5'(10')-estratrien-16'alpha-yl]-dodecanoyl)adenosine
-
IC50: 1000 nM
5'-O-(6-[3',17'beta-dihydroxy-1',3',5'(10')-estratrien-16'alpha/beta-yl]-hexanoyl)adenosine
-
IC50: 6900 nM
5'-O-(7-[3',17'beta-dihydroxy-1',3',5'(10')-estratrien-16'alpha-yl]-heptanoyl)adenosine
-
IC50: 430 nM
5'-O-(8-[3',17'beta-dihydroxy-1',3',5'(10')-estratrien-16'alpha-yl]-octanoyl)adenosine
-
IC50: 93 nM
5'-O-(9-[3',17'beta-dihydroxy-1',3',5'(10')-estratrien-16'alpha-yl]-nonanoyl)adenosine
-
IC50: 52 nM
5'-O-[9-[(16b,17b)-3,17-dihydroxyestra-1(10),2,4-trien-16-yl]nonanoyl]adenosine
-
5'-O-[9-[(16beta,17beta)-3,17-dihydroxyestra-1(10),2,4-trien-16-yl]nonanoyl]adenosine
EM-1745, bisubstrate inhibitor of 17beta-HSD1
5,7-dihydroxyflavone
-
IC50 below 0.001 mM, oxidation of 17beta-hydroxyestra-4-en-3-one
5-(3-ethyl-4-hydroxyphenyl)-indan-1-one
37°C, 0.01 mM, 48% inhibition, substrate: estradiol-17beta, 7beta-HSD type 2; 37°C, 0.01 mM, 86% inhibition, substrate: estrone, 7beta-HSD type 1; 86% inhibition at 0.001 mM
5-(3-fluoro-4-hydroxyphenyl)-indan-1-one
37°C, 0.01 mM, 24% inhibition, substrate: estradiol-17beta, 7beta-HSD type 2; 37°C, 0.01 mM, 75% inhibition, substrate: estrone, 7beta-HSD type 1; 75% inhibition at 0.001 mM
5-(3-fluoro-4-methoxyphenyl)-indan-1-one
37°C, 0.01 mM, 56% inhibition, substrate: estrone, 7beta-HSD type 1; 56% inhibition at 0.001 mM
5-(4-cyanophenyl)-N-(3-methoxyphenyl)-N-methylthiophene-2-carboxamide
48% inhibition
5-(4-hydroxyphenyl)-indan-1-one
37°C, 0.01 mM, 17% inhibition, substrate: estradiol-17beta, 7beta-HSD type 2; 37°C, 0.01 mM, 81% inhibition, substrate: estrone, 7beta-HSD type 1; 81% inhibition at 0.001 mM
5-(6-hydroxy-2-naphthyl)pyridin-3-ol
0.001 mM, 58% inhibition, substrate: estrone
5-benzyl-3-(furan-2-ylmethyl)-8-hydroxy-2-(2-phenylethyl)[1]benzothieno[2,3-d]pyrimidin-4(3H)-one
5% inhibition at 100 nM, 26% inhibition at 0.001 mM
5-bromo-3-(2-methylpropyl)-2-(3,4,5-trimethoxyphenyl)-6,7-dihydro[1]benzothieno[2,3-d]pyrimidine-4,8(3H,5H)-dione
0.001 mM, 54% inhibition
5-butyl-3-(furan-2-ylmethyl)-8-hydroxy-2-(2-phenylethyl)[1]benzothieno[2,3-d]pyrimidin-4(3H)-one
9% inhibition at 100 nM, 27% inhibition at 0.001 mM
5-hydroxyflavone
-
IC50 below 0.001 mM, oxidation of 17beta-hydroxyestra-4-en-3-one
5-methoxyflavone
-
IC50 between 0.001 and 0.005 mM, reduction of estra-4-en-3,17-dione
5-[(15beta)-3-methoxy-17-oxoestra-1(10),2,4-trien-15-yl]-N-(2-thiophen-2-ylethyl)pentanamide
-
6-(3-ethyl-4-hydroxyphenyl)-3,4-dihydro-2H-naphthalen-1-one
37°C, 0.01 mM, 51% inhibition, substrate: estrone, 7beta-HSD type 1; 51% inhibition at 0.001 mM
6-(3-ethyl-4-methoxyphenyl)-3,4-dihydro-2H-naphthalen-1-one
37°C, 0.01 mM, 71% inhibition, substrate: estrone, 7beta-HSD type 1; 71% inhibition at 0.001 mM
6-(3-hydroxyphenyl)-1-((4-methylphenyl)sulfonyl)-2-naphthol
75% inhibition at 0.001 mM
6-(3-hydroxyphenyl)-1-(morpholin-4-ylcarbonyl)-2-naphthol
62% inhibition at 0.001 mM
6-(3-hydroxyphenyl)-1-(phenylsulfonyl)-2-naphthol
33% inhibition at 0.001 mM
6-(3-hydroxyphenyl)-1-(piperazin-1-ylcarbonyl)-2-naphthol
45% inhibition at 0.001 mM
6-(3-hydroxyphenyl)-1-(piperidin-1-ylcarbonyl)-2-naphthol
73% inhibition at 0.001 mM
6-(3-hydroxyphenyl)-1-naphthol
0.001 mM, 23% inhibition, substrate: estrone
6-(3-hydroxyphenyl)-3,4-dihydronaphthalen-1(2H)-one
0.001 mM, 23% inhibition, substrate: estrone
6-(4-hydroxy-phenyl)-3,4-dihydro-2H-naphthalen-1-one
37°C, 0.01 mM, 89% inhibition, substrate: estrone, 7beta-HSD type 1; 89% inhibition at 0.001 mM
6-(4-hydroxyphenyl)-1-naphthol
0.001 mM, 55% inhibition, substrate: estrone
6-(hexylsulfanyl)estra-1(10),2,4-triene-3,17beta-diol
-
30% inhibition at 0.001 mM, reduction of estrone with NADH as cofactor
6-butyl-3-(furan-2-ylmethyl)-8-hydroxy-2-(2-phenylethyl)[1]benzothieno[2,3-d]pyrimidin-4(3H)-one
52% inhibition at 100 nM, 81% inhibition at 0.001 mM
6-[(1,3-benzothiazol-2-ylsulfanyl)methyl]-4-butoxy-2-(trifluoromethyl)quinoline
-
6-[4-(hydroxymethyl)phenyl]-2-naphthol
0.001 mM, 13% inhibition, substrate: estrone
7-(3-hydroxyphenyl)-2-naphthol
0.001 mM, 62% inhibition, substrate: estrone
7-hydroxy-3-(3-hydroxyphenyl)-1-naphthonitrile
53% inhibition at 0.001 mM
8-((13S,16S,17S)-3,17-Dihydroxy-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-16-yl)-octanoic acid 5-(6-amino-purin-9-yl)-3,4-dihydroxy-tetrahydro-furan-2-ylmethyl ester
-
IC50: 93 nM
8-hydroxy-3-(2-methylbutyl)-2-(3,4,5-trimethoxyphenyl)[1]benzothieno[2,3-d]pyrimidin-4(3H)-one
91% inhibition at 100 nM, 94% inhibition at 0.001 mM
8-hydroxy-3-(2-methylprop-1-en-1-yl)-2-(3,4,5-trimethoxyphenyl)[1]benzothieno[2,3-d]pyrimidin-4(3H)-one
0.001 mM, 97% inhibition
8-hydroxy-3-(2-methylpropyl)-2-(3,4,5-trimethoxyphenyl)[1]benzothieno[2,3-d]pyrimidin-4(3H)-one
93% inhibition at 100 nM, 98% inhibition at 0.001 mM
9-((13S,16S,17S)-3,17-Dihydroxy-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-16-yl)-nonanoic acid 5-(6-amino-purin-9-yl)-3,4-dihydroxy-tetrahydro-furan-2-ylmethyl ester
-
IC50: 52 nM
9-(5-O-(9-[(16alpha,17alpha)-3,17-dihydroxyestra-1(10),2,4-trien-16-yl]nonanoyl)-alpha-L-arabinofuranosyl)-9H-purin-6-amine
-
shows key interactions with two different enzyme-binding sites, namely the substrate- and the cofactor-binding sites
Benzoic acid (13S,17R)-7-[10-(butyl-methyl-carbamoyl)-decyl]-17-ethynyl-17-hydroxy-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-yl ester
-
-
benzyl (2E)-3-(3,4,5-trimethoxyphenyl)prop-2-enoate
60% inhibition at 0.006 mM
cholest-4-ene-3,6-dione
cholest-4-ene-3,6-dione arrests the enzymatic conversion of estrone to 17-beta estradiol, by inhibiting AKR1C3 in intact MCF-7 cells. It can be used as a molecular scaffold for further development of l small-molecules with better specificity towards AKR1C3; the inhibitor occupies the binding region of AKR1C3 with almost similar orientation as indomethacin, thereby acting as an antagonistic agent for AKR1C3. It induces inhibition of AKR1C3 and cell death in MCF-7 cells. IT can be used as a molecular scaffold for development of novel small-molecules with better specificity towards AKR1C3
chrysoeriol
i.e. 4',5,7-trihydroxy-3'-methoxyflavone, 82% inhibition at 0.006 mM
cyclobutyl-(4-hydroxyphenyl)-methanone
-
weak inhibitor with 43.9% inhibition at 0.1 mM
cycloheptyl-(4-hydroxyphenyl)-methanone
-
weak inhibitor with 47.2% inhibition at 0.1 mM
cyclohexyl-(4-hydroxyphenyl)-methanone
-
weak inhibitor with 47.2% inhibition at 0.1 mM
cyclopentyl-(4-hydroxyphenyl)-methanone
-
weak inhibitor with 49.5% inhibition at 0.1 mM
diosmetin
i.e. 3',5,7-trihydroxy-4'-methoxyflavone, more than 90% inhibition at 0.006 mM
Dithiocarbamate
irreversible inhibition of 17beta-HSD1, preincubation with NADPH protects from inhibition
ethyl (2Z)-hydroxy[(16Z)-3-hydroxy-17-oxoestra-1(10),2,4-trien-16-ylidene]ethanoate
-
ethyl 4-[([4-[(15alpha)-3-hydroxy-17-oxoestra-1(10),2,4-trien-15-yl]butyl]carbamoyl)amino]benzoate
-
ethyl [(6aS)-2-hydroxy-6a-methyl-4b,5,6,6a,8,10,10a,10b,11,12-decahydronaphtho[2',1':4,5]indeno[1,2-c]pyrazol-9-yl]acetate
-
gossypol
-
and derivatives of gossypol, competitive with respect to NAD+ in reverse reaction
medrogestone
-
although the inhibitor is not selective for the type 1 17beta-HSD, it is weakly active and has a mechanism that appears to be complex, it offers new possibilities in treatment of estrogen-dependent diseases
methyl 3-hydroxy-17-oxoestra-1(10),2,4-triene-16-carboxylate
0.01 mM, 69% inhibition
methyl [(6aS)-2-hydroxy-6a-methyl-4b,6,6a,10,10a,10b,11,12-octahydronaphtho[2',1':4,5]indeno[1,2-c]pyrazol-8(5H)-yl]acetate
-
myricetin
i.e. 3,3',4',5',5,7-hexahydroxyflavone, 52% inhibition at 0.006 mM
N'-[(2,4-difluorophenyl)sulfonyl]-2-pyridin-3-yl-4,5-dihydro-1,3-thiazole-4-carbohydrazide
-
N-(1,3-benzodioxol-5-ylmethyl)-5-[(15beta)-3-methoxy-17-oxoestra-1(10),2,4-trien-15-yl]pentanamide
-
N-(2,1,3-benzothiadiazol-4-yl)-2-[(4-hydroxypyrimidin-2-yl)sulfanyl]acetamide
92% inhibition at 0.02 mM
N-(2,3-dihydro-1,4-benzodioxin-6-yl)-4-methyl-1,2,3-thiadiazole-5-carboxamide
-
N-(2,4-difluorobenzyl)-4-[(15beta)-3-hydroxy-17-oxoestra-1(10),2,4-trien-15-yl]butanamide
-
N-(2-hydroxyphenyl)-2-methyl-4-(trifluoromethyl)benzenesulfonamide
94% inhibition at 0.02 mM
N-(3-chloro-4-fluorophenyl)-4-fluorobenzenesulfonamide
45% inhibition at 0.02 mM
N-(3-chloro-4-hydroxyphenyl)-4-fluorobenzenesulfonamide
91% inhibition at 0.02 mM
N-(3-hydroxy-4-methylphenyl)-3-(trifluoromethyl)benzenesulfonamide
75% inhibition at 0.02 mM
N-(3-hydroxy-4-methylphenyl)-4-methoxybenzenesulfonamide
47% inhibition at 0.02 mM
N-(3-hydroxybenzyl)-5-(4-methoxyphenyl)-N-methylthiophene-2-carboxamide
-
N-(3-hydroxyphenyl)-2,4,5-trimethylbenzenesulfonamide
47% inhibition at 0.02 mM
N-(3-hydroxyphenyl)-3'-methoxy-N-methyl-[1,1'-biphenyl]-4-sulfonamide
18% inhibition at 0.001 mM
N-(3-hydroxyphenyl)-4-methoxy-2,5-dimethylbenzenesulfonamide
85% inhibition at 0.02 mM
N-(3-hydroxyphenyl)-4-methoxy-2-methyl-5,6,7,8-tetrahydronaphthalene-1-sulfonamide
-
N-(3-hydroxyphenyl)-N,3'-dimethyl-[1,1'-biphenyl]-4-sulfonamide
15% inhibition at 0.001 mM; 22% inhibition at 0.001 mM
N-(3-hydroxyphenyl)-N-methyl-4-(thiophen-2-yl)benzenesulfonamide
31% inhibition at 0.001 mM
N-(3-methoxyphenyl)-N-methyl-4-(thiophen-2-yl)benzenesulfonamide
32% inhibition at 0.001 mM
N-(3-methoxyphenyl)-N-methyl-4-(thiophen-3-yl)benzenesulfonamide
23% inhibition at 0.001 mM
N-(4-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)-4-methoxybenzenesulfonamide
-
N-(4-hydroxyphenyl)-2,4,6-trimethylbenzenesulfonamide
33% inhibition at 0.02 mM
N-(4-hydroxyphenyl)-2,5-dimethylbenzenesulfonamide
39% inhibition at 0.02 mM
N-(4-hydroxyphenyl)-N-methyl-4-(pyridin-3-yl)benzenesulfonamide
14% inhibition at 0.001 mM; 15% inhibition at 0.001 mM
N-(4-[[3alpha-hydroxy-17-oxoandrostan-3beta-yl]methyl]piperazin-1-yl)[3-(trifluoromethyl)phenyl]ethanethioamide
0.1 mM, 34.2% inhibition in the reaction with allopregnanolone. 0.3 mM, 8.5% inhibition in the reaction with 17beta-estradiol
N-(5-chloro-2-hydroxyphenyl)-4-fluoro-3-methylbenzenesulfonamide
44% inhibition at 0.02 mM
N-benzyl-4-[(15alpha)-3-hydroxy-17-oxoestra-1(10),2,4-trien-15-yl]butanamide
-
N-benzyl-4-[(15beta)-3-hydroxy-17-oxoestra-1(10),2,4-trien-15-yl]butanamide
-
N-benzyl-4-[(15beta)-3-methoxy-17-oxoestra-1(10),2,4-trien-15-yl]-N-methylbutanamide
-
N-butyl-6-[[(6beta,17beta)-17-hydroxyestra-1(10),2,4-trien-6-yl]sulfanyl]-N-methylhexanamide
N-butyl-6-[[(6beta,17beta)-3,17-dihydroxyestra-1(10),2,4-trien-6-yl]oxy]-N-methylhexanamide
N-butyl-6-[[(6beta,17beta)-3,17-dihydroxyestra-1(10),2,4-trien-6-yl]sulfanyl]-N-methylhexanamide
N-butyl-7-[(6beta,17beta)-3,17-dihydroxyestra-1(10),2,4-trien-6-yl]-N-methylheptanamide
-
N-butyl-N-methyl-11-[16beta-(3-carbamoylbenzyl)-3,17-dihydroxy-estra-1,3,5(10)-trien-7alpha-yl]-undecanamide
0.01 mM, 61% inhibition, substrate: estrone
N-cyclohexyl-3-[(15beta)-3-hydroxy-17-oxoestra-1(10),2,4-trien-15-yl]propanimidamide
-
N-cyclohexyl-3-[(15beta)-3-methoxy-17-oxoestra-1(10),2,4-trien-15-yl]-N-methylpropanamide
-
N-cyclohexyl-3-[(15beta)-3-methoxy-17-oxoestra-1(10),2,4-trien-15-yl]propanamide
-
N-cyclooctyl-3-[(15beta)-3-methoxy-17-oxoestra-1(10),2,4-trien-15-yl]propanamide
-
N-decyl-N-[(4aR,6aS,7S)-1,4a,6a-trimethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]formamide
-
N-decyl-N-[(4aR,6aS,7S)-4a,6a-dimethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]formamide
-
N-ethyl-4-[[3alpha-hydroxy-17-oxoandrostan-3beta-yl]methyl]-N-methylpiperazine-1-sulfonamide
N-ethylmaleimide
irreversible inhibition; irreversible inhibition of 17beta-HSD1, preincubation with NADPH protects from inhibition
N-n-butyl-N-methyl-11-(16'a-bromo-3',17'b-dihydroxyestra-1',3',5'(10')-trien-7'a-yl)undecanamide
-
-
N-n-butyl-N-methyl-11-(16'a-chloro-3',17'a-dihydroxyestra-1',3',5'(10')-trien-7'a-yl)undecanamide
-
-
N-n-butyl-N-methyl-11-(16'a-chloro-3',17'b-dihydroxyestra-1',3',5'(10')-trien-7'a-yl)undecanamide
-
-
N-n-butyl-N-methyl-11-(16'a-fluoro-3',17'a-dihydroxyestra-1',3',5'(10')-trien-7'a-yl)undecanamide
-
-
N-n-butyl-N-methyl-11-(16'a-fluoro-3',17'b-dihydroxyestra-1',3',5'(10')-trien-7'a-yl)undecanamide
-
-
N-n-butyl-N-methyl-11-(16'a-iodo-3',17'b-dihydroxyestra-1',3',5'(10')-trien-7'a-yl)undecanamide
-
-
N-n-Butyl-N-methyl-11-(3,17b-dihydroxyestra-1,3,5(10)-trien-7a-yl)undecanamide
-
-
N-nonyl-N-[(4aR,6aS,7S)-1,4a,6a-trimethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]formamide
-
N-[2-(4-hydroxyphenyl)ethyl]-3-[(15beta)-3-methoxy-17-oxoestra-1(10),2,4-trien-15-yl]propanamide
-
N-[3-(6-hydroxy-2-naphthyl)phenyl]acetamide
0.001 mM, 19% inhibition, substrate: estrone
N-[4-(dimethylsulfamoyl)phenyl]-4-[[3alpha-hydroxy-17-oxoandrostan-3beta-yl]methyl]piperazine-1-carbothioamide
-
-
N-[[(15alpha)-3-hydroxy-17-oxoestra-1(10),2,4-trien-15-yl]methyl]-N-methylthiophene-2-sulfonamide
-
N-[[(15alpha)-3-hydroxy-17-oxoestra-1(10),2,4-trien-15-yl]methyl]benzenesulfonamide
-
N-[[(15alpha)-3-hydroxy-17-oxoestra-1(10),2,4-trien-15-yl]methyl]thiophene-2-sulfonamide
-
N-[[5-(2,5-dichlorophenyl)furan-2-yl]methyl]-2H-tetrazol-5-amine
71% inhibition at 0.02 mM
naphthalen-2-yl (2E)-3-(3,4,5-trimethoxyphenyl)prop-2-enoate
56% inhibition at 0.006 mM
nomegestrol acetate
-
although the inhibitor is not selective for the type 1 17beta-HSD, it is weakly active and has a mechanism that appears to be complex, it offers new possibilities in treatment of estrogen-dependent diseases
palm oil carotenoids
-
0.0001 mM, significant inhibition of the conversion of estradiol to estrone in the MCF-7 cell line
-
phenyl (2E)-3-(3,4,5-trimethoxyphenyl)prop-2-enoate
35% inhibition at 0.006 mM
S-[(7R,10R,13S,17R)-10,13-dimethyl-3,5'-dioxo-1,2,3,4',5',6,7,8,9,10,11,12,13,14,15,16-hexadecahydro-3'H-spiro[cyclopenta[a]phenanthrene-17,2'-furan]-7-yl] ethanethioate
-
0.003 mM, 57% inhibition, substrate: 4-androstene-3,17-dione
scutellarein
i.e. 4',5,6,7-tetrahydroxyflavone, 88% inhibition at 0.006 mM
tibolone
-
although the inhibitor is not selective for the type 1 17beta-HSD, it is weakly active and has a mechanism that appears to be complex, it offers new possibilities in treatment of estrogen-dependent diseases
[6-(3,4-dihydroxyphenyl)pyridin-2-yl]-(4-fluoro-3-hydroxyphenyl)methanone
a potent nonsteroidal inhibitor, binding structure, overview
(6aS)-2-hydroxy-6a-methyl-N-(2-pyridin-3-ylethyl)-4b,5,6,6a,8,10,10a,10b,11,12-decahydronaphtho[2',1':4,5]indeno[1,2-c]pyrazole-9-carboxamide
0.01 mM, 99% inhibition, IC50: 0.0003 mM
(6aS)-2-hydroxy-6a-methyl-N-(2-pyridin-3-ylethyl)-4b,5,6,6a,8,10,10a,10b,11,12-decahydronaphtho[2',1':4,5]indeno[1,2-c]pyrazole-9-carboxamide
-
(6aS)-2-hydroxy-6a-methyl-N-(pyridin-2-ylmethyl)-4b,5,6,6a,8,10,10a,10b,11,12-decahydronaphtho[2',1':4,5]indeno[1,2-c]pyrazole-9-carboxamide
0.01 mM, 93% inhibition, IC50: 0.00088 mM
(6aS)-2-hydroxy-6a-methyl-N-(pyridin-2-ylmethyl)-4b,5,6,6a,8,10,10a,10b,11,12-decahydronaphtho[2',1':4,5]indeno[1,2-c]pyrazole-9-carboxamide
-
(6aS)-2-hydroxy-6a-methyl-N-(pyridin-3-ylmethyl)-4b,5,6,6a,8,10,10a,10b,11,12-decahydronaphtho[2',1':4,5]indeno[1,2-c]pyrazole-9-carboxamide
0.01 mM, 92% inhibition, IC50: 0.00078 mM
(6aS)-2-hydroxy-6a-methyl-N-(pyridin-3-ylmethyl)-4b,5,6,6a,8,10,10a,10b,11,12-decahydronaphtho[2',1':4,5]indeno[1,2-c]pyrazole-9-carboxamide
-
3'-hydroxy-N-(3-hydroxyphenyl)-N-methylbiphenyl-4-carboxamide
13% inhibition at 0.001 mM
3'-methoxy-N-(3-methoxyphenyl)-N-methylbiphenyl-3-carboxamide
1 micromol, 25% inhibition
3,7-dihydroxyflavone
-
IC50 below 0.001 mM, oxidation of 17beta-hydroxyestra-4-en-3-one
3-benzyl-2-(2-bromo-3,4,5-trimethoxyphenyl)-8-hydroxy[1]benzothieno[2,3-d]pyrimidin-4(3H)-one
87% inhibition at 100 nM, 95% inhibition at 0.001 mM. IC50: 5 nM
3-benzyl-2-(2-bromo-3,4,5-trimethoxyphenyl)-8-hydroxy[1]benzothieno[2,3-d]pyrimidin-4(3H)-one
0.001 mM, 95% inhibition
3-benzyl-8-hydroxy-2-(3,4,5-trimethoxyphenyl)[1]benzothieno[2,3-d]pyrimidin-4(3H)-one
94% inhibition at 100 nM, 99% inhibition at 0.001 mM. IC50: 5 nM
3-benzyl-8-hydroxy-2-(3,4,5-trimethoxyphenyl)[1]benzothieno[2,3-d]pyrimidin-4(3H)-one
0.001 mM, 99% inhibition
3-hydroxyflavone
-
IC50 below 0.001 mM, oxidation of 17beta-hydroxyestra-4-en-3-one; IC50 between 0.001 and 0.005 mM, reduction of estra-4-en-3,17-dione
3beta-[[4-(3,5-dimethylbenzoyl)piperazin-1-yl]methyl]-3alpha-hydroxyandrostan-17-one
0.1 mM, 1.5% inhibition in the reaction with allopregnanolone
3beta-[[4-(3,5-dimethylbenzoyl)piperazin-1-yl]methyl]-3alpha-hydroxyandrostan-17-one
-
-
3beta-[[4-(3-acetylbenzoyl)piperazin-1-yl]methyl]-3alpha-hydroxyandrostan-17-one
0.1 mM, 5.0% inhibition in the reaction with allopregnanolone
3beta-[[4-(3-acetylbenzoyl)piperazin-1-yl]methyl]-3alpha-hydroxyandrostan-17-one
-
-
4'-methoxy-N-(3-methoxyphenyl)-N-methylbiphenyl-3-carboxamide
1 micromol, 11% inhibition
5-(2-fluoro-3-methoxyphenyl)-N-(3-hydroxybenzyl)-N-methylthiophene-2-carboxamide
-
5-(2-fluoro-3-methoxyphenyl)-N-(3-hydroxybenzyl)-N-methylthiophene-2-carboxamide
1 micromol, 65% inhibition
5-(2-fluoro-3-methoxyphenyl)-N-(3-methoxyphenyl)-N-methylthiophene-2-carboxamide
-
5-(2-fluoro-3-methoxyphenyl)-N-(3-methoxyphenyl)-N-methylthiophene-2-carboxamide
1 micromol, 26% inhibition
5-(2-fluoro-3-methoxyphenyl)-N-methyl-N-(3-methylphenyl)thiophene-2-carboxamide
-
5-(2-fluoro-3-methoxyphenyl)-N-methyl-N-(3-methylphenyl)thiophene-2-carboxamide
1 micromol, 45% inhibition
5-(2-hydroxyphenyl)-N-(3-hydroxyphenyl)-N-methylthiophene-2-carboxamide
-
5-(2-hydroxyphenyl)-N-(3-hydroxyphenyl)-N-methylthiophene-2-carboxamide
1 micromol, 18% inhibition
5-(2-methoxyphenyl)-N-(3-methoxyphenyl)-N-methylthiophene-2-carboxamide
-
5-(2-methoxyphenyl)-N-(3-methoxyphenyl)-N-methylthiophene-2-carboxamide
1 micromol, 19% inhibition
5-(3-fluorophenyl)-N-(3-hydroxybenzyl)-N-methylthiophene-2-carboxamide
1 micromol, 37% inhibition
5-(3-fluorophenyl)-N-(3-methoxyphenyl)-N-methylthiophene-2-carboxamide
1 micromol, 40% inhibition
6-(3-hydroxyphenyl)-2-naphthol
0.0001 mM, 91% inhibition, substrate: estrone
coumestrol
-
IC50 between 0.001 and 0.005 mM, reduction of estra-4-en-3,17-dione
EM-1745
strong competitive inhibitor, inhibition reversible, 50% inhibition at 52 nM
N,4'-dimethyl-N-(3-methylphenyl)biphenyl-4-carboxamide
1 micromol, 50% inhibition
N,5-bis(3-methoxyphenyl)-N-methylthiophene-2-carboxamide
1 micromol, 29% inhibition
N-(3-hydroxybenzyl)-5-(3-hydroxyphenyl)-N-methylthiophene-2-carboxamide
-
N-(3-hydroxybenzyl)-5-(3-hydroxyphenyl)-N-methylthiophene-2-carboxamide
1 micromol, 26% inhibition
N-(3-hydroxybenzyl)-5-(4-hydroxyphenyl)-N-methylthiophene-2-carboxamide
-
N-(3-hydroxybenzyl)-5-(4-hydroxyphenyl)-N-methylthiophene-2-carboxamide
1 micromol, 35% inhibition
N-(3-hydroxybenzyl)-N-methyl-5-(3-methylphenyl)thiophene-2-carboxamide
-
N-(3-hydroxybenzyl)-N-methyl-5-(3-methylphenyl)thiophene-2-carboxamide
1 micromol, 45% inhibition
N-(3-methoxybenzyl)-5-(3-methoxyphenyl)-N-methylthiophene-2-carboxamide
-
N-(3-methoxybenzyl)-5-(3-methoxyphenyl)-N-methylthiophene-2-carboxamide
1 micromol, 16% inhibition
N-(3-methoxyphenyl)-N-methyl-5-(3-methylphenyl)thiophene-2-carboxamide
1 micromol, 30% inhibition
N-butyl-6-[[(6beta,17beta)-17-hydroxyestra-1(10),2,4-trien-6-yl]sulfanyl]-N-methylhexanamide
-
38% inhibition at 0.001 mM, reduction of estrone with NADH as cofactor
N-butyl-6-[[(6beta,17beta)-17-hydroxyestra-1(10),2,4-trien-6-yl]sulfanyl]-N-methylhexanamide
-
N-butyl-6-[[(6beta,17beta)-3,17-dihydroxyestra-1(10),2,4-trien-6-yl]oxy]-N-methylhexanamide
-
73% inhibition at 0.001 mM, IC50: 0.0008 mM, reduction of estrone with NADH as cofactor
N-butyl-6-[[(6beta,17beta)-3,17-dihydroxyestra-1(10),2,4-trien-6-yl]oxy]-N-methylhexanamide
-
N-butyl-6-[[(6beta,17beta)-3,17-dihydroxyestra-1(10),2,4-trien-6-yl]sulfanyl]-N-methylhexanamide
-
92% inhibition at 0.001 mM, IC50: 0.00016 mM, reduction of estrone with NADH as cofactor
N-butyl-6-[[(6beta,17beta)-3,17-dihydroxyestra-1(10),2,4-trien-6-yl]sulfanyl]-N-methylhexanamide
-
N-butyl-6-[[(6beta,17beta)-3,17-dihydroxyestra-1(10),2,4-trien-6-yl]sulfanyl]-N-methylhexanamide
EM-678
N-ethyl-4-[[3alpha-hydroxy-17-oxoandrostan-3beta-yl]methyl]-N-methylpiperazine-1-sulfonamide
0.1 mM, no inhibition in the reaction with allopregnanolone. 0.3 mM, 10.2% inhibition in the reaction with 17beta-estradiol
N-ethyl-4-[[3alpha-hydroxy-17-oxoandrostan-3beta-yl]methyl]-N-methylpiperazine-1-sulfonamide
-
-
N-methyl-N,5-bis(3-methylphenyl)thiophene-2-carboxamide
1 micromol, 42% inhibition
additional information
-
activity with estradiol-17beta is not inhibited by high concentrations of C19-steroids or C21-steroids
-
additional information
-
steroids which inhibit conversion of estrone to estradiol in normal breast tissue fail to do so when added to growing monolayers in the breast cancer cell lines T47D and MCF-7
-
additional information
-
modulation of local synthesis of estradiol is one potential mechanism through which genistein, enterolactone and enterodiol may protect against breast cancer
-
additional information
-
not inhibited by 1-(4'-methoxy-biphenyl-4-yl)-ethanone, 1-(4-benzo[1,3]dioxol-5-yl-phenyl)-ethanone, 1-(3'-ethyl-4'-methoxy-biphenyl-4-yl)-ethanone, 1-(4'-methoxy-2'-methyl-biphenyl-4-yl)-ethanone, 1-(4'-methoxy-2-methyl-biphenyl-4-yl)-ethanone, 1-(4'-hydroxy-2-methyl-biphenyl-4-yl)-ethanone, 1-(7-methoxy-9H-fluoren-2-yl)-ethanone, 5-(4-methoxyphenyl)-indan-1-one, 5-(3-ethyl-4-methoxyphenyl)-indan-1-one, 2,3-dihydro-5-phenylinden-1-one, 6-(4-methoxy-phenyl)-3,4-dihydro-2H-naphthalen-1-one, 4-(3'-ethyl-4'-hydroxy-biphenyl)-4-oxo-N-pyridin-2-ylmethyl-butyramide, 2-[5-(3-ethyl-4-hydroxyphenyl)-1-oxo-indan-2-yl]-N-pyridin-2-ylmethyl-acetamide, and 2-[5-(3-ethyl-4-hydroxyphenyl)-1-oxo-indan-2-yl]-N-(5-methyl-pyrazin-2-ylmethyl)-acetamide
-
additional information
not inhibited by 1-(4'-methoxy-biphenyl-4-yl)-ethanone, 1-(4-benzo[1,3]dioxol-5-yl-phenyl)-ethanone, 1-(3'-ethyl-4'-methoxy-biphenyl-4-yl)-ethanone, 1-(4'-methoxy-2'-methyl-biphenyl-4-yl)-ethanone, 1-(4'-methoxy-2-methyl-biphenyl-4-yl)-ethanone, 1-(4'-hydroxy-2-methyl-biphenyl-4-yl)-ethanone, 1-(7-methoxy-9H-fluoren-2-yl)-ethanone, 5-(4-methoxyphenyl)-indan-1-one, 5-(3-ethyl-4-methoxyphenyl)-indan-1-one, 2,3-dihydro-5-phenylinden-1-one, 6-(4-methoxy-phenyl)-3,4-dihydro-2H-naphthalen-1-one, 4-(3'-ethyl-4'-hydroxy-biphenyl)-4-oxo-N-pyridin-2-ylmethyl-butyramide, 2-[5-(3-ethyl-4-hydroxyphenyl)-1-oxo-indan-2-yl]-N-pyridin-2-ylmethyl-acetamide, and 2-[5-(3-ethyl-4-hydroxyphenyl)-1-oxo-indan-2-yl]-N-(5-methyl-pyrazin-2-ylmethyl)-acetamide
-
additional information
not inhibited by 2-hydroxy-6-(3-hydroxyphenyl)-N-pyridin-2-yl-1-naphthamide and 2-hydroxy-6-(3-hydroxyphenyl)-N-(pyrimidin-2-yl)-1-naphthamide
-
additional information
-
not inhibited by 3,3'-(1-methyl-1H-1,2,4-triazole-3,5-diyl)diphenol, 3-[5-(4-hydroxyphenyl)-1-methyl-1H-1,2,4-triazol-3-yl]phenol, 3-[3-(4-hydroxyphenyl)-1-methyl-1H-1,2,4-triazol-5-yl]phenol, 3,3'-(1-phenyl-1H-1,2,4-triazole-3,5-diyl)diphenol, 3-[5-(4-hydroxyphenyl)-1-phenyl-1H-1,2,4-triazol-3-yl]phenol, and 3-[3-(4-hydroxyphenyl)-1-phenyl-1H-1,2,4-triazol-5-yl]phenol
-
additional information
synthesis, physicochemical properties, and biological evaluation of novel N-methylsulfonamide and retro-N-methylsulfonamide derivatives as 17beta-HSD2 (the isoenzyme responsible of the reverse reaction) inhibitors showing high potency with a good selectivity toward 17beta-HSD1, and a likely good in vitro ADME profile, overview. No inhibition by 9b, 9c, 9e, 9f, 9g, 9h, 9k, 9o, and 10a; synthesis, physicochemical properties, and biological evaluation of novel N-methylsulfonamide and retro-N-methylsulfonamide derivatives as 17beta-HSD2 inhibitors showing high potency with a good selectivity toward 17beta-HSD1 (the isoenzyme responsible of the reverse reaction), and a likely good in vitro ADME profile, overview
-
additional information
synthesis, physicochemical properties, and biological evaluation of novel N-methylsulfonamide and retro-N-methylsulfonamide derivatives as 17beta-HSD2 (the isoenzyme responsible of the reverse reaction) inhibitors showing high potency with a good selectivity toward 17beta-HSD1, and a likely good in vitro ADME profile, overview. No inhibition by 9b, 9c, 9e, 9f, 9g, 9h, 9k, 9o, and 10a; synthesis, physicochemical properties, and biological evaluation of novel N-methylsulfonamide and retro-N-methylsulfonamide derivatives as 17beta-HSD2 inhibitors showing high potency with a good selectivity toward 17beta-HSD1 (the isoenzyme responsible of the reverse reaction), and a likely good in vitro ADME profile, overview
-
additional information
fused 16beta,17beta-oxazinone-estradiol derivatives act as a family of non-estrogenic 17beta-hydroxysteroid dehydrogenase type 1 inhibitors, activities in T-47D breast cancer cells, molecular docking, structure-activity relationships, overview
-
additional information
the enzyme shows sensitivity towards sulfhydryl modifying chemicals. 17beta-HSD1 is irreversibly inhibited by the sulfhydrylmodifying agents N-ethylmaleimide and dithiocarbamates. Preincubation with increasing concentrations of NADPH protects 17beta-HSD1 from inhibition by these chemicals
-
additional information
inhibitory effects of 13-epimeric estrones, D-secooxime and D-secoalcohol estrone compounds on placental enzyme 17beta-HSD1
-
additional information
-
design of a series of estradiol-derivatives from potent inhibitor 16beta-(m-carbamoylbenzyl)-E2 to eliminate estrogenic activity, evaluation as 17beta-HSD1 inhibitors, and their proliferative (estrogenic) activity on estrogen-sensitive cells, structure-activity relationship study, overview
-
additional information
ligand-based pharmacophore models for 17beta-HSD2 inhibitors are constructed and employed for virtual screening, structure-activity relationships, overview. No inhibition by 18, 25, 26, 27, 28, 33, 34, 36, 37, 38, 41, 42, 43, 44, 45, and 47
-
additional information
design of inhibitors displaying h17beta-HSD2 inhibitory activity and selectivity toward h17beta-HSD1. No inhibition by 5-(4-cyanophenyl)-N-(3-hydroxybenzyl)-N-methylthiophene-2-carboxamide
-
additional information
17beta-HSD1 and 17beta-HSD2 inhibitor structures and their biological activities are reviewed; 17beta-HSD1 and 17beta-HSD2 inhibitor structures and their biological activities are reviewed. Dual 17beta-HSD1/STS inhibitors and inhibitors are covered
-
additional information
17beta-HSD1 and 17beta-HSD2 inhibitor structures and their biological activities are reviewed; 17beta-HSD1 and 17beta-HSD2 inhibitor structures and their biological activities are reviewed. Dual 17beta-HSD1/STS inhibitors and inhibitors are covered
-
additional information
the status of inhibitors against 17beta-hydroxysteroid dehydrogenases 1 is reviewed
-
additional information
the status of inhibitors against 17beta-hydroxysteroid dehydrogenases 1 is reviewed
-
additional information
design of inhibitors displaying h17beta-HSD2 inhibitory activity and selectivity toward h17beta-HSD1. No inhibition by N,5-bis(3-hydroxyphenyl)-N-methylthiophene-2-carboxamide, 5-(4-cyanophenyl)-N-(3-methoxyphenyl)-N-methylthiophene-2-carboxamide, 5-(4-cyanophenyl)-N-(3-methoxyphenyl)-N-methylthiophene-2-carboxamide, 5-(4-cyanophenyl)-N-(3-hydroxybenzyl)-N-methylthiophene-2-carboxamide, 3'-hydroxy-N-(3-hydroxyphenyl)-N-methylbiphenyl-3-carboxamide, and 3'-methoxy-N-(3-methoxybenzyl)-N-methylbiphenyl-3-carboxamide
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
ACTIVATING COMPOUND
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
activin A
-
stimulates an increase in transcription and enzymatic activity in LbetaT2 cells
-
palm oil carotenoids
-
0.001 mM, significant stimulation of the conversion of estradiol to estrone in the MCF-7 cell line
-
retinoic acid
-
0.001 mM, significant stimulation of the conversion of estradiol to estrone in the MCF-7 cell line and MDA-MB-231 cell line, 0.0001 mM has no effect
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
KM VALUE [mM]
SUBSTRATE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
0.0192
5alpha-androstane 3alpha,17beta-diol
pH 7.4, 37°C recombinant His-tagged enzyme
0.015
allopregnanolone
pH and temperature not specified in the publication
0.0019
DELTA4-3,17-androstendione
pH 7.4, 37°C recombinant His-tagged enzyme
0.86
NADH
25°C, pH 8.0, mutant enzyme Y49D, cosubstrate: 4-estrene-3,17-dione
0.00062
17beta-estradiol
17beta-HSD14 variant S205, pH and temperature not specified in the publication
0.00079
17beta-estradiol
17beta-HSD14 variant T205, pH and temperature not specified in the publication
0.043
17beta-estradiol
pH and temperature not specified in the publication
0.068
17beta-estradiol
-
pH and temperature not specified in the publication
0.0066
5-androstene-3beta,17beta-diol
17beta-HSD14 variant S205, pH and temperature not specified in the publication
0.0078
5-androstene-3beta,17beta-diol
17beta-HSD14 variant T205, pH and temperature not specified in the publication
0.5
NAD+
25°C, pH 8.0, mutant enzyme Y49D, cosubstrate: 4-estrene-17beta-ol-3-one
0.000088
NADP+
25°C, pH 8.0, wild-type enzyme, cosubstrate: 4-estrene-17beta-ol-3-one
0.00019
NADP+
25°C, pH 8.0, mutant enzyme H164W, cosubstrate: 4-estrene-17beta-ol-3-one
0.00028
NADP+
25°C, pH 8.0, mutant enzyme H164G, cosubstrate: 4-estrene-17beta-ol-3-one
9
NADP+
25°C, pH 8.0, mutant enzyme Y49D, cosubstrate: 4-estrene-17beta-ol-3-one
0.00035
NADPH
25°C, pH 8.0, mutant enzyme H164G, cosubstrate: 4-estrene-3,17-dione
0.0004
NADPH
25°C, pH 8.0, mutant enzyme H164W, cosubstrate: 4-estrene-3,17-dione
0.0065
NADPH
25°C, pH 8.0, wild-type enzyme, cosubstrate: 4-estrene-3,17-dione
0.16
NADPH
25°C, pH 8.0, mutant enzyme Y49D, cosubstrate: 4-estrene-3,17-dione
additional information
additional information
-
Km-values for mutant enzymes in cell homogenate
-
additional information
additional information
-
effects of ethanol, glycerol, propanediol and other organic solvents on the Km-values
-
additional information
additional information
-
kinetics of wild-type and mutant enzymes, Theorell-Chance reaction mechanism
-
additional information
additional information
Michaelis-Menten kinetics, binding of dinucleotide cofactors to AKR1B15.1, overview
-
additional information
additional information
kinetics of wild-type and mutant enzymes, overview
-
additional information
additional information
Michaelis-Menten kinetics
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
TURNOVER NUMBER [1/s]
SUBSTRATE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
3
5alpha-androstane 3alpha,17beta-diol
pH 7.4, 37°C recombinant His-tagged enzyme
1.1
DELTA4-3,17-androstendione
pH 7.4, 37°C recombinant His-tagged enzyme
0.24
NAD+
25°C, pH 8.0, mutant enzyme Y49D, cosubstrate: 4-estrene-17beta-ol-3-one
0.27
NADH
25°C, pH 8.0, mutant enzyme Y49D, cosubstrate: 4-estrene-3,17-dione
0.0004
17beta-estradiol
17beta-HSD14 variant S205, pH and temperature not specified in the publication
0.00055
17beta-estradiol
17beta-HSD14 variant T205, pH and temperature not specified in the publication
0.011
17beta-estradiol
pH and temperature not specified in the publication
0.00028
5-androstene-3beta,17beta-diol
17beta-HSD14 variant S205, pH and temperature not specified in the publication
0.00032
5-androstene-3beta,17beta-diol
17beta-HSD14 variant T205, pH and temperature not specified in the publication
0.54
NADP+
25°C, pH 8.0, mutant enzyme Y49D, cosubstrate: 4-estrene-17beta-ol-3-one
0.65
NADP+
25°C, pH 8.0, wild-type enzyme, cosubstrate: 4-estrene-17beta-ol-3-one
3.1
NADP+
25°C, pH 8.0, mutant enzyme H164W, cosubstrate: 4-estrene-17beta-ol-3-one
4.7
NADP+
25°C, pH 8.0, mutant enzyme H164G, cosubstrate: 4-estrene-17beta-ol-3-one
0.065
NADPH
25°C, pH 8.0, mutant enzyme Y49D, cosubstrate: 4-estrene-3,17-dione
1.8
NADPH
25°C, pH 8.0, mutant enzyme H164W, cosubstrate: 4-estrene-3,17-dione
1.9
NADPH
25°C, pH 8.0, mutant enzyme H164G, cosubstrate: 4-estrene-3,17-dione
3.8
NADPH
25°C, pH 8.0, wild-type enzyme, cosubstrate: 4-estrene-3,17-dione
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
kcat/KM VALUE [1/mMs-1]
SUBSTRATE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
2.67
5alpha-androstane 3alpha,17beta-diol
pH 7.4, 37°C recombinant His-tagged enzyme
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Ki VALUE [mM]
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
0.0041
(6aS)-6a-methyl-4b,5,6,6a,8,10,10a,10b,11,12-decahydronaphtho[2',1':4,5]indeno[1,2-c]pyrazol-2-ol
-
0.4245
(S)-2-Methoxy-6a-methyl-5,6,6a,10,10a,10b,11,12-octahydro-4bH-7-oxa-8-aza-pentaleno[2,1-a]phenanthrene
-
-
0.0694
(S)-6a-Methyl-5,6,6a,10,10a,10b,11,12-octahydro-4bH-7-oxa-8-aza-pentaleno[2,1-a]phenanthren-2-ol
-
-
0.00061
1-[2-[4-(6-Methoxy-2-phenyl-3,4-dihydro-naphthalen-1-yl)-phenoxy]-ethyl]-pyrrolidine
-
-
0.0000009
3-([(16beta,17beta)-3,17-dihydroxyestra-1(10),2,4-trien-16-yl]methyl)benzamide
-
pH and temperature not specified in the publication
0.000007
[6-(3,4-dihydroxyphenyl)pyridin-2-yl]-(4-fluoro-3-hydroxyphenyl)methanone
pH and temperature not specified in the publication
0.000004
3-bromo-5-phenylsalicylic acid
-
pH not specified in the publication, 25°C
0.000087
3-bromo-5-phenylsalicylic acid
-
pH not specified in the publication, 25°C
0.0042
3-bromo-5-phenylsalicylic acid
-
pH not specified in the publication, 25°C
0.0182
3-bromo-5-phenylsalicylic acid
-
pH not specified in the publication, 25°C
0.00014
3-phenyl-5-bromosalicylic acid
-
pH not specified in the publication, 25°C
0.00197
3-phenyl-5-bromosalicylic acid
-
pH not specified in the publication, 25°C
0.021
3-phenyl-5-bromosalicylic acid
-
pH not specified in the publication, 25°C
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
IC50 VALUE [mM]
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
0.0012
(13alpha)-3-hydroxyestra-1(10),2,4-trien-17-one
Homo sapiens
pH and temperature not specified in the publication
0.000049
(13S,17R)-3-hydroxy-13-methyl-6,7,8,9,11,12,13,14,15,16-decahydrospiro[cyclopenta[a]phenanthrene-17,2'-pyran]-6'(3'H)-one
Homo sapiens
-
-
0.000019
(13S,17R)-3-hydroxy-4',13-dimethyl-4',5',6,7,8,9,11,12,13,14,15,16-dodecahydrospiro[cyclopenta[a]phenanthrene-17,2'-pyran]-6'(3'H)-one
Homo sapiens
-
-
0.000016
(13S,17R)-3-hydroxy-5',13-dimethyl-4',5',6,7,8,9,11,12,13,14,15,16-dodecahydrospiro[cyclopenta[a]phenanthrene-17,2'-pyran]-6'(3'H)-one
Homo sapiens
-
-
0.000028
(13S,17R)-3-hydroxy-5',5',13-trimethyl-4',5',6,7,8,9,11,12,13,14,15,16-dodecahydrospiro[cyclopenta[a]phenanthrene-17,2'-pyran]-6'(3'H)-one
Homo sapiens
-
-
0.000107
(13S,17R)-5'-cyclopropyl-3-hydroxy-13-methyl-4',5',6,7,8,9,11,12,13,14,15,16-dodecahydrospiro[cyclopenta[a]phenanthrene-17,2'-pyran]-6'(3'H)-one
Homo sapiens
-
-
0.00002
(13S,17S)-3-hydroxy-13-methyl-4',5',6,7,8,9,11,12,13,14,15,16-dodecahydrospiro[cyclopenta[a]phenanthrene-17,2'-pyran]-6'(3'H)-one
Homo sapiens
-
-
0.000042
(13S,17S)-3-hydroxy-13-methyl-6,7,8,9,11,12,13,14,15,16-decahydro-7'H-spiro[cyclopenta[a]phenanthrene-17,2'-oxepan]-7'-one
Homo sapiens
-
-
0.000101
(16alpha)-2-chloro-16-fluoro-3-hydroxyestra-1(10),2,4-trien-17-one
Homo sapiens
-
0.00032
(16beta)-16-(ethoxymethyl)-3-hydroxyestra-1(10),2,4-trien-17-one
Homo sapiens
-
0.000035
(16beta)-2-chloro-16-fluoro-3-hydroxyestra-1(10),2,4-trien-17-one
Homo sapiens
-
0.01
(16beta)-3-hydroxy-16-methyl-17-oxoestra-1(10),2,4-triene-16-carbonitrile
Homo sapiens
-
0.00011
(16Z)-3-hydroxy-16-(hydroxymethylidene)estra-1(10),2,4-trien-17-one
Homo sapiens
-
0.00051
(17beta)-3,17-dihydroxy-N-(pyridin-3-ylmethyl)estra-1(10),2,4-triene-16-carboxamide
Homo sapiens
-
0.000087
(2R,4aS,4bR,10bS,12aS)-9-chloro-2-fluoro-8-hydroxy-12a-methyl-3,4,4a,4b,5,6,10b,11,12,12a-decahydrochrysen-1(2H)-one
Homo sapiens
-
0.000126
(2S,4aS,4bR,10bS,12aS)-9-chloro-2-fluoro-8-hydroxy-12a-methyl-3,4,4a,4b,5,6,10b,11,12,12a-decahydrochrysen-1(2H)-one
Homo sapiens
-
0.00203
(3alpha,7alpha,17beta)-17-ethynyl-7-methylestr-5(10)-ene-3,17-diol
Homo sapiens
-
0.00483
(3beta,7alpha,17beta)-17-ethynyl-7-methylestr-5(10)-ene-3,17-diol
Homo sapiens
-
0.00041 - 0.0006
(4aR,6aS,7S)-7-[heptyl(methyl)amino]-1,4a,6a-trimethylhexadecahydro-2H-indeno[5,4-f]quinolin-2-one
0.00096
(4aR,6aS,7S)-7-[heptyl(methyl)amino]-4a,6a-dimethylhexadecahydro-2H-indeno[5,4-f]quinolin-2-one
Homo sapiens
pH and temperature not specified in the publication
0.000015
(4aS,4bR,10bS,12aS)-8-hydroxy-12a-methyl-9-(2-phenylethyl)-3,4,4a,4b,5,6,10b,11,12,12a-decahydrochrysen-1(2H)-one
Homo sapiens
-
0.000024
(4aS,4bR,10bS,12aS)-8-hydroxy-12a-methyl-9-prop-2-en-1-yl-3,4,4a,4b,5,6,10b,11,12,12a-decahydrochrysen-1(2H)-one
Homo sapiens
-
0.000052
(4aS,4bR,10bS,12aS)-8-hydroxy-9-iodo-12a-methyl-3,4,4a,4b,5,6,10b,11,12,12a-decahydrochrysen-1(2H)-one
Homo sapiens
-
0.000085
(4aS,4bR,10bS,12aS)-8-hydroxy-9-methoxy-12a-methyl-3,4,4a,4b,5,6,10b,11,12,12a-decahydrochrysen-1(2H)-one
Homo sapiens
-
0.000052
(4aS,4bR,10bS,12aS)-9-bromo-8-hydroxy-12a-methyl-3,4,4a,4b,5,6,10b,11,12,12a-decahydrochrysen-1(2H)-one
Homo sapiens
-
0.000077
(4aS,4bR,10bS,12aS)-9-chloro-8-hydroxy-12a-methyl-3,4,4a,4b,5,6,10b,11,12,12a-decahydrochrysen-1(2H)-one
Homo sapiens
-
0.00001
(4R,5R)-4-(2-fluorophenyl)-5-[hydroxy(5-phenylthiophen-2-yl)methyl]-1-methylpyrrolidin-2-one
Homo sapiens
pH 7.4, 37°C
0.00005
(4R,5R)-5-[hydroxy[5-(pyridin-3-yl)thiophen-2-yl]methyl]-1-methyl-4-phenylpyrrolidin-2-one
Homo sapiens
pH 7.4, 37°C
0.00042
(4S,5S)-5-[biphenyl-3-yl(hydroxy)methyl]-4-(2-fluorophenyl)-1-methylpyrrolidin-2-one
Homo sapiens
pH 7.4, 37°C
0.00102
(4S,5S)-5-[biphenyl-4-yl(hydroxy)methyl]-4-(2-fluorophenyl)-1-methylpyrrolidin-2-one
Homo sapiens
pH 7.4, 37°C
0.00005
(4S,5S)-5-[hydroxy[5-(pyridin-3-yl)thiophen-2-yl]methyl]-1-methyl-4-phenylpyrrolidin-2-one
Homo sapiens
pH 7.4, 37°C
0.000044
(6-hydroxy-1,3-benzothiazol-2-yl)(3-hydroxyphenyl)methanone
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.0003
(6aS)-2-hydroxy-6a-methyl-N-(2-pyridin-3-ylethyl)-4b,5,6,6a,8,10,10a,10b,11,12-decahydronaphtho[2',1':4,5]indeno[1,2-c]pyrazole-9-carboxamide
Homo sapiens
0.01 mM, 99% inhibition, IC50: 0.0003 mM
0.00088
(6aS)-2-hydroxy-6a-methyl-N-(pyridin-2-ylmethyl)-4b,5,6,6a,8,10,10a,10b,11,12-decahydronaphtho[2',1':4,5]indeno[1,2-c]pyrazole-9-carboxamide
Homo sapiens
0.01 mM, 93% inhibition, IC50: 0.00088 mM
0.00078
(6aS)-2-hydroxy-6a-methyl-N-(pyridin-3-ylmethyl)-4b,5,6,6a,8,10,10a,10b,11,12-decahydronaphtho[2',1':4,5]indeno[1,2-c]pyrazole-9-carboxamide
Homo sapiens
0.01 mM, 92% inhibition, IC50: 0.00078 mM
0.0023
(6aS)-2-hydroxy-6a-methyl-N-[(1-methyl-1H-pyrrol-2-yl)methyl]-4b,5,6,6a,8,10,10a,10b,11,12-decahydronaphtho[2',1':4,5]indeno[1,2-c]pyrazole-9-carboxamide
Homo sapiens
0.01 mM, 90% inhibition, IC50: 0.0023 mM
0.0007
(6aS)-3-ethyl-2-hydroxy-6a-methyl-N-(2-pyridin-3-ylethyl)-4b,5,6,6a,8,10,10a,10b,11,12-decahydronaphtho[2',1':4,5]indeno[1,2-c]pyrazole-9-carboxamide
Homo sapiens
-
0.00053
(6aS)-8-(2-methoxyethyl)-6a-methyl-4b,5,6,6a,8,10,10a,10b,11,12-decahydronaphtho[2',1':4,5]indeno[1,2-c]pyrazol-2-ol
Homo sapiens
-
0.00095
(6aS)-9-(hydroxymethyl)-6a-methyl-4b,5,6,6a,8,10,10a,10b,11,12-decahydronaphtho[2',1':4,5]indeno[1,2-c]pyrazol-2-ol
Homo sapiens
-
0.000066
(6aS,6bS,11aS)-2-hydroxy-6a-methyl-4b,5,6,6a,6b,9,10,11,11a,12,12a,12b,13,14-tetradecahydro-8H-naphtho[2',1':4,5]indeno[1,2-b]oxepin-8-one
Homo sapiens
-
-
0.000173
1,1':4',1''-terphenyl-3,3''-diol
Homo sapiens
-
at 37°C in phosphate buffer (50 mM) with 20% (v/v) glycerol and 1 mM EDTA
0.00004
1-bromo-6-(3-hydroxyphenyl)-2-naphthol
Homo sapiens
in 20 mM KH2PO4, pH 7.4, at 25°C
0.00014
10-((13S,16S,17S)-3,17-Dihydroxy-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-16-yl)-decanoic acid 5-(6-amino-purin-9-yl)-3,4-dihydroxy-tetrahydro-furan-2-ylmethyl ester
Homo sapiens
-
IC50: 140 nM
0.00046
16alpha-bromopropyl-estradiol
Homo sapiens
-
IC50: 0.00046 mM, reduction of estrone, the inhibitor is totally inactive against type 2 17beta-HSD and type type 1 17beta-HSD
0.0043
2,2'-diimino-7,7'-dimethyl-5,5'-bis(1-methylethyl)-2H,2'H-8,8'-binaphtho[1,8-bc]furan-3,3',4,4'-tetrol
Homo sapiens
-
0.023
2-(2-bromo-4,6-dimethylphenoxy)-N'-[(E)-(2,4-dihydroxyphenyl)methylidene]acetohydrazide
Homo sapiens
pH 7.4, 37°C
0.0000222
2-chloro-4-[5-(2,6-difluoro-3-hydroxybenzoyl)thiophen-2-yl]phenyl sulfamate
Homo sapiens
whole cell assay, pH not specified in the publication, temperature not specified in the publication
0.0051
2-ethyl-17-oxo-16-[2-oxo-2-[(pyridin-3-ylmethyl)amino]ethyl]estra-1(10),2,4-trien-3-yl sulfamate
Homo sapiens
-
0.00000362 - 0.000165
2-[2-ethyl-3-hydroxy-17-oxoestra-1(10),2,4-trien-16-yl]-N-(pyridin-2-ylmethyl)acetamide
0.000027
2-[2-ethyl-3-hydroxy-17-oxoestra-1(10),2,4-trien-16-yl]-N-(pyridin-3-ylmethyl)acetamide
Homo sapiens
-
0.000037
2-[3-hydroxy-17-oxoestra-1(10),2,4-trien-16-yl]-N-(pyridin-3-ylmethyl)acetamide
Homo sapiens
-
0.0047
2-[5-(3-ethyl-4-hydroxyphenyl)-1-oxo-indan-2-yl]-N-pyridin-3-ylmethyl-acetamide
Homo sapiens
-
0.00064
3'-hydroxy-N-(3-hydroxybenzyl)-N-methylbiphenyl-3-carboxamide
Homo sapiens
pH 7.4, 37°C
0.000594
3'-hydroxy-N-(3-hydroxybenzyl)-N-methylbiphenyl-4-carboxamide
Homo sapiens
pH 7.4, 37°C
0.00054
3'-hydroxy-N-(3-hydroxyphenyl)-N-methyl-[1,10-biphenyl]-3-sulfonamide
Homo sapiens
pH 7.4, 37°C
0.000061
3'-hydroxy-N-(3-hydroxyphenyl)-N-methylbiphenyl-4-carboxamide
Homo sapiens
pH 7.4, 37°C
0.000494
3'-methoxy-N-(3-methoxybenzyl)-N-methylbiphenyl-4-carboxamide
Homo sapiens
pH 7.4, 37°C
0.00052
3'-methoxy-N-(3-methoxyphenyl)-N-methylbiphenyl-3-carboxamide
Homo sapiens
pH 7.4, 37°C
0.000517
3'-methoxy-N-(3-methoxyphenyl)-N-methylbiphenyl-4-carboxamide
Homo sapiens
pH 7.4, 37°C
0.0022
3,3',4,4'-tetrahydroxy-7,7'-dimethyl-5,5'-bis(1-methylethyl)-2H,2'H-8,8'-binaphtho[1,8-bc]furan-2,2'-dione
Homo sapiens
-
0.041
3,3'-(1-phenyl-1H-1,2,4-triazole-3,5-diyl)diphenol
Homo sapiens
-
37°C, pH not specified in the publication
0.000101
3,3'-pyridine-2,5-diyldiphenol
Homo sapiens
-
at 37°C in phosphate buffer (50 mM) with 20% (v/v) glycerol and 1 mM EDTA
0.001 - 0.005
3,5,7,4'-tetrahydroxyflavone
Curvularia lunata
-
IC50 between 0.001 and 0.005 mM, reduction of estra-4-en-3,17-dione
0.001
3,7-dihydroxyflavone
Curvularia lunata
-
IC50 below 0.001 mM, oxidation of 17beta-hydroxyestra-4-en-3-one
0.000044
3-(3,17beta-dihydroxy-estra-1,3,5(10)-trien-16beta-ylmethyl)-benzamide
Homo sapiens
-
0.000171
3-(3-hydroxy-17-oxo-estra-1,3,5(10)-trien-16beta-ylmethyl)-benzamide
Homo sapiens
-
0.000042
3-([(16beta,17beta)-3,17-dihydroxyestra-1(10),2,4-trien-16-yl]methyl)benzamide
Homo sapiens
-
pH and temperature not specified in the publication
0.000083
3-([(16beta,17beta)-3-(2-bromoethyl)-17-hydroxyestra-1(10),2,4-trien-16-yl]methyl)benzamide
Homo sapiens
-
pH and temperature not specified in the publication
0.000005
3-benzyl-2-(2-bromo-3,4,5-trimethoxyphenyl)-8-hydroxy[1]benzothieno[2,3-d]pyrimidin-4(3H)-one
Homo sapiens
87% inhibition at 100 nM, 95% inhibition at 0.001 mM. IC50: 5 nM
0.000005
3-benzyl-8-hydroxy-2-(3,4,5-trimethoxyphenyl)[1]benzothieno[2,3-d]pyrimidin-4(3H)-one
0.00046
3-bromo-5-phenylsalicylic acid
Homo sapiens
-
pH not specified in the publication, 25°C
0.0063
3-bromo-N-(3-hydroxy-4-methylphenyl)benzenesulfonamide
Homo sapiens
pH 7.4, 37°C
0.00095
3-hydroxy-1,3,5(10)-triene-[17,16-c]-(5'-hydroxymethyl)-pyrazole
Homo sapiens
-
0.01 mM: 94% inhibition, IC50: 0.00095 mM
0.00185
3-hydroxy-1,3,5(10)-triene-[17,16-c]-[5'-(carboxylic acid ethyl ester)]-pyrazole
Homo sapiens
-
0.01 mM: 94% inhibition, IC50: 0.00185 mM
0.00007
3-hydroxy-13alpha-D-secooxime
Homo sapiens
pH and temperature not specified in the publication
0.00053
3-hydroxy-estra-1,3,5(10)-triene-[17,16-c]-(1'-methoxyethyl)-pyrazole
Homo sapiens
-
0.01 mM: 95% inhibition, IC50: 0.00053 mM
0.00092
3-hydroxy-estra-1,3,5(10)-triene-[17,16-c]-(1'-methyl acetate)-pyrazole
Homo sapiens
-
0.01 mM: 95% inhibition, IC50: 0.00092 mM
0.00275
3-hydroxy-estra-1,3,5(10)-triene-[17,16-c]-(1'-methyl)-pyrazole
Homo sapiens
-
0.01 mM: 94% inhibition, IC50: 0.00275 mM
0.00073
3-hydroxy-estra-1,3,5(10)-triene-[17,16-c]-(1'-propionitrile)-pyrazole
Homo sapiens
-
0.01 mM: 95% inhibition, IC50: 0.00073 mM
0.0023
3-hydroxy-estra-1,3,5(10)-triene-[17,16-c]-[5'-(1'-methylpyrrol-2''-ylmethyl)carbamoyl]-pyrazole
Homo sapiens
-
0.01 mM: 89% inhibition, IC50: 0.0023 mM
0.00088
3-hydroxy-estra-1,3,5(10)-triene-[17,16-c]-[5'-(pyridin-2''-ylmethyl)carbamoyl]-pyrazole
Homo sapiens
-
0.01 mM: 93% inhibition, IC50: 0.00088 mM
0.0003
3-hydroxy-estra-1,3,5(10)-triene-[17,16-c]-[5'-(pyridin-3''-ylethyl)carbamoyl]-pyrazole
Homo sapiens
-
0.01 mM: 99% inhibition, IC50: 0.0003 mM
0.00078
3-hydroxy-estra-1,3,5(10)-triene-[17,16-c]-[5'-(pyridin-3''-ylmethyl)carbamoyl]-pyrazole
Homo sapiens
-
0.01 mM: 92% inhibition, IC50: 0.00078 mM
0.000159
3-hydroxy-N-(3'-hydroxy-[1,1'-biphenyl]-3-yl)-N-methylbenzenesulfonamide
Homo sapiens
pH 7.4, 37°C
0.000511
3-hydroxy-N-(3'-hydroxy-[1,1'-biphenyl]-4-yl)-N-methylbenzenesulfonamide
Homo sapiens
pH 7.4, 37°C
0.000243
3-hydroxy-N-(6-hydroxy-1,3-benzothiazol-2-yl)benzamide
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.0019
3-hydroxyestra-1,3,5(10),7-tetraen-17-one
Homo sapiens
-
IC50: 0.0019 mM, oxidation of estradiol
0.00073
3-[(6aS)-2-hydroxy-6a-methyl-4b,6,6a,10,10a,10b,11,12-octahydronaphtho[2',1':4,5]indeno[1,2-c]pyrazol-8(5H)-yl]propanenitrile
Homo sapiens
-
0.021
3-[3-(4-hydroxyphenyl)-1-methyl-1H-1,2,4-triazol-5-yl]phenol
Homo sapiens
-
37°C, pH not specified in the publication
0.000077
3-[4-(4-hydroxyphenyl)thiophen-2-yl]phenol
Homo sapiens
-
at 37°C in phosphate buffer (50 mM) with 20% (v/v) glycerol and 1 mM EDTA
0.02
3-[5-(4-hydroxyphenyl)-1-methyl-1H-1,2,4-triazol-3-yl]phenol
Homo sapiens
-
37°C, pH not specified in the publication
0.044
3-[5-(4-hydroxyphenyl)-1-phenyl-1H-1,2,4-triazol-3-yl]phenol
Homo sapiens
-
37°C, pH not specified in the publication
0.000069
3-[5-(4-hydroxyphenyl)thiophen-2-yl]phenol
Homo sapiens
-
at 37°C in phosphate buffer (50 mM) with 20% (v/v) glycerol and 1 mM EDTA
0.000151
3-[5-(4-hydroxyphenyl)thiophen-3-yl]phenol
Homo sapiens
-
at 37°C in phosphate buffer (50 mM) with 20% (v/v) glycerol and 1 mM EDTA
0.0031
3alpha-hydroxy-3beta-([4-[(2-methoxy-4-methylphenyl)methyl]piperazin-1-yl]methyl)-androstan-17-one
Homo sapiens
-
pH and temperature not specified in the publication, transformation of E2 to E1 by HEK-293[17beta-HSD10] cells
0.00042
3alpha-hydroxy-3beta-([4-[(3-methoxy-4-methylphenyl)methyl]piperazin-1-yl]methyl)-androstan-17-one
Homo sapiens
-
pH and temperature not specified in the publication, transformation of E2 to E1 by HEK-293[17beta-HSD10] cells
0.0026
3alpha-hydroxy-3beta-([4-[(3-methoxyphenyl)methyl]piperazin-1-yl]methyl)-androstan-17-one
Homo sapiens
-
pH and temperature not specified in the publication, transformation of E2 to E1 by HEK-293[17beta-HSD10] cells
0.00097
3alpha-hydroxy-3beta-([4-[(quinolin-3-yl)methyl]piperazin-1-yl]methyl)-androstan-17-one
Homo sapiens
-
pH and temperature not specified in the publication, transformation of E2 to E1 by HEK-293[17beta-HSD10] cells
0.00014
3alpha-hydroxy-3beta-[(4-[[3-methoxy-4-(trifluoromethyl)phenyl]methyl]piperazin-1-yl)methyl]-androstan-17-one
Homo sapiens
-
pH and temperature not specified in the publication, transformation of E2 to E1 by HEK-293[17beta-HSD10] cells
0.00126
3beta-[(4-[[3-methoxy-4-(trifluoromethyl)phenyl]methyl]piperazin-1-yl)methyl]-17alpha-pregn-20-yne-3alpha,17-diol
Homo sapiens
-
pH and temperature not specified in the publication, transformation of E2 to E1 by HEK-293[17beta-HSD10] cells
-
0.00095
3beta-[(4-[[3-methoxy-4-(trifluoromethyl)phenyl]methyl]piperazin-1-yl)methyl]-androstane-3alpha,17alpha-diol
Homo sapiens
-
pH and temperature not specified in the publication, transformation of E2 to E1 by HEK-293[17beta-HSD10] cells
0.00205
3beta-[[4-(3,5-dimethylbenzoyl)piperazin-1-yl]methyl]-3alpha-hydroxyandrostan-17-one
Homo sapiens
-
pH and temperature not specified in the publication, transformation of E2 to E1 by HEK-293[17beta-HSD10] cells
0.0023
3beta-[[4-(3-acetylbenzoyl)piperazin-1-yl]methyl]-3alpha-hydroxyandrostan-17-one
Homo sapiens
-
pH and temperature not specified in the publication, transformation of E2 to E1 by HEK-293[17beta-HSD10] cells
0.0026
3beta-[[4-([1,1'-biphenyl]-4-carbonyl)piperazin-1-yl]methyl]-3alpha-hydroxyandrostan-17-one
Homo sapiens
-
pH and temperature not specified in the publication, transformation of E2 to E1 by HEK-293[17beta-HSD10] cells
0.0012
4'-methoxy-N-(3-methoxyphenyl)-N-methylbiphenyl-3-carboxamide
Homo sapiens
pH 7.4, 37°C
0.0018
4-(3'-ethyl-4'-hydroxy-biphenyl)-2,2-dimethyl-4-oxo-N-pyridin-3-ylmethyl-butyramide
Homo sapiens
-
0.0037
4-(3'-ethyl-4'-hydroxy-biphenyl)-4-oxo-N-pyridin-3-ylmethyl-butyramide
Homo sapiens
-
0.0018
4-(3-ethyl-4-hydroxy-biphenyl)-2,2-dimethyl-4-oxo-N-pyridin-3-ylmethyl-butyramide
Homo sapiens
-
0.0017
4-(4-[[3alpha-hydroxy-17-oxoandrostan-3beta-yl]methyl]piperazine-1-carbonyl)benzonitrile
Homo sapiens
-
pH and temperature not specified in the publication, transformation of E2 to E1 by HEK-293[17beta-HSD10] cells
0.001
4-chloro-N-(3-hydroxyphenyl)-2,5-dimethylbenzenesulfonamide
Homo sapiens
pH 7.4, 37°C
0.000023
4-fluoro-3-hydroxy-N-(3'-hydroxybiphenyl-3-yl)-N-methylbenzenesulfonamide
Homo sapiens
pH 7.4, 37°C
0.000046
4-[5-(3-hydroxyphenyl)thiophen-2-yl]-2-methylphenol
Homo sapiens
-
at 37°C in phosphate buffer (50 mM) with 20% (v/v) glycerol and 1 mM EDTA
0.0014
4-[[3alpha-hydroxy-17-oxoandrostan-3beta-yl]methyl]-N-[[3-(trifluoromethyl)phenyl]methyl]piperazine-1-carbothioamide
Homo sapiens
-
pH and temperature not specified in the publication, transformation of E2 to E1 by HEK-293[17beta-HSD10] cells
0.00014
5'-O-(10-[3',17'beta-dihydroxy-1',3',5'(10')-estratrien-16'alpha-yl]-decanoyl)adenosine
Homo sapiens
-
IC50: 140 nM
0.00031
5'-O-(11-[3',17'beta-dihydroxy-1',3',5'(10')-estratrien-16'alpha-yl]-undecanoyl) adenosine
Homo sapiens
-
IC50: 310 nM
0.00009
5'-O-(11-[3',17'beta-dihydroxy-1',3',5'(10')-estratrien-16'alpha/beta-yl]-undecanoyl)adenosine
Homo sapiens
-
IC50: 90 nM
0.00012
5'-O-(11-[3',17'beta-dihydroxy-1',3',5'(10')-estratrien-16'beta-yl]-undecanoyl)adenosine
Homo sapiens
-
IC50: 120 nM
0.001
5'-O-(12-[3',17'beta-(dihydroxy)-1',3',5'(10')-estratrien-16'alpha-yl]-dodecanoyl)adenosine
Homo sapiens
-
IC50: 1000 nM
0.0069
5'-O-(6-[3',17'beta-dihydroxy-1',3',5'(10')-estratrien-16'alpha/beta-yl]-hexanoyl)adenosine
Homo sapiens
-
IC50: 6900 nM
0.00043
5'-O-(7-[3',17'beta-dihydroxy-1',3',5'(10')-estratrien-16'alpha-yl]-heptanoyl)adenosine
Homo sapiens
-
IC50: 430 nM
0.000093
5'-O-(8-[3',17'beta-dihydroxy-1',3',5'(10')-estratrien-16'alpha-yl]-octanoyl)adenosine
Homo sapiens
-
IC50: 93 nM
0.000052
5'-O-(9-[3',17'beta-dihydroxy-1',3',5'(10')-estratrien-16'alpha-yl]-nonanoyl)adenosine
Homo sapiens
-
IC50: 52 nM
0.000052
5'-O-[9-[(16b,17b)-3,17-dihydroxyestra-1(10),2,4-trien-16-yl]nonanoyl]adenosine
Homo sapiens
-
0.001
5,7-dihydroxyflavone
Curvularia lunata
-
IC50 below 0.001 mM, oxidation of 17beta-hydroxyestra-4-en-3-one
0.000061
5-(2-fluoro-3-methoxyphenyl)-N-(3-hydroxybenzyl)-N-methylthiophene-2-carboxamide
Homo sapiens
pH 7.4, 37°C
0.000062
5-(2-fluoro-3-methoxyphenyl)-N-(3-methoxyphenyl)-N-methylthiophene-2-carboxamide
Homo sapiens
pH 7.4, 37°C
0.000062
5-(2-fluoro-3-methoxyphenyl)-N-methyl-N-(3-methylphenyl)thiophene-2-carboxamide
Homo sapiens
pH 7.4, 37°C
0.00041
5-(2-hydroxyphenyl)-N-(3-hydroxyphenyl)-N-methylthiophene-2-carboxamide
Homo sapiens
pH 7.4, 37°C
0.00049
5-(2-methoxyphenyl)-N-(3-methoxyphenyl)-N-methylthiophene-2-carboxamide
Homo sapiens
pH 7.4, 37°C
0.00033
5-(3-fluorophenyl)-N-(3-hydroxybenzyl)-N-methylthiophene-2-carboxamide
Homo sapiens
pH 7.4, 37°C
0.00017
5-(3-fluorophenyl)-N-(3-methoxyphenyl)-N-methylthiophene-2-carboxamide
Homo sapiens
pH 7.4, 37°C
0.00051
5-(4-cyanophenyl)-N-(3-methoxyphenyl)-N-methylthiophene-2-carboxamide
Homo sapiens
pH 7.4, 37°C
0.001
5-hydroxyflavone
Curvularia lunata
-
IC50 below 0.001 mM, oxidation of 17beta-hydroxyestra-4-en-3-one
0.001 - 0.005
5-methoxyflavone
Curvularia lunata
-
IC50 between 0.001 and 0.005 mM, reduction of estra-4-en-3,17-dione
0.00002
6-(3-hydroxyphenyl)-1-phenyl-2-naphthol
Homo sapiens
in 20 mM KH2PO4, pH 7.4, at 25°C
0.000093
8-((13S,16S,17S)-3,17-Dihydroxy-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-16-yl)-octanoic acid 5-(6-amino-purin-9-yl)-3,4-dihydroxy-tetrahydro-furan-2-ylmethyl ester
Homo sapiens
-
IC50: 93 nM
0.000052
9-((13S,16S,17S)-3,17-Dihydroxy-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-16-yl)-nonanoic acid 5-(6-amino-purin-9-yl)-3,4-dihydroxy-tetrahydro-furan-2-ylmethyl ester
Homo sapiens
-
IC50: 52 nM
0.00185
ethyl [(6aS)-2-hydroxy-6a-methyl-4b,5,6,6a,8,10,10a,10b,11,12-decahydronaphtho[2',1':4,5]indeno[1,2-c]pyrazol-9-yl]acetate
Homo sapiens
-
0.000072
methyl (13S,17R)-3-hydroxy-13-methyl-6'-oxo-3',4',5',6,6',7,8,9,11,12,13,14,15,16-tetradecahydrospiro[cyclopenta[a]phenanthrene-17,2'-pyran]-5'-carboxylate
Homo sapiens
-
-
0.00092
methyl [(6aS)-2-hydroxy-6a-methyl-4b,6,6a,10,10a,10b,11,12-octahydronaphtho[2',1':4,5]indeno[1,2-c]pyrazol-8(5H)-yl]acetate
Homo sapiens
-
0.0011
N,4'-dimethyl-N-(3-methylphenyl)biphenyl-4-carboxamide
Homo sapiens
pH 7.4, 37°C
0.000068
N,5-bis(3-methoxyphenyl)-N-methylthiophene-2-carboxamide
Homo sapiens
pH 7.4, 37°C
0.0011
N-(2,1,3-benzothiadiazol-4-yl)-2-[(4-hydroxypyrimidin-2-yl)sulfanyl]acetamide
Homo sapiens
pH 7.4, 37°C
0.24 - 0.52
N-(2-hydroxyphenyl)-2-methyl-4-(trifluoromethyl)benzenesulfonamide
Homo sapiens
pH 7.4, 37°C
0.003 - 0.01
N-(3-chloro-4-hydroxyphenyl)-4-fluorobenzenesulfonamide
Homo sapiens
pH 7.4, 37°C
0.0071
N-(3-hydroxy-4-methylphenyl)-3-(trifluoromethyl)benzenesulfonamide
Homo sapiens
pH 7.4, 37°C
0.00039
N-(3-hydroxybenzyl)-5-(3-hydroxyphenyl)-N-methylthiophene-2-carboxamide
Homo sapiens
pH 7.4, 37°C
0.00033
N-(3-hydroxybenzyl)-5-(4-hydroxyphenyl)-N-methylthiophene-2-carboxamide
Homo sapiens
pH 7.4, 37°C
0.000161
N-(3-hydroxybenzyl)-5-(4-methoxyphenyl)-N-methylthiophene-2-carboxamide
Homo sapiens
pH 7.4, 37°C
0.0033
N-(3-hydroxyphenyl)-2,4,5-trimethylbenzenesulfonamide
Homo sapiens
pH 7.4, 37°C
0.0069
N-(3-hydroxyphenyl)-4-methoxy-2,5-dimethylbenzenesulfonamide
Homo sapiens
pH 7.4, 37°C
0.015
N-(3-hydroxyphenyl)-4-methoxy-2-methyl-5,6,7,8-tetrahydronaphthalene-1-sulfonamide
Homo sapiens
pH 7.4, 37°C
0.00037
N-(3-methoxybenzyl)-5-(3-methoxyphenyl)-N-methylthiophene-2-carboxamide
Homo sapiens
pH 7.4, 37°C
0.000058
N-(3-methoxyphenyl)-N-methyl-5-(3-methylphenyl)thiophene-2-carboxamide
Homo sapiens
pH 7.4, 37°C
0.0096
N-(4-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)-4-methoxybenzenesulfonamide
Homo sapiens
pH 7.4, 37°C
0.0008
N-butyl-6-[[(6beta,17beta)-3,17-dihydroxyestra-1(10),2,4-trien-6-yl]oxy]-N-methylhexanamide
Homo sapiens
-
73% inhibition at 0.001 mM, IC50: 0.0008 mM, reduction of estrone with NADH as cofactor
0.00016
N-butyl-6-[[(6beta,17beta)-3,17-dihydroxyestra-1(10),2,4-trien-6-yl]sulfanyl]-N-methylhexanamide
0.00291 - 0.00396
N-decyl-N-[(4aR,6aS,7S)-1,4a,6a-trimethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]formamide
0.00112 - 0.00578
N-decyl-N-[(4aR,6aS,7S)-4a,6a-dimethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]formamide
0.0016
N-ethyl-4-[[3alpha-hydroxy-17-oxoandrostan-3beta-yl]methyl]-N-methylpiperazine-1-sulfonamide
Homo sapiens
-
pH and temperature not specified in the publication, transformation of E2 to E1 by HEK-293[17beta-HSD10] cells
0.000052
N-methyl-N,5-bis(3-methylphenyl)thiophene-2-carboxamide
Homo sapiens
pH 7.4, 37°C
0.0007 - 0.00332
N-nonyl-N-[(4aR,6aS,7S)-1,4a,6a-trimethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]formamide
0.00107
N-[4-(dimethylsulfamoyl)phenyl]-4-[[3alpha-hydroxy-17-oxoandrostan-3beta-yl]methyl]piperazine-1-carbothioamide
Homo sapiens
-
pH and temperature not specified in the publication, transformation of E2 to E1 by HEK-293[17beta-HSD10] cells
0.00285
[[4-(4-benzoylbenzoyl)piperazin-1-yl]methyl]-3alpha-hydroxyandrostan-17-one
Homo sapiens
-
pH and temperature not specified in the publication, transformation of E2 to E1 by HEK-293[17beta-HSD10] cells
0.00041
(4aR,6aS,7S)-7-[heptyl(methyl)amino]-1,4a,6a-trimethylhexadecahydro-2H-indeno[5,4-f]quinolin-2-one
Homo sapiens
pH and temperature not specified in the publication
0.0006
(4aR,6aS,7S)-7-[heptyl(methyl)amino]-1,4a,6a-trimethylhexadecahydro-2H-indeno[5,4-f]quinolin-2-one
Homo sapiens
pH and temperature not specified in the publication, substrate: progesterone
0.00291
17beta-[(N-decyl)formamido]-4-methyl-4-aza-5alpha-androstan-3-one
Homo sapiens
pH 7.4, 37°C, reduction of estrone
0.00396
17beta-[(N-decyl)formamido]-4-methyl-4-aza-5alpha-androstan-3-one
Homo sapiens
pH 7.4, 37°C, reduction of dihydrotestosterone
0.00424
17beta-[(N-decyl)formamido]-4-methyl-4-aza-5alpha-androstan-3-one
Homo sapiens
pH 7.4, 37°C, reduction of progesterone
0.00578
17beta-[(N-heptyl)methylamino]-4-aza-5alpha-androstan-3-one
Homo sapiens
pH 7.4, 37°C, reduction of dihydrotestosterone
0.00601
17beta-[(N-heptyl)methylamino]-4-aza-5alpha-androstan-3-one
Homo sapiens
pH 7.4, 37°C, reduction of progesterone
0.00041
17beta-[(N-heptyl)methylamino]-4-methyl-4-aza-5alpha-androstan-3-one
Homo sapiens
pH 7.4, 37°C, reduction of estrone
0.0006
17beta-[(N-heptyl)methylamino]-4-methyl-4-aza-5alpha-androstan-3-one
Homo sapiens
pH 7.4, 37°C, reduction of progesterone
0.00119
17beta-[(N-heptyl)methylamino]-4-methyl-4-aza-5alpha-androstan-3-one
Homo sapiens
pH 7.4, 37°C, reduction of dihydrotestosterone
0.0007
17beta-[(N-nonyl)formamido]-4-methyl-4-aza-5alpha-androstan-3-one
Homo sapiens
pH 7.4, 37°C, reduction of estrone
0.00316
17beta-[(N-nonyl)formamido]-4-methyl-4-aza-5alpha-androstan-3-one
Homo sapiens
pH 7.4, 37°C, reduction of progesterone
0.00332
17beta-[(N-nonyl)formamido]-4-methyl-4-aza-5alpha-androstan-3-one
Homo sapiens
pH 7.4, 37°C, reduction of dihydrotestosterone
0.00000362
2-[2-ethyl-3-hydroxy-17-oxoestra-1(10),2,4-trien-16-yl]-N-(pyridin-2-ylmethyl)acetamide
Homo sapiens
-
0.000165
2-[2-ethyl-3-hydroxy-17-oxoestra-1(10),2,4-trien-16-yl]-N-(pyridin-2-ylmethyl)acetamide
Homo sapiens
-
0.00137
3'-(1-benzothien-2-yl)biphenyl-3-ol
Homo sapiens
37°C, pH not specified in the publication
0.00194
3'-(1-benzothien-2-yl)biphenyl-3-ol
Homo sapiens
37°C, pH not specified in the publication
0.00056
3'-(5-chloro-2-thienyl)biphenyl-3-ol
Homo sapiens
37°C, pH not specified in the publication
0.00237
3'-(5-chloro-2-thienyl)biphenyl-3-ol
Homo sapiens
37°C, pH not specified in the publication
0.000934
3'-hydroxy-N-(3-hydroxybenzyl)-N-methyl-[1,10-biphenyl]-4-sulfonamide
Homo sapiens
pH 7.4, 37°C
0.004299
3'-hydroxy-N-(3-hydroxybenzyl)-N-methyl-[1,10-biphenyl]-4-sulfonamide
Homo sapiens
pH 7.4, 37°C
0.001179
3'-hydroxy-N-(3-hydroxyphenyl)-N-methyl-[1,10-biphenyl]-4-sulfonamide
Homo sapiens
pH 7.4, 37°C
0.002031
3'-hydroxy-N-(3-hydroxyphenyl)-N-methyl-[1,10-biphenyl]-4-sulfonamide
Homo sapiens
pH 7.4, 37°C
0.017
3,3'-(1H-1,2,3-triazole-1,4-diyl)diphenol
Homo sapiens
-
37°C, pH not specified in the publication
0.000005
3-benzyl-8-hydroxy-2-(3,4,5-trimethoxyphenyl)[1]benzothieno[2,3-d]pyrimidin-4(3H)-one
Homo sapiens
94% inhibition at 100 nM, 99% inhibition at 0.001 mM. IC50: 5 nM
0.000005
3-benzyl-8-hydroxy-2-(3,4,5-trimethoxyphenyl)[1]benzothieno[2,3-d]pyrimidin-4(3H)-one
Homo sapiens
-
0.001
3-hydroxyflavone
Curvularia lunata
-
IC50 below 0.001 mM, oxidation of 17beta-hydroxyestra-4-en-3-one
0.001 - 0.005
3-hydroxyflavone
Curvularia lunata
-
IC50 between 0.001 and 0.005 mM, reduction of estra-4-en-3,17-dione
0.00132
3-[1-(4-hydroxyphenyl)-1H-1,2,3-triazol-4-yl]-phenol
Homo sapiens
substrate: estrone, 17beta-HSD1
0.00812
3-[1-(4-hydroxyphenyl)-1H-1,2,3-triazol-4-yl]-phenol
Homo sapiens
substrate: estradiol-17beta, 17beta-HSD2
0.00132
3-[1-(4-hydroxyphenyl)-1H-1,2,3-triazol-4-yl]phenol
Homo sapiens
-
37°C, pH not specified in the publication
40.88
3-[1-(4-hydroxyphenyl)-1H-1,2,3-triazol-4-yl]phenol
Homo sapiens
-
37°C, pH not specified in the publication
0.00047
3-[2-(5-chloro-2-thienyl)pyridin-4-yl]phenol
Homo sapiens
37°C, pH not specified in the publication
0.00238
3-[2-(5-chloro-2-thienyl)pyridin-4-yl]phenol
Homo sapiens
37°C, pH not specified in the publication
0.00027
3-[3-(4-hydroxyphenyl)isoxazol-5-yl]-phenol
Homo sapiens
substrate: estradiol-17beta, 17beta-HSD2
0.00161
3-[3-(4-hydroxyphenyl)isoxazol-5-yl]-phenol
Homo sapiens
substrate: estrone, 17beta-HSD1
0.00025
3-[4-(4-hydroxyphenyl)-1,3-oxazol-2-yl]-phenol
Homo sapiens
substrate: estradiol-17beta, 17beta-HSD2
0.00185
3-[4-(4-hydroxyphenyl)-1,3-oxazol-2-yl]-phenol
Homo sapiens
substrate: estrone, 17beta-HSD1
0.00084
3-[4-(4-hydroxyphenyl)-1H-1,2,3-triazol-1-yl]-phenol
Homo sapiens
substrate: estrone, 17beta-HSD1
0.00728
3-[4-(4-hydroxyphenyl)-1H-1,2,3-triazol-1-yl]-phenol
Homo sapiens
substrate: estradiol-17beta, 17beta-HSD2
0.00084
3-[4-(4-hydroxyphenyl)-1H-1,2,3-triazol-1-yl]phenol
Homo sapiens
-
37°C, pH not specified in the publication
46.94
3-[4-(4-hydroxyphenyl)-1H-1,2,3-triazol-1-yl]phenol
Homo sapiens
-
37°C, pH not specified in the publication
0.00085
3-[4-(5-chloro-2-thienyl)pyridin-2-yl]phenol
Homo sapiens
37°C, pH not specified in the publication
0.00364
3-[4-(5-chloro-2-thienyl)pyridin-2-yl]phenol
Homo sapiens
37°C, pH not specified in the publication
0.00031
3-[5-(4-hydroxyphenyl)-1,3-oxazol-2-yl]-phenol
Homo sapiens
substrate: estrone, 17beta-HSD1
0.0175
3-[5-(4-hydroxyphenyl)-1,3-oxazol-2-yl]-phenol
Homo sapiens
substrate: estrone, 17beta-HSD2
0.00139
3-[6-(5-chloro-2-thienyl)pyridin-2-yl]phenol
Homo sapiens
37°C, pH not specified in the publication
0.00711
3-[6-(5-chloro-2-thienyl)pyridin-2-yl]phenol
Homo sapiens
37°C, pH not specified in the publication
0.00102
4'-(5-chloro-2-thienyl)biphenyl-3-ol
Homo sapiens
37°C, pH not specified in the publication
0.01
4'-(5-chloro-2-thienyl)biphenyl-3-ol
Homo sapiens
value higher than 0.01, 37°C, pH not specified in the publication
0.00069
4'-(6-methoxypyridin-3-yl)biphenyl-3-ol
Homo sapiens
37°C, pH not specified in the publication
0.00297
4'-(6-methoxypyridin-3-yl)biphenyl-3-ol
Homo sapiens
37°C, pH not specified in the publication
0.00048
4'-hydroxy-N-(3-hydroxybenzyl)-N-methylbiphenyl-3-carboxamide
Homo sapiens
pH 7.4, 37°C
0.000482
4'-hydroxy-N-(3-hydroxybenzyl)-N-methylbiphenyl-3-carboxamide
Homo sapiens
pH 7.4, 37°C
0.001 - 0.005
coumestrol
Curvularia lunata
-
IC50 between 0.001 and 0.005 mM, reduction of estra-4-en-3,17-dione
0.00016
N-(3-hydroxybenzyl)-N-methyl-5-(3-methylphenyl)thiophene-2-carboxamide
Homo sapiens
pH 7.4, 37°C
0.000164
N-(3-hydroxybenzyl)-N-methyl-5-(3-methylphenyl)thiophene-2-carboxamide
Homo sapiens
pH 7.4, 37°C
0.00016
N-butyl-6-[[(6beta,17beta)-3,17-dihydroxyestra-1(10),2,4-trien-6-yl]sulfanyl]-N-methylhexanamide
Homo sapiens
-
92% inhibition at 0.001 mM, IC50: 0.00016 mM, reduction of estrone with NADH as cofactor
0.00016
N-butyl-6-[[(6beta,17beta)-3,17-dihydroxyestra-1(10),2,4-trien-6-yl]sulfanyl]-N-methylhexanamide
Homo sapiens
-
0.00291
N-decyl-N-[(4aR,6aS,7S)-1,4a,6a-trimethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]formamide
Homo sapiens
pH and temperature not specified in the publication, substrate: progesterone
0.00396
N-decyl-N-[(4aR,6aS,7S)-1,4a,6a-trimethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]formamide
Homo sapiens
pH and temperature not specified in the publication, substrate: progesterone
0.00112
N-decyl-N-[(4aR,6aS,7S)-4a,6a-dimethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]formamide
Homo sapiens
pH and temperature not specified in the publication
0.00578
N-decyl-N-[(4aR,6aS,7S)-4a,6a-dimethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]formamide
Homo sapiens
pH and temperature not specified in the publication, substrate: progesterone
0.0007
N-nonyl-N-[(4aR,6aS,7S)-1,4a,6a-trimethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]formamide
Homo sapiens
pH and temperature not specified in the publication
0.00332
N-nonyl-N-[(4aR,6aS,7S)-1,4a,6a-trimethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]formamide
Homo sapiens
pH and temperature not specified in the publication, substrate: progesterone
additional information
(2,4-dihydroxyphenyl)-phenylmethanone
Homo sapiens
-
value higher than 0.02, pH 7.4, 37°C
additional information
(2,4-dihydroxyphenyl)-phenylmethanone
Homo sapiens
-
value higher than 0.065, pH 7.4, 37°C
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
SPECIFIC ACTIVITY [µmol/min/mg]
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
additional information
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
pH OPTIMUM
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
7.4
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
pH RANGE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
6 - 11
ANI02794.1
pH 6.0: about 30% of maximal activity, pH 11.0: about 40% of maximal activity
6.7 - 9.2
-
pH 6.7: about 45% of maximal activity, pH 9.2: about 60% of maximal activity
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
TEMPERATURE OPTIMUM
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
25
37
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
TEMPERATURE RANGE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
24 - 54
-
24°C: about 60% of maximal activity, 54°C: about 50% of maximal activity, enzyme from crude washed mitochondria
25 - 50
ANI02794.1
25°C: about 35% of maximal activity, 50°C: about 40% of maximal activity
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
pI VALUE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
ORGANISM
COMMENTARY
LITERATURE
UNIPROT
SEQUENCE DB
SOURCE
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
SOURCE TISSUE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
SOURCE
no sex differences in enzyme expression
brenda
-
cultured cells, enzyme expression is stimulated with all-trans and 9-cis retinoic acid
brenda
-
EpiskinTM is a cultured human epidermis. 17beta-hydroxysteroid dehydrogenase and 3alpha-hydroxysteroid dehdyrogenase activities are present at moderate levels in EpiskinTM, while 3beta-hydroxysteroid dehdyrogenase activity is low
brenda
-
association of 17HSD1 with extravillous cells indicates that the enzyme perhaps plays a role in trophoblast invasion
brenda
-
epithelial cells. Increased expression of 17HSD1 in epithelial cells of fallopian tube may lead to a local estradiol supply sufficient for maintenance of tubal pregnancy
brenda
-
3beta- and 17beta-hydroxysteroid dehydrogenase are not altered in metyrapone-treated cells
brenda
HSD17B2 expression is significantly higher in invasive lobular carcinoma (ILC) than in invasive ductal carcinoma
brenda
HSD17B2 expression is significantly higher in invasive lobular carcinoma (ILC) than in invasive ductal carcinoma
brenda
high levels of 17betaHSD1 transcript are detected. Downregulation during follicular luteinization
brenda
NSCLC, immunihostichemic enzyme analysis: higher 17betaHSD1 immunoreactivity tends to be positively associated with aromatase and tumor stage. A higher 17betaHSD1 immunoreactivity is also significantly associated with lower intratumoral estrone concentration and a higher intratumoral estradiol/estrone concentration ratio. On the other hand a higher 17betaHSD2 immunoreactivity is significantly associated with higher intratumoral estrone concentration
brenda
-
normal and tubal pregancies possess identical expression of 17HSD1 in syncytiotrophoblast cells and therefore, similar estradiol production in the placenta
brenda
additional information
expression of type 7 17beta-hydroxysteroid dehydrogenase in zona fasciculata and reticularis in the cortex
brenda
-
HSD17B4 mRNA and activity are detectable in the early developing and adult brain
brenda
HSD17B4 mRNA is expressed more in the song regions of males compared to females throughout development. Females have significantly higher levels of HSD17B4 mRNA in auditory (caudomedial nidopallium) and visual (hyperpalliumapicale)regions than does males at day 25
brenda
17beta-HSD1 is overexpressed in many breast tumors
brenda
the inhibition of the enzyme (17beta-HSD7) constitutes the basis of breast cancer cell proliferation
brenda
-
17beta-HSD type 12 in 83% of the breast cancer specimen. The expression of 17beta-HSD type 12 is significantly higher in breast carcinoma specimen than in normal tissues
brenda
-
the 17beta-HSD type 1 can be detected only in one tumor
brenda
-
17beta-HSD type 7 activity is detected in 47% of the breast cancer specimen
brenda
-
breast cells, activity is far greater in epithelial cells than in fibroblasts
brenda
type 7 17beta-hydroxysteroid dehydrogenase is expressed in epithelial cells of both acini and small ducts
brenda
HSD17B2 is normally expressed in the epithelial cells of the colon lumen, and to a lesser extent in the crypt epithelium small intestine endometrium
brenda
type 7 17beta-hydroxysteroid dehydrogenase is restricted to epithelial cells of the mucosa
brenda
detectable throughout the luteal phase of the ovarian cycle and during pregnancy
brenda
ubiquitously expressed in all tissues analyzed, with higher levels in organs with high metabolic rates, such as kidney and digestive gland
brenda
-
of fallopian tube. Increased expression of 17HSD1 in epithelial cells of fallopian tube may lead to a local estradiol supply sufficient for maintenance of tubal pregnancy
brenda
-
cultured cells, enzyme expression is stimulated with all-trans and 9-cis retinoic acid
brenda
ubiquitously expressed in all tissues analyzed, with higher levels in organs with high metabolic rates, such as kidney and digestive gland
brenda
type 7 17beta-hydroxysteroid dehydrogenase is found in all the hepatocytes
brenda
-
male pigs with high androstenone concentrations in fat have low 3betaHSD gene expression in liver and testis. Immunocastrated and surgically castrated male pigs shows significant increase of 3betaHSD expression. Fat androstenone is negatively correlated with liver 3betaHSD gene expression. The mRNA expression is generally much greater from the 3betaHSD than from the 17betaHSD gene
brenda
-
17betaHSD gene expression in liver, but not in testis, varies negatively with fat androstenone concentration. Immunocastrated and surgically castrated male pigs show significant increase of 3betaHSD expression. Fat androstenone is negatively correlated with liver 17betaHSD gene expression. The mRNA expression is generally much greater from the 3betaHSD than from the 17betaHSD gene
brenda
moderate expression. Strong labeling expression is observed in epithelial cells and stromal cells
brenda
type 7 17beta-hydroxysteroid dehydrogenase is expressed in stromal cells surrounding the duct
brenda
-
MCF-7.8H cell derived from MCF-7 via transfection, high enzyme activity
brenda
-
modulation of local synthesis of estradiol is one potential mechanism through which genistein, enterolactone and enterodiol may protect against breast cancer
brenda
-
enzyme type 2 from ovarian tumors: OVCAR-3, CAOV-3 and epidermoid tumor of the vulva, A431
brenda
-
cultured granulosa cells, detectable in large follicles, very weak in medium follicles
brenda
-
high expression in granulosa cells of growing follicles
brenda
type 12 17beta-hydroxysteroid dehydrogenase is most highly expressed in ovary and mammary gland
brenda
-
17beta-HSD8 in cumulus cells, not in granulosa and luteal cells, vice versa for isozymes 17beta-HSD1 and 17beta-HSD7
brenda
the enzyme is primarily expressed in the placenta and ovarian granulose cells
brenda
type 7 17beta-hydroxysteroid dehydrogenase is restricted to corpus luteum cells
brenda
-
-
285977, 285981, 287172, 287173, 287174, 287176, 287181, 287182, 287183, 287184, 287186, 287187, 287188, 287190, 287191, 656371
brenda
-
normal and tubal pregancies possess identical expression of 17HSD1 in syncytiotrophoblast cells and therefore, similar estradiol production in the placenta
brenda
-
organotin compounds are potent stimulators of 17beta-estradiol biosynthesis to enhance 17beta-HSD I activity in placenta
brenda
the enzyme is primarily expressed in the placenta and ovarian granulose cells
brenda
expressed in estrogen receptor beta-positive epithelial cells of the human prostate
brenda
-
detectable in sebaceous glands, absent in epidermis, stroma, hair follicles and sweat glands
brenda
-
17beta-hydroxysteroid dehydrogenase has a pivotal role in regulating the synthesis of estradiol within breast tumours
brenda
isozyme AKR1B15.1, very low expression of isozyme AKR1B15.2
brenda
-
only in germ cells, absent in seminiferous tubules and Leydig cells
brenda
-
male pigs with high androstenone concentrations in fat have low 3betaHSD gene expression in liver and testis. Immunocastrated and surgically castrated male pigs shows significant increase of 3betaHSD expression. The mRNA expression is generally much greater from the 3betaHSD than from the 17betaHSD gene
brenda
-
Immunocastrated and surgically castrated male pigs shows significant increase of 17betaHSD expression. The mRNA expression is generally much greater from the 3betaHSD than from the 17betaHSD gene
brenda
moderate expression, epithelial cells and stromal cells
brenda
endometrial 17beta-hydroxysteroid dehydrogenase activity is decreased on days 15-16 in pregnant and cyclic pigs compared with the preceding days
brenda
additional information
not detectable in brain, colon, jejunum, pancreas, kidney, liver, adrenal, prostate, testis, uterus, lung, and spleen
brenda
additional information
not detectable in brain, colon, jejunum, pancreas, kidney, liver, adrenal, prostate, testis, uterus, lung, and spleen
brenda
additional information
not detectable in brain, lung and spleen
brenda
additional information
not detectable in brain, lung and spleen
brenda
additional information
enzyme identified from transcriptomic analysis. Lack of correlation of Ea17beta-hsd 14 transcript levels with the coral's reproductive cycle. Ea17beta-hsd 14 transcript and protein are detected in all tissues examined, such as the tentacles, mesenterial filaments, and gonads, at similar levels in both sexes, as determined by quantitative RT-PCR analysis and Western blotting with an anti-Ea17beta-Hsd 14 antibody. Immunohistochemical analysis reveals that Ea17beta-Hsd 14 is mainly distributed in the endodermal regions of the polyps, but the protein is also observed in all tissues examined. Seasonal variation in the levels of Ea17beta-hsd 14 transcripts, overview
brenda
additional information
-
enzyme identified from transcriptomic analysis. Lack of correlation of Ea17beta-hsd 14 transcript levels with the coral's reproductive cycle. Ea17beta-hsd 14 transcript and protein are detected in all tissues examined, such as the tentacles, mesenterial filaments, and gonads, at similar levels in both sexes, as determined by quantitative RT-PCR analysis and Western blotting with an anti-Ea17beta-Hsd 14 antibody. Immunohistochemical analysis reveals that Ea17beta-Hsd 14 is mainly distributed in the endodermal regions of the polyps, but the protein is also observed in all tissues examined. Seasonal variation in the levels of Ea17beta-hsd 14 transcripts, overview
brenda
additional information
in prostate cancers of Gleason grade higher than 3, both estrogen receptor beta and isoform 17betaHSD6 are undetectable
brenda
additional information
17beta-HSD1 is highly expressed in breast and ovary tissues and represents a prognostic marker for the tumor progression and survival of patients with breast cancer and other estrogen-dependent tumors
brenda
additional information
isozyme tissue-specific expression analysis, overview
brenda
additional information
-
not detectable in corpora lutea, interstitial cells, anterior and posterior lobes, mammary gland, uterus, vagina, adrenal gland, kidney, liver, brain, and lung
brenda
additional information
-
tissue distribution, in situ hybridization, overview
brenda
additional information
ubiquitously expressed in all tissues analyzed, with higher levels in organs with high metabolic rates, such as kidney and digestive gland
brenda
additional information
-
ubiquitously expressed in all tissues analyzed, with higher levels in organs with high metabolic rates, such as kidney and digestive gland
brenda
additional information
NlHsd17b12 is ubiquitously expressed in all tissues analyzed, with higher levels in organs with high metabolic rates, such as kidney and digestive gland, a pattern consistent with an involvement in lipid metabolism, detailed tissue distribution through quantitative PCR
brenda
additional information
-
NlHsd17b12 is ubiquitously expressed in all tissues analyzed, with higher levels in organs with high metabolic rates, such as kidney and digestive gland, a pattern consistent with an involvement in lipid metabolism, detailed tissue distribution through quantitative PCR
brenda
additional information
-
weak expression in the tissues examined, except for gastrointestinal tract and liver. No expression in lung
brenda
additional information
co-localization of HSD17B4 and androgen receptor mRNA
brenda
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
LOCALIZATION
ORGANISM
UNIPROT
COMMENTARY
GeneOntology No.
LITERATURE
SOURCE
-
isozymes 17beta-HSD2, 17beta-HSD3, and 17beta-HSD7
brenda
Highest Expressing Human Cell Lines
Cell Line LinksPlease wait a moment until the data is sorted. This message will disappear when the data is sorted.
GENERAL INFORMATION
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
drug target
evolution
malfunction
metabolism
physiological function
additional information
drug target
inhibition of 17beta-hydroxysteroid dehydrogenases 1 may be a prime candidate for inhibition in patients with breast cancer who develop aromatase inhibitor resistance or in combination with aromatase inhibitors as a first line treatment
drug target
inhibition of 17beta-hydroxysteroid dehydrogenases 1 is proposed to be a prime candidate for inhibition in patients who develop aromatase inhibitor resistance or in combination with aromatase inhibitors as a first line treatment
drug target
the ratio of HSD17B1 to HSD17B2 is a good indicator of tamoxifen treatment benefit, as post-menopausal patients with tumors expressing a high HSD17B1/HSD17B2 protein ratio have less benefit from tamoxifen treatment
drug target
-
possible role in Alzheimer's disease, inhibition appears to be a therapeutic strategy
drug target
inhibition of 17beta-HSD7 constitutes the basis of breast cancer cell proliferation
evolution
17beta-HSD1 belongs to the short-chain dehydrogenase/reductase (SDR) family and contains the conserved Rossmann-fold for nucleotide binding, the catalytic triad with residues Ser142, Tyr155, and Lys159 and a dimerization region. Residue Cys10 is highly conserved among species, including rodents and zebrafish, suggesting a role for this residue in the stability and/or function of the protein. The cysteine residue at this position is conserved in all members of the SDR9C family, except for 17beta-HSD2, which has a cysteine residue downstream by two positions
evolution
17beta-Hsd 14 from Euphyllia ancora clusters with other animal 17beta-HSD 14s but not with other members of the 17beta-HSD family
evolution
HSD17B12 is a member of the hydroxysteroid dehydrogenase superfamily, a multifunctional group of enzymes involved in the metabolism of steroids, retinoids, bile and fatty acids
malfunction
substitution of Cys10 with Ser in the enzyme results in a decreased protein half-life, without significantly altering kinetic properties
malfunction
estrone treatment in 17betaHSD1 positive NSCLC cells, A-549 and LK-87, results in estradiol production and enhances cell proliferation, which is abrogated effectively by 17betaHSD1 siRNA knockdown
malfunction
enzyme inhibition can lead to desired increase of estradiol and testosterone levels in the bone tissue and may be used for the treatment of osteoporosis
malfunction
enzyme inhibition can lead to desired increase of estradiol and testosterone levels in the bone tissue and may be used for the treatment of osteoporosis
malfunction
knockdown of 17beta-HSD1 gene, HSD17B1, modulates the transcript profile of the hormone-dependent breast cancer cell line T47D, T47D, with 105 genes regulated 1.5 fold or higher in estradiol-independent manner
malfunction
knockdown of 17beta-HSD1 gene, HSD17B1, modulates the transcript profile of the hormone-dependent breast cancer cell line T47D, with 105 genes regulated 1.5fold or higher in estradiol-independent manner. Genes that are primarily involved in the cell cycle progression, such as the cyclin A2 gene, CCNA2, are generally down-regulated whereas genes involved in apoptosis and cell death, including the pro-apoptotic gene XAF1, IFIH1 and FGF12, are upregulated by 17beta-HSD1 knockdown
metabolism
AKR1B15.1 is a mitochondrial carbonyl reductase. Two alternatively spliced protein isoforms encoded by the human AKRgene AKR1B15 exist, the AKR1B15.1 isoform catalyzes reduction of steroids and 3-keto-acyl-CoA conjugates
metabolism
HSD17B2 is controlled by estradiol, dihydrotestosterone, and miRNAs, as well as modulated by several breast cancer related genes
metabolism
besides as a biomarker in cancer, AKR1C3 is important in the reduction of steroids and prostaglandins, and function as part of a chemical barrier to defend the body from intrusion of toxic chemicals
metabolism
by acting as a 17-ketosteroid reductase, AKR1C3 produces potent androgens in peripheral tissues which activate the androgen receptor or act as substrates for aromatase. AKR1C3 is implicated in the production of androgens in castration-resistant prostate cancer and polycystic ovarian syndrome and is implicated in the production of aromatase substrates in breast cancer
metabolism
-
the enzyme can oxidize estradiol into estrone, thus reducing concentration of this neuroprotective steroid
metabolism
ANI02794.1
the enzyme plays an important role in estrogen metabolism
physiological function
-
enzyme involved in maintaining high estradiol levels in breast tumors of postmenopausal women. In certain breast cancer patients, intratumoral estradiol is produced by the 17beta-HSD1-mediated reduction of estrone produced by aromatase. A high level of 17-beta-HSD1 correlates with an increased risk of developing a late relapse of breast cancer in ER-positive breast cancer patients
physiological function
17beta-hydroxysteroid dehydrogenase type 6 converts the androgen 5alpha-dihydrotestosterone to the estrogen 5alpha-androstane-3beta,17beta-diol, and this leads to activation of the estrogen receptor beta reporter. This conversion of dihydrotestosterone occurs at concentrations that are in the physiological range of this hormone in the prostate
physiological function
endogenous production of 17beta-estradiol in hematological malignant cells might also contribute to immunohormonal imbalance in patients with these disorders. Human T and B lymphocytes are positive for ERa, ERb and GPR30 receptors. Using putative membrane receptors, estrogens are able to modulate cytokine profiles in T cells and the control of B-cell maturation and selection. In particular, estrogens are able to inhibit T cell proliferation, interleukin-2 (IL-2) biosynthesis, and increase B-cell proliferation and antibody production. 17beta-Estradiol is able to upregulate cyclic AMP response element modulator alpha leading to reduced IL-2 gene expression in human T lymphocytes. HSD17B1 may play a crucial role in the development of estrogen-dependent diseases
physiological function
17beta-hydroxysteroid dehydrogenase 2 catalyzes the inactivation of estradiol into estrone
physiological function
estrone treatment in 17betaHSD1 positive NSCLC cells, A-549 and LK-87, results in estradiol production and enhances cell proliferation, which is abrogated effectively by 17betaHSD1 siRNA knockdown
physiological function
the drop in 17beta-estradiol (E2) and testosterone levels, occurring with ageing, is the main factor driving the onset and progression of osteoporosis
physiological function
the drop in 17beta-estradiol (E2) and testosterone levels, occurring with ageing, is the main factor driving the onset and progression of osteoporosis
physiological function
17beta-hydroxysteroiddehydrogenasetype IV (HSD17B4),coding for a steroidogenic enzyme that converts estradiol (E2) into an inactive metabolite. HSD17B4 mRNA is expressed more in the song regions of males compared to females throughout development, suggesting that regulation of E2 is important for male-typical song development. 17beta-Estradiol treatments increase HSD17B4 mRNA in the auditory region of males, which is contraryto findings in the song system. Different behaviors may be guided by the same genes and hormones, but the exact nature of the gene-hormone relationships may differ according to brain region and behavior
physiological function
-
the enzyme is thought to play a pivotal role in the progression of estrogen-sensitive breast cancer by transforming estrone into estradiol
physiological function
that in mollusks, as in mammals, this enzyme is likely to be involved in lipid metabolism
physiological function
the enzyme is involved in the metabolism of steroid hormones and in the biosynthesis of cholesterol
physiological function
by its oxidative activity, the enzyme can decrease the concentration of two important neurosteroids, allopregnanolone (ALLOP) and 17beta-estradiol, respectively preventing their neurogenesis and neuroprotective effects
physiological function
the expression of 17beta-hydroxysteroid dehydrogenase 1 and 2 alone and in combination predicts outcome of patients with breast cancer
physiological function
the enzyme increases breast cancer cell proliferation via a dual effect on 17-beta-estradiol and 5alpha-dihydrotestosterone levels and impacts gene expression and protein profile of breast cancer cells cultured in 17-beta-estradiol-contained medium
physiological function
the enzyme 17beta-HSD1 may be involved in oncogenesis by favoring antiapoptosis pathway in breast cancer cells and correborates with its previously shown role in increasing breast cancer cell proliferation. The gene regulation occurring in steroid-deprived conditions shows that 17beta-HSD1 can modulate endogenous gene expression in steroid-independent manners
physiological function
17beta-HSD1 may be involved in oncogenesis by favoring antiapoptosis pathway in breast cancer cells
physiological function
the enzyme is involved in estrogen-dependent diseases
physiological function
the enzyme is involved in the biosynthesis of estradiol
additional information
Lys149 is a critical residue for the discrimination between C-18 and C-19 steroid substrate. Analysis of the role of Cys10 for 17beta-HSD1 function, overview
additional information
role of a cysteine residue, Cys10 in the Rossmann-fold NADPH binding region, for 17beta-HSD1 function, important interactions of Cys10 with residues involved in the stabilization of amino acids of the NADPH binding pocket, three-dimensional enzyme structure modeling, overview
Show AA Sequence and Transmembrane Helices (6187 entries)
Longer loading times are possible. Please use the AA Sequence and Transmembrane Helices Search for a specific query.
Longer loading times are possible. Please use the AA Sequence and Transmembrane Helices Search for a specific query.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
PDB
SCOP
CATH
UNIPROT
ORGANISM
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
MOLECULAR WEIGHT
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
32000
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
SUBUNIT
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
dimer
monomer
-
mutants R129D and H111L, the monomeric enzymes are catalytically inactive
additional information
additional information
-
the enzyme functions as dimer or tetramer, but is a dimer under native conditions, secondary structure analysis of wild-type and mutant enzymes, and structure-function analysis, residues involved in dimerization or oligomerization of the enzyme via salt bridges or hydrophobic interactions, overview
additional information
-
sequence of a tryptic peptide containing an essential cysteine
additional information
-
sequence of a histidine-bearing peptide in the catalytic region
additional information
enzyme three-dimensional structural modeling, overview
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
POSTTRANSLATIONAL MODIFICATION
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
phosphoprotein
-
enzyme is phosphorylated by protein kinase A exclusively at Ser134 in vitro, but this phosphorylation has no effect on the catalytic properties of the type 1 enzyme, and most likely it does not occur in vivo
proteolytic modification
-
17beta-hydroxysteroid dehydrogenase IV is coded by 2.9 kb mRNA translated to an 80000 Da protein which is N-terminally cleaved to a 32000 Da enzyme
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
CRYSTALLIZATION (Commentary)
ORGANISM
UNIPROT
LITERATURE
hanging-drop vapour-diffusion method, crystallization of the 17beta-HSDcl apo form and Tyr167Phe mutant, crystals diffract to 1.7 A resolution. The space group is identified as I4(1)22, with unit-call parameters a = b = 67.14, c = 266.77 A
-
active site analysis of 17beta-hydroxysteroid dehydrogenase type 1 enzyme complexes (estradiol/NADP+, equilin/NADP+, dehydroepiandrosterone) using the SPROUT program
crystal structure of 17beta-HSD1 complexed with testosterone or estradiol are shown. Both testosterone and estradiol bind in the narrow hydrophobic tunnel of 17beta-HSD1 with a high degree of complementarity. Testosterone is bound in an alternative orientation to 17beta-HSD1 compared with estradiol. Residue L149 plays an important role in the discrimination between C19 androgen and C18 estrogen
-
crystallization and crystal structure of the complex of the enzyme with the dual-site inhibitor, EM-139
-
hanging-drop vapour diffusion method at 27°C, binary and ternary crystal structures of the enzyme complexed with estrone and NADP+, crystals in this study belonged to the space group P212121 and contain a dimer per asymmetric unit
hanging-drop vapour diffusion method at 27°C, crystallization of the enzyme in complex with estrone and NADP+. His221 is the key residue responsible for the reorganization and stabilization of the reversely bound estrone, leading to the formation of a dead end complex, which exists widely in NADP(H)-preferred enzymes for the regulation of their enzymatic activity
in complex with ligands estradiol, equiline, 5-alpha-dihydrotestosterone, O5'-[9-(3,17beta-dihydroxy-1,3,5(10)-estratrien-16beta-yl)nonanoyl]adenosine and 3-[[(16beta,17beta)-3,17-dihydroxyestra-1,3,5(10)trien-16-yl]methyl]benzamide. Construction of pharmacophore model
ternary complex of the 17beta-hydroxysteroid dehydrogenase type 1 with 3-hydroxyestra-1,3,5,7-tetraen-17-one and NADP+
the purified enzyme variants T205 and S205 in apoform, as holoenzyme, or in complex with estrone or inhibitor [6-(3,4-dihydroxyphenyl)pyridin-2-yl]-(4-fluoro-3-hydroxyphenyl)methanone, ternary complex enzyme-cofactor-inhibitor, X-ray diffraction structure determination and analysis at 1.52-2.02 A resolution
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
PROTEIN VARIANTS
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
A50R
-
site-directed mutagenesis, the mutant shows increased rates of NADPH dissociation and thus enhanced substrate oxidation with NADP+ compared to the wild-type enzyme
H111A
-
site-directed mutagenesis, the mutant is dimeric like the wild-type enzyme, inactive mutant
H111L
-
site-directed mutagenesis, the mutation renders the enzyme monomeric, inactive mutant
H164G
mutation results in a conformation of the enzyme that possesses a higher catalytic activity
H164W
mutation results in a conformation of the enzyme that possesses a higher catalytic activity
N51R
-
site-directed mutagenesis, the mutant shows increased rates of NADP+ dissociation and thus enhanced substrate reduction with NADPH compared to the wild-type enzyme
R129D
-
site-directed mutagenesis, the mutation renders the enzyme monomeric, the mutant shows reduced activity compared to the wild-type enzyme
T202I
-
site-directed mutagenesis, inactive mutant due to cofactor binding deficiency
T202V
-
site-directed mutagenesis, inactive mutant due to cofactor binding deficiency
V161G
mutation increases the initial rates for the conversion of androstenedione to testosterone
Y212A
mutation increases the initial rates for the conversion of androstenedione to testosterone
Y49D
C10S
H221A
-
catalytic efficiency is reduced 20fold for oxidative reaction and 11fold for the reductive reaction
K159A
-
almost inactive enzyme, catalytic efficiencies of the substituted enzyme are more than 200fold lower for both reduction and oxidation compared with the values measured for the wild type enzyme
S142A
-
almost inactive enzyme, catalytic efficiencies of the substituted enzyme are more than 200fold lower for both reduction and oxidation compared with the values measured for the wild type enzyme
additional information
Y49D
-
site-directed mutagenesis, the mutant shows altered cofactor specificity preferring NAD+, resembling to the the cD1d subfamily of the short-chain dehydrogenase/reductase superfamily
Y49D
mutation changes the coenzyme specificity of the enzyme. The mutant can convert the steroids not only in the presence of NADP+ and NADPH, but also in the presence of NADH and NAD+
C10S
site-directed mutagenesis, substitution of Cys10 with Ser results in a decreased protein half-life, without significantly altering kinetic properties. Mutant Cys10Ser shows approximately 50% lower activity compared to the wild-type. Mutating Cys10 to Ser does not lead to significant changes in contacts between Ser10 and Ile7, Gly9 and Ala34. But all three contacts between Ser10 and Gly15 are shorter than between Cys10 and Gly15, and Gly15 is more distant from a phosphate oxygen on NADP+
C10S
site-directed mutagenesis, the Cys10Ser mutant 17beta-HSD1 is partially protected from inhibition by NEM and dithiocarbamates. Mutating Cys10 to Ser does not lead to significant changes in contacts between Ser10 and Ile7, Gly9 and Ala34, but all three contacts between Ser10 and Gly15 are shorter than between Cys10 and Gly15, and Gly15 is more distant from a phosphate oxygen on NADP+
additional information
-
deleting the last 36 amino acids does not have a dramatic effect on the catalytic properties
additional information
72 h treatment with 17betaHSD1 siRNA 2 significantly reduces the endogenous 17betaHSD1 expression in both A-549 and LK-87 cells
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
TEMPERATURE STABILITY
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
additional information
additional information
-
denaturation of monomeric enzyme at higher temperatures
additional information
-
enzyme is cold sensitive, cold inactivation is reduced by NAD+, NADP+, estradiol or glycerol
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
STORAGE STABILITY
ORGANISM
UNIPROT
LITERATURE
4°C, phosphate buffer, pH 7.0, 1 mM dithioerythritol, stable for at least 1 month
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
PURIFICATION (Commentary)
ORGANISM
UNIPROT
LITERATURE
copurification of 17beta-estradiol dehydrogenase and 20alpha-hydroxysteroid dehydrogenase
-
recombinant GST-tagged wild-type and mutant enzymes from Escherichia coli strain JM107 by glutathione affinity chromatography
-
recombinant His-tagged isozymes AKR1B15.1 and AKR1B15.2 isozymes from Escherichia coli strain BL21(DE3) by nickel affinity chromatography
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
CLONED (Commentary)
ORGANISM
UNIPROT
LITERATURE
chromosomal localizations of isozymes, DNA and amino acid sequence determination and analysis of isozymes 17beta-HSD1, 17beta-HSD3, 17beta-HSD4, overview
-
expressed as a glutathione S-transferase fusion protein in Escherichia coli BL21 cells
expressed in Sf9 insect cells
expression in Escherichia coli
expression in Escherichia coli as an enzymatically active His-tag fusion protein
-
expression of GST-tagged wild-type and mutant enzymes in Escherichia coli strain JM107
-
gene 17beta-Hsd 14, DNA and amino acid sequence determinnation and analysis, sequence comparisns and phylogenetic analysis and tree, quantitative RT-PCR expression analysis
gene AKR1B15 located on chromosome 7, cloning of two isoforms: AKR1B15.1 and AKR1B15.2, DNA and amino acid sequence determination and analysis, recombinant expression of N-terminally His-tagged isozymes in Escherichia coli strain BL21(DE3), recombinant expression of C- or N-terminally c-Myc-tagged isozymes in HEK-293 cells
gene HSD17B1, sequence comparisons, recombinant expression in HEK-293 cells
HEK-293 cells stably expressing Macaca fascicularis type 12 17beta-HSD
recombinant expression of 17beta-HSD14 wild-type variants S205 and T205 in Escherichia coli strain BL21 pLysS
the complete 17beta-HSD1 (HSD17B131) and 17beta-HSD12 (HSD17B12) cDNA sequences are cloned into the pCEP4 expression vector for expression in 293-EBNA cells
transgenic mouse lines universally overexpressing human HSD17B1 are generated and characterized at fetal and adult ages
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
EXPRESSION
ORGANISM
UNIPROT
LITERATURE
17beta-estradiol treatments increase HSD17B4 mRNA in the auditory region of males, which is contraryto findings in the song system
application of medroxyprogestrone acetate, dydrogesterone and dienogest significantly decreases isoforms HSD17B1 and CYP19A1 expression and significantly increases isoform HSD17B2 expression. Dydrogesterone and dienogest also significantly suppress estrogen receptors ESR1 and ESR2 transcription, whereas medroxyprogestrone acetate and dydrogesterone significantly reduce mRNA levels of G protein-coupled estrogen receptor 1. Results thus suggest that in peritoneal endometriosis the beneficial effects of these progestins can be explained by lower HSD17B1 and higher HSD17B2 mRNA and protein levels, which lead to reduced local estradiol biosynthesis
aromatase inhibitor treatment results in 17betaHSD1 upregulation in both A-549 and LK-87 cells
CrgA activates the expression of 17beta-hsd through its binding to the motif of T-N11-A
dihydrotestosterone treatment increases HSD17B2 expression, with limited effect on HSD17B1 expression
downregulation of CX3CL1, EPHB6, and TP63 increases HSD17B1 and HSD17B2 expression
elevated levels of 17beta-estradiol occur in male patients with chronic lymphocytic leukemia
endometrial 17beta-hydroxysteroid dehydrogenase activity is decreased on days 15-16 in pregnant and cyclic pigs compared with the preceding days
exposure to tributyltin chloride at 100 ng Sn2+/l causes a decrease in mRNA levels in digestive gland, after one and two months, while no effect is observed in gonads
expression is relatively low in most tissues and high in prostate and mammary glands in regulating androgen and estrogen levels. In many cancers, overexpression of AKR1C3 is observed
expression of HSD17B2 is increased in ERalpha-negative breast cancer
higher expression of 17beta-HSD1 mRNA is demonstrated in almost 50% of breast cancer tissues. Expression and activity of 17beta-HSD1 are significantly higher in breast cancer than in normal breast tissue
-
HSD17B1 expression is increased in breast cancer compared with unchanged tissue
HSD17B2 expression is reduced in breast cancer compared with benign tumors
HSD17B2 expression is significantly higher in invasive lobular carcinoma (ILC) than in invasive ductal carcinoma
in non-small cell lung cancer (NSCLC) the expression of HSD17B1 is increased as compared with healthy tissue
induced by 17beta-estradiol
OxyR represses the expression of 17beta-hsd by its specific binding to the conserved motif of GATA-N9-TATC
significant increment of 17beta HSD1 immunoreactivity is found in breast cancer patients treated with aromatase inhibitor exemestane
-
CrgA activates the expression of 17beta-hsd through its binding to the motif of T-N11-A
-
CrgA activates the expression of 17beta-hsd through its binding to the motif of T-N11-A
-
-
OxyR represses the expression of 17beta-hsd by its specific binding to the conserved motif of GATA-N9-TATC
-
OxyR represses the expression of 17beta-hsd by its specific binding to the conserved motif of GATA-N9-TATC
-
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
APPLICATION
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
diagnostics
drug development
medicine
diagnostics
17beta-HSD1 is highly expressed in breast and ovary tissues and represents a prognostic marker for the tumor progression and survival of patients with breast cancer and other estrogen-dependent tumors
diagnostics
the mouse monoclonal antibody for AKR1C3, 10B10, is highly specific and sensitive for detecting AKR1C3 expression including patient samples. The proper detection of AKR1C3 expression is critical for therapeutics targeting AKR1C3, 10B10 will be a valuable tool in clinic for AKR1C3 precision therapy. 10B10 is specific to AKR1C3 protein and has a very low cross-activity against other AKR1 proteins
diagnostics
the expression of 17beta-hydroxysteroid dehydrogenases 1 and 2 alone and in combination predicts outcome of patients with breast cancer
diagnostics
a high HSD17B1 to HSD17B2 ratio, as well as high HSD17B1 on its own is associated with worse prognosis and increased risk of recurrence in patients with ERalpha-positive tumors. An increased copy number of the HSD17B1 gene is correlated with decreased breast cancer survival
drug development
-
several 17beta-HSD isozymes are targets for drug development with importance in cancer, metabolic diseases, neurodegeneration and possibly immunity
drug development
the enzyme is considered a promising drug target against estrogen-dependent cancers
drug development
the enzyme constitutes an interesting therapeutic target for estrogen-dependent diseases
medicine
binding of equilin at the active site of the enzyme is the basis for inhibition of reduction of estrone to estradiol. One possible outcome of estrogen replacement therapy in vivo can be the reduction of estradiol levels in breast tissues and hence the reduced risk of estrogen-dependent breast cancer
medicine
-
as estradiol stimulates the growth and development of hormone-dependent breast cancer, inhibition of the final step of its synthesis is an attractive target for the treatment of this disease
medicine
-
estrogenic response for estrone is enhanced by the local action of HSD17B1 in vivo. Thus the enzyme is a potential target for pharmacological inhibition of estrogen activation. Targeted inhibition of HSD17B1 is a promising therapeutic approach to modulate estrogen response in the target tissue with less severe side effects as compared with antiestrogens
medicine
-
type 1 17beta-hydroxysteroid dehydrogenase is an interesting biological target for designing drugs for the treatment of estrogen-sensitive diseases such as breast cancer
medicine
17beta-HSD1 inhibitors such as STX1040 may provide a treatment for hormone-dependent breast cancer
medicine
17beta-HSD1 is overexpressed in many breast tumors. Thus, it is an attractive target for the treatment of these diseases
medicine
disease iondications for HSD17B1 inhibitors in disorders in the female reproductive organs associated with enhanced androgen action, such as ovarian serous cystadenomas
medicine
17beta-HSD1 is an attractive target for the treatment of mammary tumours
medicine
inhibitors of the enzyme have potential as treatments for hormone dependent breast cancer
medicine
isoform 17betaHSD6 is expressed in estrogen receptor beta-positive epithelial cells of the human prostate. In prostate cancers of Gleason grade higher than 3, both estrogen receptor beta and isoform 17betaHSD6 are undetectable
medicine
Patients with oestrogen positive tumours with high isoform 17betaHSD14 expression have fewer local recurrences when treated with tamoxifen compared to patients with lower tumoural 17betaHSD14 expression, for whom tamoxifen does not reduce the number of local recurrences. No prognostic importance of 17betaHSD14 is seen for systemically untreated patients
medicine
application of medroxyprogestrone acetate, dydrogesterone and dienogest significantly decreases isoforms HSD17B1 and CYP19A1 expression and significantly increases isoform HSD17B2 expression. Dydrogesterone and dienogest also significantly suppress estrogen receptors ESR1 and ESR2 transcription, whereas medroxyprogestrone acetate and dydrogesterone significantly reduce mRNA levels of G protein-coupled estrogen receptor 1. Results thus suggest that in peritoneal endometriosis the beneficial effects of these progestins can be explained by lower HSD17B1 and higher HSD17B2 mRNA and protein levels, which lead to reduced local estradiol biosynthesis
medicine
twenty four hours after addition of different concentrations of estrone and estradiol, the ratio stabilizes to around 9/1 in breast cancer cell lines with high expression of 17beta-hydroxysteroid dehydrogenase type 1, such as T47D, BT 20, and JEG 3 cells, whereas it approaches 1/5 in cells with low expression of 17beta-hydroxysteroid dehydrogenase type 1, such as MCF-7 cells. The estradiol/estrone concentration ratio is modified to 9/1 in MCF-7 and HEK-293 cells over-expressing 17beta-hydroxysteroid dehydrogenase type 1. In T47D and BT 20 cells , this ratio is decreased from 9/1 to nearly 1/5 after 17beta-hydroxysteroid dehydrogenase type 1 knockdown by specific siRNAs
medicine
17beta-hydroxysteroid dehydrogenase type 2 is mainly involved in the conversion of estradiol into estrone. Their ratio is decreased from 9/1 to 7/3 after over-expression of 17beta-hydroxysteroid dehydrogenase type 2 in MCF-7 cells already over-expressing 17beta-hydroxysteroid dehydrogenase type 1. The ratio is further decreased by the addition of the oxidative cofactor, NAD, to the cell culture to facilitate the estradiol to estrone conversion catalyzed by 17beta-hydroxysteroid dehydrogenase type 2
medicine
inhibition of 17beta-hydroxysteroid dehydrogenase type 2 (17beta-HSD2) can help maintaining the appropriate bone mass density in osteoporosis by increasing the level of estradiol and testosterone in bone
medicine
enzyme inhibition is considered as a treatment option for osteoporosis to ameliorate estrogen deficiency
medicine
17betaHSD1 is an important prognostic factor in non-small cell lung carcinoma, NSCLC, patients and targeting 17betaHSD1 activity may further improve the clinical response in estrogen responsive NSCLC patients
medicine
enzyme inhibition can lead to desired increase of estradiol and testosterone levels in the bone tissue and may be used for the treatment of osteoporosis
EXTERNAL LINKS (specific for EC-Number 1.1.1.62)
html completed
Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.
Release 2026.1 (March 2026)
About BRENDA
Social media
Help
Survey
Download
Contribution
Legal
Curated at
Member of
![DSMZ Digital Diversity]()
![Global Core Biodata Resource]()
![ELIXIR Core Data Resource]()
![German Network for Bioinformatics Infrastructure]()
